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The immune protection offered through breast milk is especially important for premature infants. 
Interleukins (ILs), found in breast milk but in varying concentrations, may provide preterm 
infants with protection against prematurity-related complications. Promoter polymorphisms have 
been associated with variable IL levels, though this relationship has never been investigated in 
breast milk. The aims of this study were to: 1) examine the relationship between maternal IL 
genotypes and weekly milk concentrations of IL4, IL6, and IL10, 2) describe the trajectories of 
milk IL change over the first three weeks postpartum, 3) examine whether maternal IL genotypes 
predict milk IL trajectories, 4) examine if weekly IL levels and/or IL trajectories predict infant 
outcomes, and 5) explore a relationship between maternal IL genotypes and infant outcomes. An 
ancillary study was conducted that extracted maternal DNA from breast milk for genotyping 
using TaqMan. Trajectory modeling was used to identify IL subgroups. After controlling for 
gestational age and prepregnancy BMI, there was an inverse association between rs1800796 
minor allele absence (MAA) and milk IL6 among African Americans (p=0.0722). Subsequently, 
higher milk IL6 was also associated with decreased risk of IVH in African Americans (OR=0.32, 
p=0.1059). Additionally, among African Americans, there was a positive association between 
IL6 milk levels and calprotectin (week one p=0.0794, week two p=0.0978). Caucasians had an 
inverse relationship between rs1800795 MAA and milk IL6 (p=0.0966). Subsequently, there is a 
relationship between milk IL6 and infant calprotectin in Caucasians (p=0.0290). MAA of 
rs1800896 was associated with milk IL10 levels among African Americans (p=0.0705), though 
there was no relationship between milk IL10 levels and outcomes. There were no associations 
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between maternal SNP and IL trajectory groups. Trajectory analysis resulted in linear group 
shapes, with two distinct subgroups in IL6, and three subgroups in both IL4 and IL10. Infants 
who received milk from IL4 group 2 were more likely to receive a blood transfusion than infants 
who received milk from group 3 (OR=4.16, p=0.0712). There was an association between IL6 
group 1 membership and both IVH (OR=6.275, p=0.0412) and fecal calprotectin (p=0.0822). 
Traditionally significant findings (p≤0.05) included relationships between maternal IL genotypes 
and NICU outcomes.  
 
vi 
TABLE OF CONTENTS 
PREFACE ................................................................................................................................. XIII 
1.0 PROPOSAL INTRODUCTION ................................................................................. 1 
1.1 PURPOSE AND SPECIFIC AIMS .................................................................... 2 
1.2 BACKGROUND AND SIGNIFICANCE .......................................................... 3 
1.2.1 Rationale for taking an epigenetic approach.............................................. 4 
1.2.2 Rationale for examining BMI and its impact on methylation of 
immunity-related genes in breast milk. ...................................................................... 6 
1.2.3 Rationale for examining fecal calprotectin as a biomarker for infant 
outcome................................................................................................................................. 7 
1.2.4 Genes selected for investigation ................................................................... 8 
1.2.5 Conceptual Framework ................................................................................ 9 
1.2.6 Significance and Innovation ......................................................................... 9 
1.2.7 Summary ...................................................................................................... 11 
1.3 PRELIMINARY STUDIES .............................................................................. 11 
1.4 RESEARCH DESIGN AND METHODS ........................................................ 12 
1.4.1 Setting and Sample ..................................................................................... 13 
1.4.1.1 Breast milk samples and DNA extraction ......................................... 14 
1.4.1.2 Data available for this project ............................................................ 14 
vii 
1.4.1.3 Methylation quality assessment and data collection ........................ 15 
1.4.2 Analysis ........................................................................................................ 16 
1.4.2.1 Sample size justification ..................................................................... 16 
1.4.2.2 Preliminary analysis ........................................................................... 16 
1.4.2.3 Analyses................................................................................................ 18 
1.5 POTENTIAL LIMITATIONS OF PROPOSED PROCEDURES AND 
ALTERNATIVE APPROACHES TO ACHIEVE THESE AIMS ................................ 21 
1.6 HAZARDOUS MATERIALS AND PROCEDURES .................................... 22 
1.7 RESEARCH PARTICIPANT RISK AND PROTECTION .......................... 23 
1.7.1 Human subjects ........................................................................................... 23 
1.7.2 Sources of materials .................................................................................... 23 
1.7.3 Potential risks, benefits, and protection against risks ............................. 24 
1.7.4 Data and safety monitoring plan ............................................................... 24 
2.0 SUMMARY OF STUDY ........................................................................................... 26 
2.1 PROPOSAL CHANGES ................................................................................... 26 
2.1.1 MOLECULAR APPROACH TO EXAMINE INTERLEUKIN 
VARIABILITY ........................................................................................................... 27 
2.1.2 CIDR amplifications ................................................................................... 28 
2.1.3 Polymorphism based assessments of the IL4, IL6, and IL10 genes ....... 29 
2.1.4 Specific Aims ............................................................................................... 30 
2.1.5 Discussion..................................................................................................... 31 
2.2 STUDY STRENGTHS AND LIMITATIONS ................................................ 31 
2.3 FUTURE STUDIES AND IMPLICATIONS FOR NURSING PRACTICE 32 
viii 
3.0 DATA-BASED MANUSCRIPT: THE IMPACT OF PROMOTER 
POLYMORPHISMS ON CYTOKINE CONCENTRATION IN PRETERM BREAST 
MILK AND SUBSEQUENT INFANT OUTCOMES ............................................................. 34 
3.1 ABSTRACT........................................................................................................ 35 
3.2 BACKGROUND ................................................................................................ 36 
3.3 MATERIALS AND METHODS ...................................................................... 40 
3.3.1 STUDY POPULATION ............................................................................. 40 
3.3.2 Breast milk collection and whey separation ............................................. 41 
3.3.3 Interleukin measurement ........................................................................... 41 
3.3.4 Fecal calprotectin ........................................................................................ 41 
3.3.5 Genotyping................................................................................................... 42 
3.4 STATISTICAL ANALYSIS ............................................................................. 42 
3.4.1 Preliminary analysis ................................................................................... 42 
3.4.2 Trajectory Modeling ................................................................................... 43 
3.4.3 Univariate analysis ...................................................................................... 44 
3.4.4 Multivariate analysis .................................................................................. 44 
3.5 RESULTS ........................................................................................................... 46 
3.5.1 Demographics, Genotype Frequencies, and Univariate Analysis ........... 46 
3.5.2 Interleukin trajectory modeling ................................................................ 48 
3.5.3 Maternal Interleukin SNPs and Breast Milk Interleukin 
Concentration/Interleukin Trajectory ..................................................................... 48 
3.5.4 Interleukin SNP and infant outcomes ....................................................... 49 
ix 
3.5.5 Interleukin Trajectory, Interleukin Concentration, and Infant Outcomes
........................................................................................................................51 
3.6 DISCUSSION ..................................................................................................... 52 
3.7 LIMITATIONS AND CONSIDERATIONS TO CONCLUSIONS.............. 58 
3.8 IMPLICATIONS FOR NURSING PRACTICE ............................................ 60 
APPENDIX A: DATA-BASED MANUSCRIPT: TABLES AND FIGURES ....................... 62 
APPENDIX B: UNIVERSITY OF PITTSBURGH INSTITUTIONAL REVIEW BOARD’S 
APPROVAL LETTER ............................................................................................................. 179 
APPENDIX C: MANUSCRIPT #1: MOLECULAR GENOMIC RESEARCH 
DESIGNS.................................................................................................................................... 181 
APPENDIX D: LICENSE AGREEMENT FOR MANUSCRIPT #1 ................................... 202
APPENDIX E: MANUSCRIPT #2: PSYCHOMETRIC EVALUATION OF THE EPWORTH 
SLEEPINESS SCALE IN AN OBSTETRIC POPULATION .............................................. 204 
APPENDIX F: LICENSE AGREEMENT FOR MANUSCRIPT #4 ................................... 211 
APPENDIX G: MANUSCRIPT #3: THE UTILITY OF BREAST MILK FOR GENETIC OR 
GENOMIC STUDIES .............................................................................................................. 219 
APPENDIX H:  LICENSE AGREEMENT FOR MANUSCRIPT #3 .................................. 228 
APPENDIX I: MANUSCRIPT #4: WIC (THE SUPPLEMENTAL NUTRITION 
PROGRAM FOR WOMEN, INFANTS, AND CHILDREN): POLICY VERSUS 
PRACTICE REGARDING BREASTFEEDING .................................................................. 230
APPENDIX J: LICENSE AGREEMENT FOR MANUSCRIPT #4 ................................... 238 
BIBLIOGRAPHY ..................................................................................................................... 246 
 x 
 LIST OF TABLES 
 
Table 1: Milestones ....................................................................................................................... 12 
Table 2: Study timeline ................................................................................................................. 13 
Table 3: Aim-specific available data ............................................................................................ 15 
Table 4: Aim specific analyses ..................................................................................................... 19 
Table 5: Maternal Demographics (n=64) ...................................................................................... 63 
Table 6: Infant demographics (n=73) ........................................................................................... 64 
Table 7: Genotype frequency and Hardy-Weinburg Equilibrgium, total population (n=64) ....... 65 
Table 8: Univariate analysis of maternal SNP and milk interleukin concentrations .................... 66 
Table 9: Multivariate analysis of maternal SNP and milk interleukin concentrations ................. 79 
Table 10: Univariate analysis of maternal SNP and milk interleukin trajectory group ................ 87 
Table 11: Univariate Analysis of Interleukin Trajectory Group and Continuous Infant Outcomes
....................................................................................................................................................... 90 
Table 12: Univariate Analysis of Interleukin Trajectory Group and Categorical Infant Outcomes
....................................................................................................................................................... 92 
Table 13: Multivariate analysis of interleukin trajectory group and continuous infant outcomes 95 
Table 14: Multivariate analysis of interleukin trajectory group and categorical infant outcomes 96 
Table 15: Multivariate analysis of interleukin concentrations and continuous infant outcomes .. 97 
 xi 
Table 16: Multivariate analysis of interleukin concentrations and continuous infant outcomes .. 97 
Table 17: Univariate analysis of maternal SNP and continuous infant outcomes ........................ 98 
Table 18: Univariate analysis of maternal SNP and categorical infant outcomes ...................... 112 
Table 19: Multivariate analysis of maternal IL SNP and continuous infant outcomes .............. 149 
Table 20: Multivariate analysis of maternal SNP and categorical infant outcomes ................... 167 
 xii 
LIST OF FIGURES 
 
Figure 1: Conceptual Framework ................................................................................................... 9 
Figure 2: Interleukin 4 Trajectory Groups .................................................................................. 176 
Figure 3: Interleukin 6 Trajectory Groups .................................................................................. 177 
Figure 4: Interleukin 10 Trajectory Groups ................................................................................ 178 
 xiii 
PREFACE 
Kelley would like to acknowledge her outstanding committee members, peers, and the following 
support that have helped her to complete this dissertation: Targeted Research and Academic 
Training of Nurses in Genomics (NR00975909), Corrine M. Barnes Award, International Society 
of Nurses in Genetics Research Award, Sigma Theta Tau Research Award (Pittsburgh chapter), 
Judith A. Erlen Research Award, and the Dorothy Drake Brookes Endowment Award.  
 
 
 
 
1 
1.0  PROPOSAL INTRODUCTION 
Breast milk is considered a medicine in the Neonatal Intensive Care Unit (NICU), as it provides 
immunological properties that cannot be prepared exogenously. The protective advantages of 
human milk are well established, and the American Academy of Pediatrics recommends that all 
preterm infants receive breast milk (American Academy of Pediatrics, 2012). There is great 
variability in breast milk protein composition among women who deliver at the same gestational 
age, including women who deliver premature babies. While this variation in breast milk 
composition has been established at the protein level, there is a dearth of information linking 
maternal factors and mechanism for variability in composition to level of protection offered 
through breast milk. This has a clinical application, as evidence shows that variability of immune 
components in breast milk may contribute to better infant outcomes (Fituch, Palkowetz, 
Goldman, & Schanler, 2004).  
 Variability in breast milk composition is influenced by lifestyle factors, including but not 
limited to: diet (Peng et al., 2009), drug use (Friguls et al., 2010), and exercise (M. W. Groer & 
Shelton, 2009). Another maternal variable that influences milk composition, and one that is 
easily measured, is Body Mass Index (BMI). For example, maternal BMI is positively associated 
with leptin concentration in breast milk (Fields & Demerath, 2012), and overweight mothers 
have lower levels of TGF-β2 and sCD14 levels in their breast milk when compared with normal 
weight mothers (Collado, Laitinen, Salminen, & Isolauri, 2012). The mechanism through which 
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BMI impacts breast milk composition is unknown, but one potential mechanism involves DNA 
methylation. The role of BMI on DNA methylation has been explored in areas unrelated to 
lactation. BMI was associated with methylation in the following studies: 1) higher BMIs are 
associated with hypomethylation of PBMC L1 gene among women with a history of abnormal 
PAP smears (Piyathilake, Badiga, Alvarez, Partridge, & Johanning, 2013); 2) methylation of the 
serotonin transporter gene increases by 1% per 0.33 increase in BMI (Zhao, Goldberg, & 
Vaccarino, 2013); 3) hypermethylation of Wnt signaling genes that are implicated in colorectal 
cancer (Rawson et al., 2012); and 4) hypermethylation of BRCA1 gene related to breast cancer 
(Bosviel et al., 2012). This evidence of BMI-influenced DNA methylation, combined with the 
impact of BMI on milk composition, led to our hypothesis that maternal BMI may influence 
breast milk variability through an epigenetic mechanism.  
This study further hypothesizes that DNA methylation is a driving force behind immune 
factor composition in breast milk, which is critical to improved infant outcomes. We hypothesize 
that methylation patterns of DNA from the milk fed to premature infants will be correlated with 
interleukin levels from those same milk samples, and that these methylation patterns will be 
associated with infant outcomes (fecal calprotectin levels, [a commonly used marker of 
gastrointestinal inflammation], weight gain, time to full enteral feeds, and time to discharge).  
1.1 PURPOSE AND SPECIFIC AIMS  
Because an epigenetic study is needed to better understand breast milk variability among women 
who deliver preterm, this study will:  
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1. Determine if maternal BMI influences extent of methylation of immunity genes 
(IL4, IL6, and IL10) that show variation in the parent study. 
2. Describe the relationship between extent of methylation of these immunity genes 
and interleukin levels in milk. 
3. Explore whether extent of methylation of the IL4, IL6, and IL10 genes is 
associated with infant outcomes. 
The candidate’s long term research interests involve the environmental impact on gene 
expression and how a potential variation in milk protective factors influences outcomes for 
preterm infants. This also has a clinical application in the use of donor breast milk, which is 
usually full term milk. Results from the proposed dissertation may contribute to the mechanistic 
understanding of breast milk variability and subsequent infant outcomes.   
1.2 BACKGROUND AND SIGNIFICANCE 
The United States experiences the 6th highest preterm birth rate in the world, which is the leading 
cause of death among infants less than four weeks old (World Health Organization, 2014). The 
World Health Organization promotes breastfeeding as a key strategy to prevent death and 
complications that often result from prematurity. While universal breastfeeding promotion is 
certainly saving lives in this vulnerable population, outcome disparities exist among preterm 
infants who receive breast milk. Breast milk composition varies greatly between women who 
deliver prematurely and those who deliver at term, perhaps contributing to the protective role of 
premature breast milk against NEC and other infections. Protective factors in preterm breast milk 
include an increase in immunogolobulins (Araujo et al., 2005), fatty acids (Berenhauser, Pinheiro 
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do Prado, da Silva, Gioielli, & Block, 2012), and cytokines (Ustundag et al., 2005). The 
mechanism of compositional variation between preterm and term breast milk remains unknown, 
despite increasing breastfeeding rates and preterm births. 
1.2.1 Rationale for taking an epigenetic approach 
Breast milk composition is influenced by the environment, and epigenetic changes to DNA are 
influenced by environmental conditions. Lifestyle contributors to milk variation include diet 
(Peng et al., 2009), exercise (M. W. Groer & Shelton, 2009), and smoking (Etem Piskin, Nur 
Karavar, Arasli, & Ermis, 2012; Szlagatys-Sidorkiewicz, Martysiak-Zurowska, Krzykowski, 
Zagierski, & Kaminska, 2013; Szlagatys-Sidorkiewicz, Wos, et al., 2013), among others. Despite 
this environmental impact on milk composition, the molecular mechanism is not understood and 
it seems the environmental component of epigenetics is an ideal approach with which to begin. 
Breast milk is highly variable among women, even those who deliver at the same gestational age. 
Protective components found in variable amounts that influence infant outcomes include: retinol 
(Ribeiro, Araujo, Pereira, & Dimenstein, 2007), IgA (Ballabio et al., 2007; Takahashi et al., 
2002), and cytokines (Ustundag et al., 2005). This milk disparity may explain why some infants, 
despite receiving breast milk, develop complications while in the NICU. Epigenetic influences, 
including diet, influence breast milk composition (Kelishadi et al., 2012; Peng et al., 2009), and 
may help explain breast milk variability.  
Epigenomic approaches have led to a better understanding of many complex diseases, 
including: oncology, cardiovascular disease and mental health disorders (Ordovas & Smith, 
2010), (Read, Bentall, & Fosse, 2009; Vineis et al., 2011). While methylation analyses of term 
breast milk have been applied to understand breast cancer (Browne et al., 2011; Qin et al., 2012; 
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Wong et al., 2010), none of these milk methylation studies examined immune-related genes, nor 
did they examine milk with respect to maternal or infant health. Few genetic studies have been 
conducted to better understand the dynamic immunologic nature of human milk, and none have 
taken an epigenetic approach, despite the many environmental factors known to influence milk. 
A few animal studies have examined methylation of DNA in breast milk, and have confirmed the 
impact of methylation on gene expression in the lactating mammary gland in the mouse, cow and 
rat (Platenburg et al., 1996). Their results found that methylation variation exists among lactating 
animals. This study also noted that lactoferrin cDNA, a protein found in breast milk that protects 
against infection (Hadsell et al., 2007; Venkatesh & Abrams, 2009), showed variable expression 
due to methylation status.  
Preterm infants who receive breast milk experience fewer complications than those who 
receive formula, though the disparity among breastfed infants who develop complications is not 
well established. It seems there is a link between milk composition and infant outcomes, as the 
milk fed to infants who present with “failure to thrive” resembles weaning milk (Motil, Sheng, & 
Montandon, 1994). Although this was a case study, this suggests that the contents in this milk 
may fail to meet the needs of a growing infant and may also explain some of the disparities seen 
among breastfed infants. For example, long chain polyunsaturated fatty acids (LCPUFA) are 
present in highly variable amounts in breast milk, and are heavily influenced by maternal 
environment and diet. Preterm infants with high levels of arachidonic acid (a major type of 
LCPUFA) experience improved growth outcomes up to one year (Carlson, Werkman, Peeples, 
Cooke, & Tolley, 1993). Perhaps the most relevant study which addresses specific milk 
components and subsequent outcomes revealed that IL-10, a regulatory cytokine examined in the 
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proposed study, was undetectable in milk fed to preterm infants who developed NEC, but was 
detectable in the milk fed to preterm infants who did not develop NEC (Fituch et al., 2004).  
1.2.2 Rationale for examining BMI and its impact on methylation of immunity-related 
genes in breast milk.  
Breast milk from women with higher BMIs has lower milk protein concentration (Bachour, 
Yafawi, Jaber, Choueiri, & Abdel-Razzak, 2012), higher fat content (Barbosa, Butte, 
Villalpando, Wong, & Smith, 1997; Nikniaz, Mahdavi, Arefhoesseini, & Sowti Khiabani, 2009; 
Rocquelin, 1998), and higher linoleic acid content (Villalpando et al., 2001). Milk samples taken 
from mothers at one and six months postpartum and were measured for immunological 
components (TGF-β2, soluble CD14 (sCD14), cytokines, and microbiota (Collado et al., 2012). 
Milk from overweight mothers contained less TGF-β2 and sCD14 when compared with normal 
weight mothers. This is significant, since TGF-β2 is a pro-immune regulatory type of cytokine 
and sCD14 is involved in the activation of the innate immune response. While TGF-β2 and 
sCD14 are present at high amounts in colostrum, they decrease significantly by the time mature 
milk is produced and failure to follow this pattern is associated with atopic dermatitis and asthma 
(Snijders et al., 2010). Additionally, overweight mothers have higher milk levels of Staphyloccus 
and lower milk levels of Bifidobacterium when compared with normal weight mothers, which 
indicates an imbalance of microbiotia in the breast milk from overweight mothers. These studies, 
especially those examining the immunological profile of breast milk as it relates to BMi, 
suggests that not all milk is created equal, and that BMI may be contributing to this disparity. 
 Leptin, known as the ‘hunger hormone’, is present in elevated amounts in the milk of 
women with higher BMIs (Fields & Demerath, 2012). This is important, since this relationship 
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affects the infant, as higher leptin levels in milk is negatively associated with infant weight gain 
(Fields & Demerath, 2012; Miralles, Sanchez, Palou, & Pico, 2006; Schuster, Hechler, Gebauer, 
Kiess, & Kratzsch, 2011). IL-6, a cytokine examined in the proposed study, increases leptin 
levels (Trujillo et al., 2004). Weight gain in the NICU is an important indicator of infant health. 
If BMI impacts infant weight gain through leptin level intake from breast milk, it is crucial to 
understand how BMI also impacts immunological components in breast milk that may 
predispose an infant to infection or complications. 
Epigenetic studies have established the influence of BMI on methylation of Wnt 
signaling genes (Rawson et al., 2012), BRCA1 gene (Bosviel et al., 2012), and PBMCL1 gene 
(Piyathilake et al., 2013). There also appears to be a dose response to BMI, as Zhao (2013) 
revealed a 1% methylation increase for every 0.33 increase in BMI (Zhao et al., 2013). The 
potential link between BMI and methylation of immunity genes and subsequent milk 
composition that may predispose or protect a preterm infant will be evaluated in the proposed 
study. If this link is established, improved education efforts could target mothers with higher 
BMIs to gain an appropriate amount of weight during pregnancy for their health and to optimize 
their milk 
1.2.3 Rationale for examining fecal calprotectin as a biomarker for infant outcome 
Fecal calprotectin has been used as a biomarker for inflammation within the preterm infant 
population, as calprotectin is an accurate indicator of neutrophil migration toward the GI tract 
(Kapel et al., 2010; Kapel et al., 2005). Preterm infants with NEC symptoms experience a 
transient rise in fecal calprotectin when compared with preterm infants of the same gestational 
age without NEC (Campeotto et al., 2007). High fecal calprotectin levels suggest increased 
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granulocytes in the intestinal lumen from high permeability and/or lymphoid tissue development. 
Kapel suggests that environmental factors, including feeding, should be evaluated, as they could 
individually impact this process (Kapel et al., 2010). This continuous variable reflects the 
inflammatory state of the environment that is being directly exposed to the breast milk being 
studied. Clinical outcomes will also be available, including: weight gain, time to full enteral 
feeds, and time to discharge. 
1.2.4 Genes selected for investigation 
Breast milk is considered medicine in the NICU, as the immunological components provide 
infants with protection that their immature immune systems are incapable of producing. 
Cytokines are an integral component of breast milk immunobiology and provide preterm infants 
with protection from infecting microbes. Interleukins are present in variable amounts and milk 
concentration of these cytokines is associated with infant outcomes (Fields & Demerath, 2012; 
Fituch et al., 2004). Il-4, present in breast milk, responds to Antigen Presenting Cells (APC) by 
inducing lymphocytic antibody production. Il-4 and Il-10 (a down-regulating cytokine), are 
produced in low levels during early infancy, but are present in breast milk. Il-6, a pro-
inflammatory cytokine, is inefficiently regulated in preterm infants (Currie et al., 2011), but is 
present in human milk. Aim 2 will focus on three of these cytokine genes (Il-4, Il-6, IL-10), 
which were found by the parent study to be present in variable amounts. 
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1.2.5 Conceptual Framework  
The following figure illustrates the conceptual framework that guided this study, which 
examined: 1) the association between maternal BMI and methylation of immunity genes, 2) 
whether methylation is correlate with breast milk cytokine concentration and 3) the relationship 
between IL gene methylation and infant outcomes.  
 
 
 
 
 
 
 
Figure 1: Conceptual Framework 
1.2.6 Significance and Innovation 
The concept that BMI is related to variability in breast milk composition is established, though 
the mechanism for this is not understood; therefore this Aim 1 will examine the impact of BMI 
on DNA methylation extracted from milk. The mechanism for breast milk variability that exists 
between normal and high BMI mothers has never been explored. Understanding the biological 
pathways in which BMI influences breast milk could lead to optimization strategies of human 
milk in the NICU. The potential impact of BMI on breast milk disparity could also inform 
preconception and prenatal education surrounding healthy weight gain during pregnancy. This 
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will be the first epigenetic study to evaluate the impact of maternal BMI on the extent of 
methylation from DNA in breast milk.  
Exploratory Aim 2 will explore whether the extent of DNA methylation is correlated with 
the concentration of immunological components in breast milk known to be important to 
neonatal outcomes. Findings may provide evidence to support that breast milk is not a uniform 
substance and reveal mechanisms surrounding disparities that could be used for targets to 
optimize human milk fed to all infants in the NICU. While epigenetic studies have been applied 
to breast milk, they were examining methylation of cancer associated genes, and none have used 
preterm milk. Milk expressed by a woman who delivers preterm is compositionally very 
different than term milk, particularly among immunological components. 
Milk differences between women who deliver preterm may explain some of the disparity 
seen among infants who develop necrotizing enterocolitis (NEC), despite receiving breast milk. 
Preterm infants born <1500 grams at birth are more susceptible to infections, particularly 
necrotizing enterocolitis, which costs an additional $6.5 million to treat per year (Bisquera, 
Cooper, & Berseth, 2002). Fituch (2004) uncovered a disparity in outcomes associated with IL-
10 concentration in breastmilk fed to preterm infants. IL-10 was undetectable in the milk of 
women whose infants had NEC, while infants who did not develop NEC were fed milk with 
measurable IL-10 levels (Fituch et al., 2004). Exploratory Aim 3 will link extent of DNA 
methylation as a mechanism to explain variability in milk composition with a subsequent link to 
infant outcomes would aid the research community in their efforts to optimize feedings and 
hence outcomes of infants in the NICU. This study is the first to conduct methylation analyses of 
immunity genes from breast milk. Methylation analysis of three interleukin genes will provide 
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valuable information on the variability of protection offered through breast milk that is 
administered to preterm infants. 
1.2.7 Summary 
Despite evidence that breast milk is variable between women, this evidence appears to be 
ignored in clinical practice, as breast milk is administered uniformly. Additionally, the 
mechanism for breast milk variability is poorly understood, despite evidence that milk variability 
may contribute to infant outcomes. The proposed study challenges the clinical assumption that 
breast milk is a uniform substance by examining the variability of DNA methylation levels from 
human milk and linking it with maternal factors and infant outcomes. Methylation variability, 
which may contribute to breast milk differences between women, has never been analyzed with 
respect to infant outcomes. The ability to differentiate methylation profiles of milk that are more 
protective may aid in better understanding the mechanism for milk variability and subsequent 
infant outcomes. The knowledge gained from this project has a potential future application in 
milk optimization strategies for preterm infants that could prevent NICU complications and 
subsequently improve child health. 
1.3 PRELIMINARY STUDIES 
The following table lists several milestones that have been achieved since entrance into the BSN 
to PhD program in May 2009. All milestones listed support the feasibility and scientific merit of 
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the proposed dissertation project titled “Breast Milk is not a Uniform Substance: Epigenetic 
Mechanisms”.  
Table 1: Milestones 
Milestone Date 
Corrine M. Barnes Award September 2010 
September 2011 
 
Sigma Theta Tau International Honor Society of Nursing, Eta Chapter 
Research Award 
 
May 2012 
University of Pittsburgh IRB Approval: pilot study “Epigenomics of 
Ductal Cells from Breastmilk” (expedited review, PRO11050673) 
 
April 2012 
University of Pittsburgh IRB Approval: “Breastmilk is not a Uniform 
Substance: Epigenetic Mechanisms” (exempt review, PRO13040181)  
 
April 2013 
Material Transfer Agreement with USF obtained July 2013 
  
Comprehensive Exam and Overview  
 
July 2013 
Judith A. Erlen Student Research Award 
 
September 2013 
International Society of Nurses in Genetics, Research Award 
 
October 2013 
Breast milk DNA extraction complete May 2014 
 
1.4 RESEARCH DESIGN AND METHODS 
This ancillary epigenetic study will utilize a retrospective, observational design that focuses on 
methylation patterns of three cytokine genes (IL-4, IL-6 and IL-10) from DNA in breast milk 
expressed by mothers who deliver preterm infants. This proposed study will take the efficient 
approach of conducting an ancillary study to an ongoing clinically-relevant NINR supported 
project titled “The Association between Preterm Milk Immunobiology and Infant Health” 
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(referred to as the parent study). Dr. Maureen Groer is the PI of the parent project that will 
provide banked breast milk samples, demographic and clinical data, fecal calprotectin level 
measurements and milk cytokine concentrations. Permission to access these samples was granted 
by the PI of the parent study  and IRB approval was obtained for this dissertation study. The 
timeline for this study is included below.  
Table 2: Study timeline 
ADJUSTED 
TIMETABLE 
FOR PROJECT: 
Year 1 Year 2 Year 3 Year 4 Year 5 
Coursework      
Summer Genetics 
Institute 
      
IRB approval – pilot 
study 
      
DNA extraction from 
breast milk (pilot 
study) 
      
IRB approval – 
dissertation 
      
DNA extraction from 
breast milk 
(dissertation) 
       
Collection of 
methylation data 
       
Analysis of data        
Preparation of 
manuscripts 
       
Defend dissertation         
 
1.4.1 Setting and Sample 
“The Association between Preterm Milk Immunobiology and Infant Health”, which was 
conducted in Tampa, FL, examined: 1) the relationship between milk immunobiology and infant 
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health with attention made to specific protein components in human milk that are most 
beneficial, and 2) the relationship of preterm infant outcomes to total volume of human milk 
received in the NICU. The breast milk collected by the parent study, the same milk that will be 
provided for this proposed study, is a pooled weekly aliquot of the milk ultimately fed to preterm 
infants over a six week NICU stay (up to six samples per infant). The inclusion criteria for the 
parent study require that women deliver their infant at the Tampa General Hospital. Infants must 
weigh <1500 grams at birth and be admitted to the NICU. Exclusion criteria include: mothers 
with HIV, infants with major congenital anomalies, and moribund infants. This proposed 
ancillary study does not have any additional inclusion or exclusion criteria. 
1.4.1.1 Breast milk samples and DNA extraction 
All breast milk samples, which are required to complete each aim, were/will be collected as part 
of the parent study. Breast milk aliquots from each feeding are collected for up to six weeks on 
infants who were born weighing less than 1500 grams. Breast milk aliquots from each feeding 
are pooled weekly. All milk is collected and stored frozen until brought to the laboratory twice 
each week.  The milk is pooled each week for a total of six maximum number of breast milk 
samples per subject, centrifuged, defatted, and filtered, and the whey is frozen at -80 C. The 
whey portion from this previously frozen milk sample contains cell-free DNA, and this will be 
extracted using the QIAmp DNA extraction minikit from Qiagen Corp. Extracted DNA will be 
stored in 1X TE buffer at 4°C.  
1.4.1.2 Data available for this project  
Demographic data includes: education, income, race, marital status and employment status. 
Maternal information includes medical history, mental health history, obstetrical history, and 
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most recent pregnancy information including labor and delivery. Lifestyle data includes: 
smoking status, drug, and alcohol use. We will also have data related to the volume of breast 
milk received by each infant. Infant data includes: SNAP-2 (severity of illness) scores, gender, 
gestational age, ethnicity, Apgar scores, birthweight, length of stay, infections, NEC, blood 
transfusions, oxygen requirements, death, and time to full feeds. Table 3 (below) illustrates aim-
specific data available.  
Table 3: Aim-specific available data 
Aim Data available 
1 Prepregnancy BMI 
2 Cytokine concentrations using a Luminex platform 
3 Fecal calprotectin, weight gain, time to full enteral feeds, and time to discharge 
 
1.4.1.3 Methylation quality assessment and data collection 
We will conduct bisfulfite conversion of the DNA followed by pyrosequencing of the promoter 
regions of IL-4, IL-6, and IL-10 genes to determine the methylation status of each gene. Epitect 
Bisulfite Kits (Qiagen Corp) will be used to convert unmethylated cytosines to uracils. This kit 
allows for conversion of previously frozen samples that have limited DNA available. Each 
sample (maximum of six pools of weekly collected breast milk per subject) will be assessed for 
each gene. Two internal controls will also be converted and used to normalize the data and assist 
in data interpretation. PyroMark PCR Kit (Qiagen Corp) will be used to generate the gene 
specific fragment for sequencing as well as perform the sequencing reaction for evaluation by 
pyrosequencing. Data will be double called by the student as well as a blinded technician in Dr. 
16 
Conley’s laboratory, results compared, and discrepancies evaluated using raw data or repeating 
data collection. Samples with incomplete bisulfite conversion or poor sequencing success will 
not pass quality checks and will be eliminated from analyses. 
1.4.2 Analysis 
1.4.2.1 Sample size justification 
Our primary aim (Aim 1) will be sufficiently powered. Our sample size of 100 achieves 80% 
power to detect a small to moderate effect size of 0.28 with a significance level of 0.05 for this 
aim. Our other aims are exploratory, and therefore may not be adequately powered, but will 
provide valuable pilot data to inform future studies. 
1.4.2.2 Preliminary analysis 
Univariate outliers will be assessed three ways: 1) frequency table evaluation (categorical/ordinal 
variables) and 2) graphical methods including: histograms, box plots, normal probability plots, 
detrended normal probability plots (continuous variables) and 3) z-scores will be evaluated for 
large standardized values (continuous variables). Potential multivariate outliers will be assessed 
three ways: 1) scatterplots, 2) calculating a critical value for Mahalanobis Distance and 3) 
leverage values >0.05.  
Should potential confounders be identified during the preliminary analysis, they will be 
considered when addressing all aims. Confounders that will be considered include but are not 
limited to: maternal age, maternal infection, gestational age at delivery and maternal 
smoking/drug use.  
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 Missing data will be assessed for both amount (percentage) and pattern. The pattern of 
missing data will be assessed to determine if missing data is random or nonrandom. At each 
time point (1-6 weeks), we will generate missing value indicators; if breast milk data is 
missing, we will dummy code it as “1” (otherwise it will be coded as 0). We will develop a 
contingency table to describe the amount of missing data across time by subject ID. SPSS 
Missing Values Analysis (MVA) will be used to highlight patterns of missing data. To test 
whether missingness is random, t-tests will be performed on the variable(s) of interest with 
percent of missing data. If only a few cases are missing, and they are missing at random, we 
will consider deleting the case(s). Another option, multiple imputation, does not assume 
randomness of missing data. If the missing data is not randomly distributed, we will 
consider multiple imputation to estimate missing data. PROC TRAJ model in SAS will be 
used with missing independent and dependent variable values at one or more follow-up time 
points. PROC TRAJ requires that missing data be missing completely at random (Arrandale, 
2006) therefore, if there is a pattern to the missingness we will implement multiple imputation. 
Normality of the distribution for each variable will be assessed graphically and 
statistically. The censored normal model will be used to analyze the trajectory groups for 
methylation, interleukin concentration, and outcomes. Values of skewness and kurtosis (peak) 
will be determined, and values of both should be close to zero and tests should be nonsignificant. 
The distribution will also be evaluated graphically at each time point, since underestimates of 
variance associated with positive kurtosis disappear with samples of ≥ 100 samples. IBM SPSS 
FREQUENCIES will be used to evaluate skewness and kurtosis. Frequency histograms will be 
used to graphically assess that the normality assumption is met. Additionally, normal probability 
plots and detrended expected normal probability plots will be evaluated to compare deviations 
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from normality. These plots are available in the IBM SPSS MANOVA. Residual plots will also 
be evaluated for normality and should be independently distributed. This diagnostic technique is 
available through IBM SPSS REGRESSION. If the normality assumption is met among the 
residuals, then both the normal probability plot and detrended normal probability plot will look 
the same. Lastly, the Shapiro-Wilks test of normality will be used to statistically examine 
normality. If the p-value is >0.05, we will conclude that the data is normally distributed.  
Linearity will be assessed by looking at the residual plots of the dependent variables for 
each aim. Nonlinearity will be diagnosed when most of the residuals are above the zero line at 
some values and below the zero line at other predicted value. Ideally, the scatterplot will be oval-
shaped, which would indicate normal distribution and linearity. Bivariate scatterplots are 
available through the IBM SPSS GRAPH function. These scatterplots will also be used to assess 
independence. Ungrouped data will be used in this analysis; therefore, homoscedasticity of the 
data should show variability in scores that is approximately the same at all values of another 
variable. Homoscedasticity will be screened using bivariate scatterplots between the continuous 
variables.  
Data transformations will be considered as a remedial measure in the following 
circumstances: 1) non-normality, 2) nonlinearity, 3) heteroscedasticity. Additionally, 
transformations with higher order effects will be considered (nonlinearity), as will weighted 
transformations (heteroscedasticity). Transformations will be checked after application to ensure 
that the appropriate transformation was applied. 
1.4.2.3 Analyses 
Trajectory modeling will be used to examine all aims. This approach is based on a 
semiparametric, group-based modeling strategy that is a mixture of probability distributions 
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specified to describe the data (Jones, 2001). Trajectories of methylation changes to DNA in 
breast milk during the first six weeks postpartum will be examined using the PROC TRAJ 
procedure in SAS. This procedure allows for estimation of multiple groups within a population, 
as opposed to a traditional regression that models only one mean within the population 
(Arrandale, 2006). Ultimately, PROC TRAJ allows for identification of distinct subgroup 
memberships within a population and estimates a regression model for each identified subgroup.  
Using contingency tables and chi-square test of independence, we will test if the independent 
variable is associated with the dependent variable for each aim. The table below outlines how 
each aim’s independent and dependent variables will be subjected to trajectory analyses:  
Table 4: Aim specific analyses 
Aim Independent Variable(s) Dependent Variables 
Determine if maternal BMI 
influences extent of methylation of 
immunity genes 
Maternal BMI Methylation trajectory group 
for each gene (IL-4, IL-6, IL-
10) 
Describe the relationship between extent of 
methylation of IL-4, IL-6 and IL-10 genes 
and interleukin concentration in breast milk 
Methylation trajectory group of 
each gene (IL-4, IL-6, IL-10) 
Milk concentration of IL-4, IL-
6 and IL-10  
Explore if methylation of immunity genes is 
associated with infant outcomes 
Methylation trajectory group of 
each gene (IL-4, IL-6, IL-10) 
NICU outcomes and fecal 
calprotectin 
 
As suggested by Nagin (2005), we will set all group orders to second order when fitting 
the maximum number of groups to our a priori group number estimate (Nagin, 2005). We will 
decide on the maximum number of trajectory groups based on prior knowledge. A Bayesian 
Information Criteria (BIC) will be compared between the models to determine the appropriate 
number of groups and trajectory weights. The change in BIC scores between the two models is a 
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measure of the evidence against the null model, which is always simpler (Arrandale, 2006). The 
best fit model will be the one with the lowest BIC score. 
 After the number of groups has been determined, trajectory shapes for each group will be 
evaluated in a step-wise manner. PROC TRAJ can model up to a fourth order polynomial of both 
linear and non-linear trajectories (Arrandale, 2006). We will evaluate shapes by comparing the 
BIC change, since prior knowledge is limited and all patients in this study are expressing preterm 
milk.    
 We will generate graphic displays of the fitted model groups from the estimated group 
membership probabilities using the TRAJ PLOT command in SAS. We also intend to use the 
average posterior probabilities to explore between group differences in covariates not in the 
model. The posterior probability values measure the probability that a subject with a specific 
methylation profile belongs to a specific trajectory group. Individuals are assigned to a group 
based on their highest posterior group probability. 
 Output from the PROC TRAJ command includes: 1) group parameter estimates, 2) group 
membership probabilities, and 3) model fit statistics. Parameter estimates will be used to 
construct group regression equations and a system of equations to describe the population. We 
will be able to make inferences about group differences by using the relative difference between 
estimates for the same covariates. 
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1.5 POTENTIAL LIMITATIONS OF PROPOSED PROCEDURES AND 
ALTERNATIVE APPROACHES TO ACHIEVE THESE AIMS 
While conducting this ancillary study is efficient and cost conscience, using data and samples 
from a parent study poses some limitations: 1) In the event that we fail to find distinct 
methylation patterns over time and/or at least 5% of the sample is not represented in each 
trajectory group, we will use traditional linear regression analyses with a time-dependent 
covariate to examine associations. Residual analysis will be performed for all models to identify 
model misspecifications or influential observations; 2) Milk samples are pooled weekly, and we 
will not be able to distinguish any daily and diurnal immunological changes in milk. Breast milk 
gene expression changes throughout the day (Maningat et al., 2009), and milk composition varies 
throughout the lactation period. We do not believe that this will compromise our ability to 
answer our research questions, since the pooled breastmilk samples will reflect the weekly 
immunological exposure the infant has received and these are the same pooled samples used for 
the parent study that identified differences in cytokine protein levels; 3) Maternal BMI for the 
parent study is self-reported, and this could introduce increased error. We will consider grouping 
subjects into BMI category (underweight, normal, overweight, obese), as this may be more 
reliable than using BMI as a continuous variable. An additional limitation is that BMI for this 
project will reflect pre-pregnancy BMI that is available through the parent study. Design of 
future studies will benefit from these data but will also attempt to collect BMI across the data 
collection timepoints; 4) The parent study does not exclude examination of donor milk samples, 
which is overwhelmingly term milk (Dempsey & Miletin, 2010), and pooled from multiple 
donors. This may influence methylation results, since preterm breast milk is very different from 
term breast milk, particularly among immunological components. Currently, of the 65 recruited 
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subjects, only eight mothers have required donor milk. For this ancillary study we may exclude 
evaluation of the donor samples or, if enough are available, we may analyze them separately; 5) 
Fecal calprotectin, while a common biomarker of infant gut inflammation, may not provide a 
global view of infant outcomes. The infants in this study are receiving breast milk, and are 
therefore receiving protection from common neonatal complications. With a sample size of 100, 
it is unlikely that we will have enough “sick” babies to test significantly (it is noteworthy to 
mention that there has been only one NEC case, to date). To further address infant outcomes we 
are including weight gain, time to full enteral feeds, and time to discharge as additional infant 
outcomes. 6) The whey portion of milk is being used from an existing study. This milk, which 
was frozen, will contain DNA from cells that lysed in the freezing process. It will therefore be 
impossible to determine the cell type that contributed the DNA for this study. This is not a big 
limitation as the DNA evaluated in this study will represent the combined DNA from the sample; 
however, future studies that allow for the possibility of isolating cells prior to DNA extraction 
would add value to the interpretation of our findings. 
 
1.6 HAZARDOUS MATERIALS AND PROCEDURES 
Although human milk is not a biohazard, the student will be exposed to bodily fluids and 
universal precautions will be implemented at all times when working with breastmilk. The 
student has received blood borne pathogen training and will complete chemical hygiene training 
prior to initiating laboratory experiments. All experiments will be conducted in an appropriately 
equipped laboratory. 
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1.7 RESEARCH PARTICIPANT RISK AND PROTECTION 
1.7.1 Human subjects 
IRB approval has been obtained for the proposed study (IRB PRO11050673). The specimens 
that will be utilized for the proposed study have been collected, or are currently being collected, 
for the ongoing trial Breast milk and the Health of Infants Study. No further involvement from 
the participants will occur under the proposed research study.  
Inclusion criteria for the parent study require the live birth of an infant who is admitted to 
the NICU at Tampa General Hospital and who weighs less than 1500 grams at birth. Mothers 
with HIV, and infants with major congenital anomalies, and moribund infants are excluded. The 
parent study collects 0.5 mL of breast milk from each feeding, which is aliquoted and pooled 
weekly.  The proposed study will investigate DNA methylation from cells in breast milk 
collected as part of this study.  
1.7.2 Sources of materials 
All of the DNA samples (extracted from breast milk) are available from the “Breastmilk and the 
Health of Infants” study. In addition, clinical data and protein levels from the study are housed in 
secure databases. Neonatal outcome data, including fecal calprotectin levels, are collected or 
measured as part of the parent study and are available to the student. The parent study’s IRB has 
provided permission to share breast milk samples and data to conduct the proposed study. The 
genetic and clinical data that is obtained will be used solely for research purposes and will be 
continuously safeguarded by the student and her advisor. For the proposed study, the banked 
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breast milk samples obtained from the “Breast milk and the Health of Infants” study will be used 
to collect DNA methylation data. 
1.7.3 Potential risks, benefits, and protection against risks 
All subjects to be included in the proposed research study have consented to the utilization of 
their breast milk for research purposes. In addition, all data generated form the proposed study 
would be reported as aggregate data and the results will not be revealed to participants. 
Furthermore, data generated from the proposed research will be stored in a database secured on a 
password-protected computer. While breach of confidentiality is of great concern with genetic 
studies, the above precautions mitigate this risk. In reference to potential benefits, there is no 
direct benefit to the research subjects; however the results generated may reveal a predisposition 
or protection from the development of NICU complications, which could ultimately direct future 
scientific inquiry and impact clinical practice by suggesting novel interventions and therapies. 
1.7.4 Data and safety monitoring plan 
This is not a clinical trial; however we do have a plan to monitor data collection and protection. 
All data obtained will be used for research purposes only and will be safeguarded by the student 
and her advisor. Data collection and analyses will be performed using a unique numerical 
identifier assigned to each specimen from the “Breast milk and the Health of Infants” study. Data 
collected will be entered using these unique numerical identifiers into a password-protected 
computer. Regular meetings will allow for the discussion of project progress and data monitoring 
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to assure that data collection and the analysis are conducted in a manner that maintains the 
anonymity of the samples and data.  
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2.0  SUMMARY OF STUDY 
The purpose of this dissertation research was to examine: 1) the relationship between maternal 
BMI and methylation of interleukin genes, 2) whether methylation drives interleukin 
concentration, and 3) if methylation of interleukin genes is associated with neonatal outcomes. 
One article written during the course of this dissertation is provided in Appendix F. Published in 
Breastfeeding Medicine, this article highlights the use of breast milk in genetic/genomic studies. 
All of the studies included in this review extracted maternal DNA or RNA from breast milk, and 
focused on the uses of breast milk for genetic studies. This article highlights that few studies 
have examined breast milk with an epigenetic approach, and the few that have do not explore 
milk properties with respect to infant outcomes. 
 
2.1 PROPOSAL CHANGES  
Several changes were made to the approved dissertation proposal. Described below are the steps 
taken to assess primer validity, DNA integrity, and modifications to the proposal to reflect the 
limited utility of the DNA. Specific modifications and the rationale for these changes are 
highlighted below.  
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2.1.1 MOLECULAR APPROACH TO EXAMINE INTERLEUKIN VARIABILITY 
CpG islands of interest were originally identified in the literature for IL4 (Kwon, Kim, Lee, Oh, 
& Choi, 2008), IL6 (Nile, Read, Akil, Duff, & Wilson, 2008), and IL10 (Fu et al., 2011). Primers 
were designed for use with the PyroMark CpG Assays for methylation array validation (Qiagen). 
DNA extraction was performed on the whey portion of preterm breast milk using the QIAGEN 
QIAamp® DNA Mini Kits (QIAGEN, Valencia, CA). To assess DNA yield, both TaqMan® 
allelic discrimination (Applied Biosystems Inc., Carlsbad, CA) and PCR was used. Following 
confirmed DNA extraction, DNA was converted using the Epitect Bisulfite Kit (QIAGEN, 
Valencia, CA). Following bisulfite conversion, the three representative IL promoter regions were 
subjected to amplification using Pyromark PCR kits. Less than 10% of the samples were 
successfully amplified for pyrosequencing. Described below are the steps taken to troubleshoot 
the amplification for each of the three targeted areas: 
1. Breast milk DNA concentration is variable, so DNA volume in the PCR master 
mix was added at variable amounts (from 1.0 µL to 2.2 µL).  
2. Initial PCR amplification using the recommended annealing temperatures yielded 
no PCR product. We conducted a temperature gradient for each gene, and 
discovered that annealing temperatures required for amplification were variable: 
IL4 at 49°C, IL6 at 60°C, and IL10 at 56°C. Unfortunately, we were unable to 
obtain at least 90% PCR product for each plate, despite using modified annealing 
temperatures. 
3. We performed volume gradients on the PCR products when running the gel (1 µL 
to 14 µL), but this did not yield a noticeable difference.  
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4. The number of cycles was increased from 45 to 60, and this provided more PCR 
products. We used 60 cycles for all subsequent PCR reactions. 
Despite these PCR protocol modifications, we were unable to obtain any more than 10% 
success per run. The issue was not with the bisulfite conversions or the CpG island 
amplifications with the pyromark assays given that the lab control DNAs and 
methylated/unmethylated controls were successfully amplified.  
2.1.2 CIDR amplifications  
The DNA extracted from breast milk samples was sent to the Center for Inherited Disease 
Research (CIDR) (Johns Hopkins University, Baltimore, MD). CIDR was to do the 
pyrosequencing after we had completed the bisulfite conversions and amplifications of the CpG 
islands; however because we were unable to accomplish this we decided to have CIDR give the 
entire process a try and sent them unmodified DNA samples to work with. CIDR had the exact 
same experience that we had in-house. They were able to bisulfite convert and amplify a subset 
of samples but the majority of them were not amplifiable. CIDR then further assessed the DNA 
integrity by subjecting thirty-nine samples that represented different subjects’ milk to gDNA 
analysis using a fragment analyzer. None of the samples subjected to the fragment analyzer with 
peaks (1K-2K range, 4-14 ng/uL) amplified, despite successful amplification of the methylated 
controls. The fact that our in-house attempts failed, CIDRs attempts failed, and the DNA was 
noted to not be of high enough quality to proceed with evaluation of methylation status of these 
genes, we decided to attempt a polymorphism based approach to assess the variability in these 
genes. 
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2.1.3 Polymorphism based assessments of the IL4, IL6, and IL10 genes 
Fortunately the DNA extracted from whey was of high enough quality to allow for 
polymorphism based data collection using TaqMan allelic discrimination for data collection.  
This meant that the genes could be assessed for this project, just not from a DNA methylation 
point of view, but from a polymorphism point of views. Data collection was successfully 
conducted on the same breast milk samples to genotype seven functional promoter SNPs of IL4, 
IL6, and IL10. It is well documented that interleukin variability is at least partially attributed to 
SNPs (Nguyen et al., 2004; Qaddourah et al., 2014; Velez, Fortunato, Williams, & Menon, 
2008); however, this relationship has never been explored in breast milk. It was decided that 
functional SNPs in the promoter regions of Il4, IL6, and IL10 were another reasonable way to 
examine variable interleukin concentrations in breast milk.  
Genotype data was collected at the University of Pittsburgh School of Nursing using 
TaqMan allele discrimination assays to genotype the seven functional promoter polymorphisms 
of IL4 (rs2070874, rs2243250), IL6 (rs1800795, rs1800796), and IL10 (rs1800871, rs1800872, 
rs1800896). We performed TaqMan allelic discrimination with the ABI Prism 7000 Sequence 
Detection System and SDS software v1.2.3 (Applied Biosystems Inc., Carlsbad, CA). Negative 
controls were included and a portion of the samples were repeated to confirm that they 
repeatedly discriminated into the same genotype. The following cycling conditions were used: 1) 
Activation at 95°C for 10 minutes, 2) denaturation at 95°C for 15 seconds, 3) anneal/extend at 
58°C for 1:30 minutes, 4) go to step 2 50 times, and 5) hold at 10°C forever. We were able to 
successfully amplify and genotype 100% of the breast milk samples (n=63).  
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2.1.4 Specific Aims 
Due to the tissue available (whey milk), and the scientific reasoning behind examining IL SNPs 
and their relationship to milk concentrations, it was decided that we would explore how maternal 
SNPs impact milk IL concentration, and subsequent infant outcomes. Trajectory analyses would 
remain, but at a protein level. The BMI aim was excluded because genotypes are not impacted by 
lifestyle factors; however, given the impact of BMI on milk composition, this was included as a 
covariate. A new set of Specific Aims were constructed to reflect a genotype approach rather 
than a methylation analysis:  
Primary Aim 1: Examine the relationship between maternal IL SNPs and cross-sectional 
breast milk concentrations. Functional SNPs in the promoter region of IL4, IL6, and IL10 will 
be genotyped and we will determine if they predict milk interleukin concentration during the first 
three weeks postpartum.  
Specific Aim 2: Describe the trajectories of breast milk IL concentration change over time. 
Trajectory analysis will be used to examine IL4, IL6, and IL10 milk concentration changes over 
the first three weeks postpartum. 
Exploratory Specific Aim 3: Explore whether maternal IL genotypes predict milk IL 
trajectory groups. Data from Aim 2 will be used in a univariate analysis to explore whether 
maternal IL genotype is associated with IL changes.  
Specific Aim 4: Examine if cross-sectional IL levels and/or IL trajectories predict infant 
outcomes. IL levels from significant SNP/IL associations will be examined for relationships to 
infant outcomes, including: SNAPPEII scores, length of stay, weight at 6 weeks, days on 
oxygen, fecal calprotectin levels, necrotizing enterocolitis, sepsis, retinopathy of prematurity, 
bronchopulmonary dysplasia, feeding intolerance, and blood transfusions. 
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Exploratory Aim 5: Explore if there is a relationship between maternal IL SNPs and infant 
outcomes. Controlling for gestational age at delivery and ratio of human milk to total milk, the 
association between maternal IL SNPs and infant outcomes (described above) will be analyzed.  
2.1.5 Discussion 
At the beginning of the study, we did not anticipate poor DNA quality. We assumed that DNA 
from lysed cells would be available for pyrosequencing. It seems that the available DNA in 
breast milk whey is not appropriate for examining methylation using pyrosequencing. Despite 
this, there is enough high quality DNA to successfully genotype and this was done in all of the 
available breast milk samples. The specific aims of this dissertation were changed to reflect the 
examination of IL genotypes rather than IL methylation.  
 
2.2 STUDY STRENGTHS AND LIMITATIONS 
There were several limitations associated with this dissertation project. The sample size was 
small, and this was further decreased when we performed race-specific analyses. Trajectory 
analysis includes, ideally, 100 subjects with at least three time points, and we did not reach this 
recommended sample size. Hardy-Weinburg Equilibrium was violated for three of the SNPs 
evaluated; however, many of the SNPs investigated are associated with a variety of obstetrical 
outcomes so we likely enriched for the alleles of interest because our sample included a group of 
high-risk women who delivered preterm infants. Additionally, we did not examine donor milk 
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interleukin levels which could influence the amount of ILs each infant was exposed to. Lastly, 
we did not measure infant serum IL levels which would have allowed us to also consider 
endogenous IL exposure. 
 There were also strengths associated with this study. This is the first study to examine the 
influence of maternal SNPs on milk IL levels, which is highly innovative. This was a 
heterogeneous sample of obstetrically high risk mothers, and the collection of preterm breast 
milk in this population is difficult. While the sample size was small, there were consistent 
findings that inform current knowledge related to mechanisms for variability, and how milk 
immunological profiles might influence NICU outcomes.  
2.3 FUTURE STUDIES AND IMPLICATIONS FOR NURSING PRACTICE 
Future studies should include a larger sample size, with at least 100 mother-infant dyads so as to 
perform an adequately powered trajectory analysis. More studies are needed to confirm the 
relationships observed, particularly among different ethnicities. Because breast milk composition 
is heavily influenced by lifestyle factors, future studies should examine how epigenetic 
influences impact milk composition. These studies should collect whole, fresh breast milk that 
would allow for pyrosequencing.  
 The administration of breast milk, including donor milk, is done by the bedside nurse. 
Unfortunately, breast milk is treated as unchanging in the NICU, despite evidence that it is 
variable between women. This study further informs the knowledge related to the dynamic 
nature of breast milk, and this is important to nursing because milk differences influence infant 
outcomes. Nearly 70% of mothers who deliver preterm are unable to provide MOM to their 
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infants. As a result, donor breast milk has become the standard of care in NICUs. This study has 
potential clinical application to personalized medicine, where donor breast milk can be screened 
for SNPs that are associated with high or low interleukin levels, and breast milk can be matched 
based on infant needs and/or risks related to NICU complications.  
 
34 
3.0  DATA-BASED MANUSCRIPT: THE IMPACT OF PROMOTER 
POLYMORPHISMS ON CYTOKINE CONCENTRATION IN PRETERM BREAST 
MILK AND SUBSEQUENT INFANT OUTCOMES  
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3.1 ABSTRACT  
Background: Preterm infants are at risk for complications, and breast milk protects against many 
complications. Breast milk is variable between women and interleukin (IL) differences are 
associated with infant outcomes. The molecular mechanism for milk variability remains 
unknown.  
Objective: The aims of this ancillary study were to: 1) examine the relationship between 
maternal IL genotypes and weekly milk concentrations of IL4, IL6, and IL10, 2) describe the 
trajectories of milk IL change over the first three weeks postpartum, 3) examine whether 
maternal IL genotypes predict milk IL trajectories, 4) examine if weekly IL levels and/or IL 
trajectories predict infant outcomes, and 5) explore a relationship between maternal IL genotypes 
and infant outcomes. 
Methods: Preterm breast milk aliquots (0.5 mL) were collected from each feeding of mom’s own 
milk and pooled weekly for three weeks. DNA was extracted from the whey portion of breast 
milk using QIAmp DNA Extraction MiniKit and genotyped with TaqMan. Milk IL 
concentrations were measured using MagPix and Millipore kits. Trajectory analysis examined 
milk change over time. 
Results: Multivariate analysis resulted in associations between IL6 and IL10 SNPs and 
subsequent IL6 and IL10 milk levels. Infant outcomes associated with varying IL milk levels 
included calprotectin and IVH. Trajectory analysis resulted in linear group shapes, with two 
distinct subgroups in IL6, and three subgroups in both IL4 and IL10. Trajectory groups were 
associated with calprotectin, IVH, and blood transfusions. There were also significant 
relationships between maternal IL genotypes and NICU outcomes. 
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Conclusions: Maternal IL SNPs are associated with IL breast milk levels and IL milk levels are 
associated with infant outcomes.  
3.2 BACKGROUND 
The immune protection offered through breast milk is perhaps the original function of the 
mammary gland (Vorbach, Capecchi, & Penninger, 2006). The impact of gestational age of 
delivery on breast milk composition (Gidrewicz & Fenton, 2014) and the protection provided to 
preterm infants who receive Mother’s Own Milk (MOM) (Corpeleijn et al., 2012; Vohr et al., 
2007) suggest that preterm infants may benefit from breast milk that is immunologically 
appropriate for their needs. MOM provides preterm infants with immunofactors that are at levels 
appropriate for their development. Preterm birth complications are the leading cause of death 
among children under the age of five (World Health Organization, 2014). Preterm infants face 
increased risks of: pneumonia, retinopathy, necrotizing enterocolitis (NEC), and sepsis. Breast 
milk provides protection against these complications (Barsam et al., 2013; Corpeleijn et al., 
2012; Cristofalo et al., 2013; Maayan-Metzger, Avivi, Schushan-Eisen, & Kuint, 2012; Manzoni 
et al., 2013; Schanler, 2005), and for this reason, the American Academy of Pediatrics (AAP) 
recommends that all infants, particularly those weighing less than 1500 grams at birth, receive 
human milk (American Academy of Pediatrics, 2012). The robust immunological profile of 
breast milk, which contains white blood cells, cytokines, and immunoglobulins, may contribute 
to this protective influence on vulnerable infants. 
 Preterm infants are no longer receiving maternal immunological protection in utero; 
therefore, it is essential that they receive passive immunity through breast milk. ILs are an 
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integral part of the inflammatory response, and the preterm infant is vulnerable to complications 
due, in part, to an underdeveloped immunological system. ILs are present in breast milk, though 
their concentration is highly variable between women (Lawrence & Lawrence, 2005). 
Interleukin-4 (IL4) is involved in adaptive immunity and acts as both a pro- and anti-
inflammatory cytokine. Breast milk from mothers with allergies has a higher IL4 concentration 
when compared to breast milk from mothers who do not report allergies (Bottcher, Jenmalm, 
Garofalo, & Bjorksten, 2000; Marek et al., 2009). IL4 variability is relevant to the preterm 
population because it induces both antibody and IgE production. IL4 also contributes to 
macrophage activation, which results in microbial phagocytosis. Varying levels of IL4 in breast 
milk may contribute to disparate outcomes. To date, no studies have examined the relationship 
between maternal SNPs, subsequent milk composition, and resulting infant outcomes; however, 
there is evidence that varying IL4 in breast milk may contribute to the development of allergic 
dermatitis in healthy term infants (Ochiai et al., 2013).  
 Interleukin-6 (IL6), a pleiotropic cytokine, is involved in both adaptive and innate 
immune responses. IL6 stimulates both neutrophil production and proteins by hepatocytes to 
help with acute-phase responses. IL6 also promotes the growth of monoclonal antibodies. There 
are a number of factors associated with varying IL6 concentration in breast milk, including: 
mastitis (Mizuno et al., 2012), preeclampsia (Erbagci et al., 2005), cesarean section delivery 
(Mehta & Petrova, 2011), and maternal smoking (Etem Piskin et al., 2012). IL6 concentration is 
relevant to the preterm population because this interleukin is poorly regulated in preterm infants 
(Currie et al., 2011); therefore it is essential that vulnerable infants receive adequate amounts of 
IL6 through breast milk. Variable IL6 in breast milk has been related to subsequent outcomes, 
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with higher levels associated with decreased infant weight gain, percent fat, and fat mass among 
healthy breastfed infants (Fields & Demerath, 2012).  
Interleukin-10 (IL10) is produced by many cells of both the adaptive and innate immune 
systems. The role of IL10 in the prevention of inflammatory pathologies, as well as its function 
as a feedback regulator (Saraiva & O'Garra, 2010), illustrates its potential impact on preterm 
infants who are vulnerable to infection. IL10 concentration in breast milk is higher at three 
months postpartum among mothers who report allergies (Prokesova et al., 2006). Variable levels 
of IL10 in breast milk have been implicated in disparate neonatal outcomes. Milk fed to infants 
who developed NEC had immeasurable levels of IL10 when compared with milk fed to infants 
who did not develop NEC (Fituch et al., 2004). In another study, higher IL10 milk levels were 
associated with neonatal jaundice (Zanardo et al., 2007).  
Potential mechanisms for IL breast milk differences include variability in the DNA 
coding for these ILs, for example, single nucleotide polymorphisms (SNPs), particularly in 
regulatory regions of the genes. Serum concentrations of IL4 have been associated with two 
SNPs at the gene’s promoter region in pregnant women (rs2244350 -589 T/C) (Nguyen et al., 
2004), and children with malaria or anemia with the C allele (rs2070874 -33 T/C) produce higher 
levels of IL4 (Cabantous et al., 2009). Patients in septic shock experience higher IL6 if they have 
the G allele (rs1800795 -174 C/G), and Malarstig demonstrated that subjects at risk for a 
cardiovascular event had lower IL6 levels if they had the G allele for another SNP for the same 
IL6 gene (rs1800796 -572 C/G) (Malarstig, Lindahl, Wallentin, & Siegbahn, 2006). Women with 
idiopathic recurrent miscarriage had reduced IL10 production with the minor alleles at two SNPs 
in the promoter region of IL10 (rs1800871 -819 C/T; rs1800872 -592 A/C) (Qaddourah et al., 
2014). Lowe had similar results in one of these SNPs (rs1800872), with the A allele resulting in 
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lower IL10 production (Lowe, Galley, Abdel-Fattah, & Webster, 2003). In a third SNP in the 
IL10 promoter region (rs1800896 -1082 G/A), the A allele is also associated with low production 
in healthy individuals (Yilmaz, Yentur, & Saruhan-Direskeneli, 2005), and preterm infants with 
RDS (Capasso et al., 2007).  
A relationship between IL concentration and SNPs has been established in serum. 
Additionally, amniotic fluid shows variable IL6 concentration associated with a haplotype 
containing rs1800795 and rs1800796 (Velez et al., 2008). IL10 concentration is also variable in 
the amniotic fluid of women who experienced term and preterm birth, and rs1800896 is 
associated with this relationship. The relationship between these SNPs and breast milk IL 
concentration has never been explored, despite evidence that IL concentration is variable 
between women and linked to infant outcomes. If maternal SNPs do impact breast milk 
composition, which influences NICU outcomes, it is reasonable to explore a direct relationship 
between maternal IL SNPs and subsequent infant outcomes. The aims of this study were to, over 
the first three weeks postpartum and in a population who delivered preterm: 1) examine the 
relationship between maternal IL genotypes and cross-sectional (weekly) breast milk 
concentrations of IL4 (rs2243250 -589 T/C, rs2070874 -33 T/C), IL6 (rs1800795 -174 C/G, 
rs1800796 -572 G/C), and IL10 (rs1800871 -819 C/T, rs1800872 -592 A/C, rs1800896 -1082 
G/A), 2) describe the trajectories of breast milk IL concentration change over time, 3) examine 
whether maternal IL genotypes are associated with breast milk IL trajectories, 4) examine if 
weekly IL levels and/or IL trajectories predict infant outcomes, and 5) explore a relationship 
between maternal IL genotypes and infant outcomes. 
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3.3 MATERIALS AND METHODS 
3.3.1 STUDY POPULATION  
This ancillary study included women (n=64) who delivered infants (n=73, including multiples) 
with a birth weight <1500 grams and delivered at Tampa General Hospital (Tampa, FL). We 
were able to collect genotype data from DNA in prospectively collected breast milk samples 
(n=192) over the first three weeks postpartum. The parent study, The Association between 
Preterm Milk Immunobiology and Infant Health Study (NINR, R21 NR01309401A1), was 
conducted at the University of South Florida, and investigated the relationship between milk 
immunity and milk volume with clinical outcomes in preterm infants. Mothers with HIV, infants 
with major congenital anomalies, and moribund infants were excluded from enrollment. All 
aspects of the parent study were approved by the University of South Florida’s Institutional 
Review Board (IRB). Separate IRB approval from the University of Pittsburgh was also obtained 
for this study, which added genomic data collection to the parent project.  
 The following variables were collected and available for analyses: maternal age, parity, 
income, education, ethnicity, race, marital status, working status, and pregnancy history. Medical 
record data provided information about the labor and delivery of the infant(s). Maternal BMI was 
self-reported prepregnancy weight (pounds), and the height was obtained from the subjects’ 
medical chart (inches). The following CDC recommended equation was used to obtain a BMI for 
each subject: weight (pounds) / [height (inches)] 2 x 703. Infant data was obtained from the 
NICU medical record, and included: gender, ethnicity, gestational age at birth, birth weight, 
APGAR scores, ratio of human milk to total milk, SNAPPE-II scores (severity of illness), length 
of stay, weight gain at 6 weeks, days on oxygen, sepsis, retinopathy of prematurity (ROP), 
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necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), blood transfusions, and 
feeding intolerance.  
3.3.2 Breast milk collection and whey separation  
Any volume and source of milk the infant received (including MOM, donor breast milk, and 
formula) was recorded from the infant’s medical record. Breast milk aliquots from each feeding 
were collected for up to three weeks and these aliquots were pooled weekly (n=192). All milk 
was collected and stored frozen until brought to the laboratory twice weekly. The pooled MOM 
was centrifuged, defatted, and filtered, and the whey was frozen at -80 C. Although infants 
received both donor milk and MOM, only MOM was examined and genotyped for this study. 
3.3.3 Interleukin measurement 
IL4, IL6, and IL10 concentration was measured using a bead based assay on a MagPix 
instrument (Luminex, Austin, TX), and Millipore kits (Emd Millipore, Billerica, MA), and is 
detailed in previous work (M. Groer, Kane, B., Williams, N. , 2013). IL concentrations were 
measured weekly in all pooled samples of MOM for the first three weeks. Each assay included a 
standard curve and quality controls, and all samples were done in duplicate.  
3.3.4 Fecal calprotectin 
Fecal calprotectin has been used as a biomarker of inflammation within the preterm population, 
as calprotectin is an accurate indicator of neutrophil migration toward the GI tract (Kapel et al., 
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2005). Calprotectin levels were measured in a weekly stool sample using the PhiCal™ Fecal 
Calprotectin Immunoassay (Geneva Diagnostics, 2006). 
3.3.5 Genotyping 
Genotype data was collected using TaqMan allele discrimination assays to genotype seven 
functional promoter polymorphisms of IL4 (rs2070874, rs2243250), IL6 (rs1800795, 
rs1800796), and IL10 (rs1800871, rs1800872, rs1800896). We performed TaqMan allelic 
discrimination with the ABI Prism 7000 Sequence Detection System and SDS software v1.2.3 
(Applied Biosystems Inc., Carlsbad, CA). Negative controls were included and a portion of the 
samples were repeated to confirm that they repeatedly discriminated into the same genotype. We 
also included duplicates, performed independent blinded double calls, and discrepancies were 
regenotyped. The following cycling conditions were used: 1) Activation at 95°C for 10 minutes, 
2) denaturation at 95°C for 15 seconds, 3) anneal/extend at 58°C for 1:30 minutes, 4) go to step 
2-3 50 times, and 5) hold at 10°C forever. Blinded raw data was reexamined of the SNPs for 
which Hardy-Weinburg Equilibrium (HWE) was violated to rule out genotyping error. 
3.4 STATISTICAL ANALYSIS 
3.4.1 Preliminary analysis 
All statistical analyses were performed using SAS (v. 9.4). Univariate outliers were assessed 
using frequency tables and graphical methods including histograms and normal probability plots. 
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Multivariate outliers were assessed using scatterplots. Missing data was assessed for both 
amount (percentage), and pattern (random versus nonrandom). In addition to the Shapiro-Wilks 
test, normality was also evaluated graphically and at each time point with: frequency histograms 
and normal probability plots. Linearity, independence, and homoscedasticity were assessed by 
evaluating bivariate scatterplots. Data transformations were performed when a regression 
assumption (normality, linearity, homoscedasticity) was compromised. Transformations were 
checked after each application to ensure that the appropriate transformation was applied. There 
were eight sets of multiples, including one set of triplets. Milk-specific analyses excluded one 
twin, or two triplets, removed randomly, to ensure that each mother was represented only once 
(n=64). For infant-specific aims, all infants were included in the analyses (n=73).   
3.4.2 Trajectory Modeling 
Trajectory modeling with the censored normal model was used to examine changes in breast 
milk IL levels over the first three weeks postpartum. All modeling was done using the PROC 
TRAJ procedure in SAS (v 9.4). This approach is based on a semiparametric, group-based 
modeling strategy that is a mixture of probability distributions specified to describe the data 
(Jones, 2001). This procedure allows for estimation of multiple, distinct groups, within a 
population, as opposed to a traditional regression or growth curve that models only one mean 
within the population (Arrandale, 2006). Ultimately, PROC TRAJ allows for identification of 
distinct subgroup memberships within a population and estimates a regression model for each 
identified subgroup.  
When determining the number of trajectory groups, all group orders were set to second 
order when fitting the maximum number of groups (Nagin, 2005). After the number of groups 
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was determined, trajectory shapes were evaluated in a step-wise manner, up to a second order 
polynomial, as only three time points are represented. Subjects were assigned to a trajectory 
group based on their highest posterior group probability, which measures the probability that a 
subject with a specific milk IL concentration profile belongs to a definite trajectory group. We 
compared Bayesian Information Criteria (BIC) between the models to determine the appropriate 
number of groups and trajectory weights. The best fit model was the one with the lowest BIC 
score. 
3.4.3 Univariate analysis 
Univariate analyses were first performed for each association and any relationship with a p-value 
≤0.20 was subjected to multivariate regression models, where p≤0.10 was considered significant 
due to: 1) the exploratory nature of a pilot study, 2) small sample size, and 3) race-specific 
subgroup analyses, which further decreased our sample size. We also considered relationships 
with p≤0.150 as trending toward significance. SNP-specific analyses included both maternal 
genotype and minor allele presence (yes/no). The Fisher’s Exact test was used to examine the 
relationships between: 1) SNP and categorical infant outcomes, 2) SNP and IL trajectory group, 
and 3) IL trajectory group and categorical infant outcomes. 
3.4.4 Multivariate analysis 
Multivariate breast milk IL concentration analyses controlled for both gestational age and 
prepregnancy BMI. Multivariate infant outcomes analyses controlled for gestational age and the 
ratio of human milk to total milk administered. Infant outcomes were examined using a 
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multivariate approach only when there was a significant relationship (p≤0.10) between maternal 
SNP and IL milk concentration in the multivariate analysis. The association between maternal 
SNPs and IL trajectory grouping was examined without covariates because this relationship has 
never been explored and our sample size is less than ideal for trajectory modeling.  
Due to a small sample size and the need for ethnic subset analyses which further 
decreased our sample size, SNP-specific analyses included minor allele absence, with the 
exception of rs2243250. The minor alleles for rs2243250 are inconsistent between the 
represented ethnicities in this sample; therefore, genotypes were included in the rs2243250 
analysis for each ethnicity and total population. Multivariate models that included the total 
population were examined using both minor allele absence and genotype as an independent 
variable. This was done because including the total population increased our sample size, giving 
more power to examine genotype-specific relationships.  
Continuous outcomes were examined using multiple linear regression and binary 
outcomes were examined with multiple logistical regression. The relationship between trajectory 
group and continuous infant outcomes was assessed by generating multiple contingency tables 
using IL trajectory group and outcomes. We also performed general linear regression models to 
measure these associations, since a samples size of at least 100 is ideal to perform trajectory 
analyses (Nagin, 2005) and our sample size was smaller than this recommendation. We also used 
a contingency table and chi-square test of independence to evaluate if the independent variable 
was associated with the dependent variable for each aim. 
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3.5 RESULTS 
3.5.1 Demographics, Genotype Frequencies, and Univariate Analysis 
The average maternal age was 28.27 years old, the sample was mostly African American 
(39.68%), and the average gestational age at delivery was 28 weeks. Additional maternal and 
infant demographics are presented in Tables 5 and 6. There were three SNPs not in HWE (Table 
7). Relationships in the univariate analyses (Table 8) that met our criteria for inclusion in the 
multivariate model that examined SNP/milk IL (Table 9) were: A) rs2070874: Caucasian IL4 
weeks 1, 2; Hispanic IL4 weeks 2, 3, B) rs2243250: Caucasian IL4 week 1; Hispanic IL4 weeks 
1, 2, 3, C) rs1800795: Caucasian IL6 week 1; African American IL6 weeks 1, 2, average; 
Hispanic IL6 weeks 1, 2, 3, D) rs1800796: Caucasian IL6 week 1; African American IL6 week 
2; E) rs1800871: African American IL10 weeks 1, 2, 3, average; F) rs1800872: African 
American IL10 weeks 1, 2, 3, average, G) rs1800896: Total population IL10 week 1, Caucasians 
IL10 weeks 1, 3, average; African Americans IL10 weeks 3, average; Hispanic IL10 weeks 1, 3. 
There were no significant univariate findings between SNP and milk IL trajectory group (Table 
10). Relationships in the univariate analysis (Tables 11 and 12) that met our criteria for inclusion 
in the multivariate model that examined milk IL trajectory groups and infant outcomes (Tables 
13 and 14) were: A) IL4 and sepsis, B) IL4 and blood transfusions, C) IL6 and IVH, D) IL6 and 
fecal calprotectin, and E) IL10 and fecal calprotectin. Relationships between SNP and interleukin 
concentration that met our criteria for inclusion in the multivariate model that examined cross-
sectional milk IL concentration and subsequent infant outcomes (Tables 15 and 16) were: A) 
Caucasians: IL6 and sepsis, ROP, transfusions, feeding intolerance, calprotectin, SNAPPEII, 
length of stay, weight at six weeks, and days on oxygen, B) African Americans: IL6 and IVH, 
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calprotectin, SNAPPEII, weight at six weeks, and days on oxygen, and C) African Americans: 
IL10 and sepsis, IVH, feeding intolerance, calprotectin, SNAPPEII, length of stay, weight at six 
weeks, and days on oxygen. Relationships in the univariate analysis (Tables 17 and 18) that met 
our criteria for inclusion in the multivariate model that examined maternal SNP and infant 
outcomes (Tables 19 and 20) were: A) rs2070874: length of stay, days on oxygen, weight at six 
weeks (Caucasian); weight at six weeks, calprotectin, and SNAPPEII (African American); 
calprotectin (Hispanic); ROP (total population); B) rs2243250: length of stay, weight at six 
weeks, days on oxygen, calprotectin (Caucasian); length of stay, weight at six weeks, oxygen, 
calprotectin (African American); calprotectin (Hispanic); blood transfusions and calprotectin 
(total population); C) rs1800795: days on oxygen, calprotectin (Caucasian); IVH and SNAPPEII 
(African American); length of stay, calprotoctin (Hispanic); ROP, blood transfusions, 
SNAPPEII, days on oxygen, calprotectin (total population); D) rs1800796: calprotectin 
(Caucasian); sepsis, length of stay, SNAPPEII, calprotectin (African American); feeding 
intolerance, weight at six weeks, calprotectin (Hispanic); ROP, BPD, NEC, blood transfusions, 
feeding intolerance, length of stay, weight at six weeks, calprotectin (Total population); E) 
rs1800871: IVH, length of stay, calprotectin (Caucasian); sepsis, length of stay (African 
American); calprotectin (Hispanic); calprotectin (total population); F) rs1800872: length of stay, 
weight at six weeks, and calprotectin (Caucasian); length of stay (African American); 
calprotectin (Hispanic); length of stay and calprotectin (Total population); G) rs1800896: 
calprotectin (Caucasian); days on oxygen (African American); length of stay and calprotectin 
(Hisapnic); sepsis, length of stay, and calprotectin (total population). 
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3.5.2 Interleukin trajectory modeling 
All interleukins levels were natural log transformed to fulfill the normality distribution 
assumption. The resulting model from the IL4 trajectory model included three groups with order 
1) low linear (34.7%), 2) middle linear (46.5%) and high linear (18/8%) (Figure 2).  The IL6 
trajectory resulted in two groups, ordered: 1) low linear (49.7%), and 3) high linear (50.3%) 
(Figure 3). IL10 resulted in three groups, ordered: 1) low linear (33.2%), 2) middle linear 
(46.5%) and 3) high linear (20.3%) (Figure 4). 
3.5.3 Maternal Interleukin SNPs and Breast Milk Interleukin Concentration/Interleukin 
Trajectory 
Controlling for gestational age at delivery and maternal prepregnancy BMI, there were no 
significant associations between IL4 genotypes and subsequent IL4 breast milk concentrations. 
However, there were trends (p≤0.150) toward significance between rs2070874 minor allele 
absence and IL4 milk concentration among Caucasians at week one (p=0.1417), and for 
Hispanics at weeks two (p=0.1406). Caucasians have a similar relationship between rs2243250 
genotype and IL4 milk concentration at week one (p=0.1492), however there were no TT 
genotype subjects represented during this week (Table 9). 
There was a significant inverse relationship between absence of minor allele rs1800795 
and IL6 milk concentration among Caucasians at week three (p=0.0966). At week one, 
Caucasians experience a trend toward significance between rs1800796 minor allele absence and 
IL6 milk concentrations (p=0.1173). African Americans have a significant inverse relationship 
between rs1800796 minor allele absence and IL6 milk levels at week two (p=0.0772). 
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Additionally, prepregnancy BMI was inversely associated with IL6 milk concentrations in only 
the African American population in the rs1800795 model for week one (p=0.0411) and average 
IL6 (p=0.0126). A similar association between prepregnancy BMI and IL6 milk concentration 
was also seen among African Americans in the rs1800796 model for week two (p=0.0288).  
While there were no significant relationships between rs1800871 minor allele absence 
and subsequent IL10 milk concentration, prepregnancy BMI was inversely associated with milk 
IL10 levels at week one (p=0.061), week two (p=0.0350), and average IL10 (p=0.0263), though 
this relationships was seen only among African Americans. Prepregnancy BMI was also 
significantly related to IL10 milk concentration when examining minor allele absence of 
rs1800872 at weeks one (p=0.0260), two (p=0.0250), and average IL10 (p=0.015), though there 
was only a trend toward significance between minor allele absence and IL10 at week three 
(p=0.1662). Absence of minor allele rs1800896 was significantly associated with IL10 at week 
three among African Americans (p=0.0705).   
3.5.4 Interleukin SNP and infant outcomes 
When controlling for gestational age at delivery and ratio of human milk to total milk 
received, there was a significant association between rs2070874 genotype TT and ROP in the 
total population (p=0.0706) (Tables 19 and 20). There was also a significant association, among 
African American infants, between minor allele absence of rs2070874 and fecal calprotectin at 
week two (p=0.0589). When examining the relationship between rs2243250 genotype and 
outcomes, Caucasian infants with a TT genotype was associated with a longer length of stay 
(p=0.0720). Among African Americans, it was the CC genotype that significantly 
associated with length of stay (p=0.0518), and days on oxygen 
(p=0.0809). 
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There was a significant association between rs1800795 genotype CC and SNAPPEII 
scores among the total population (p=0.0625). There was also an association between genotype 
GG and SNAPPEII (p=0.1075), though there was no significance between rs1800795 CG 
genotype and SNAPPEII scores. Rs1800795 genotype GG was also significantly associated with 
number of days on oxygen (p=0.0316), as was minor allele absence (p=0.0316) in the total infant 
population. Among Caucasians, rs1800795 minor allele absence was significantly associated 
with calprotectin at week two (p=0.0222). When examining the relationship between rs1800796 
and outcomes, there was a significant association between ROP and genotype AA (p=0.0687) 
and minor allele absence (p=0.0573) in the total population. There was also an association 
between NEC and minor allele absence rs1800796 (p=0.0833), though there were only three 
NEC cases in this sample. Additionally, among the total population, there was a significant 
inverse relationship between minor allele absence rs1800796 and length of stay (p=0.0688), 
genotype GG and length of stay (p=0.0034), and genotype GG and calprotectin at week three 
(p=0.0213). Among Caucasians, there was a significant association between rs1800796 minor 
allele absence and calprotectin at week 3 (p=0.0429). African Americans exhibit a significant 
relationship between rs1800796 minor allele absence and length of stay (p=0.0158), SNAPPEII 
(p=0.0497), and calprotectin at week three (p=0.0868). There is a significant relationship among 
Hispanics between rs1800796 minor allele absence and weight at six weeks (p=0.0272).  
When examining the relationship between rs1800871 and infant outcomes, Caucasians 
had a significant association between absence of minor allele and length of stay (p=0.0989) and 
calprotectin week one (p=0.0890). African Americans also had a relationship between minor 
allele absence rs1800871 and length of stay (p=0.0989). There was a significant relationship 
between rs1800871 genotype TT and calprotectin week three in the total population (p=0.0270). 
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There were significant associations between rs1800872 minor allele absence among Caucasians 
and calprotectin at week one (p=0.0196) and this relationship was also observed in the total 
population but with genotype AA at week three (p=0.0158). There was a significant association 
between rs1800896 minor allele absence and days on oxygen (p=0.0320) in African Americans. 
rs1800896 minor allele absence was also significant associated with calprotectin week two 
(p=0.0737) among Caucasians. Among the total population, there was a significant association 
between rs1800896 genotype AA calprotectin at weeks two (p=0.0045) and three (p=0.0744), 
and minor allele absence and calprotectin weeks two p=0.0057) and three (p=0.0825). 
3.5.5 Interleukin Trajectory, Interleukin Concentration, and Infant Outcomes 
Multivariate analysis of trajectory group and infant outcomes are presented in Tables 13 and 
14. When controlling for gestational age at delivery and ratio of human milk to total milk 
received, infants who received breast milk from group 2 were 4.16 times more likely to receive a 
blood transfusion when compared with infants who received breast milk from trajectory group 
3 (OR=4.162, CI 0.778, 22.277, p=0.0712). When controlling for gestational age at delivery 
and ratio of human milk to total milk, there was a significant association between IL6 
group 1 membership and IVH (OR=6.275, CI 1.076, 36.584, p=0.0412). There was also a 
significant relationship between IL6 group 1 and fecal calprotectin level at week 3 
(p=0.0822). There was no significant association between IL SNPs and interleukin trajectory 
group.  There was a significant and positive association between IL6 milk levels at weeks one 
and two and calprotectin at week three (p=0.0794, p=0.0978) among African Americans. 
Caucasians also experience a significant relationship between IL6 at three weeks and infant 
calprotectin at week two (p=0.0290). There is a positive and significant relationship between IL6 
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at weeks one (p=0.1059) and a trend toward significance between IL6 at week two (p=0.1362) 
and subsequent IVH among African Americans (p=0.1059, p=0.1362) (Tables 15 and 16). 
3.6 DISCUSSION 
This study suggests that maternal SNPs influence IL milk concentration, and resulting IL levels 
impact neonatal outcomes. Further, our trajectory analysis of IL change over time 
illustrates the dynamic nature of breast milk and that IL patterns also contribute to infant 
outcomes. This study is consistent with previous work that demonstrates a functional impact of 
SNPs on subsequent IL concentration for rs2243250 (Nguyen et al., 2004), 
rs1800795 (Tischendorf et al., 2007), rs1800796 (Malarstig et al., 2006), rs1800871 
(Qaddourah et al., 2014), rs1800872 (Lowe et al., 2003), rs1800896 (Capasso et al., 2007; 
Yilmaz et al., 2005); however, this is the first study to reveal this relationship in breast milk. 
There are race and/or ethnic specific associations, as noted in the Caucasian (1800795) 
and African American (1800796, 1800896) subgroups.  
Interestingly, IL6 was implicated for both 1) SNP/IL level and 2) IL level/outcome in the 
African American subgroup. While rs1800796 does not impact week one IL6 milk levels, there 
is a significant positive relationship in African Americans between IL6 week one levels and 
subsequent infant IVH. There is a trend toward significance at week two between milk IL6 levels 
and subsequent IVH, and this is a time when there is a significant relationship between rs180076 
and IL6 milk levels. Additionally, the trajectory analysis revealed that infants who received 
breast milk from the low-linear IL6 trajectory group one were more likely to develop IVH that 
infants who received milk from IL6 trajectory group two. Together, these findings reveal a 
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relationship between maternal genetics’ influence on milk IL6 levels and subsequent IVH. Given 
the time-sensitive associations among subgroups, it appears that its influence may occur over 
time.  
IL6 has been proposed as a strong candidate to modify the risk of perinatal brain injury 
(Baier, 2006). Preterm infants face deficient cerebral structural support, and are vulnerable to 
brain injury from compromised blood flow. IL6 crosses the blood brain barrier and enters the 
cerebrospinal fluid and interstitial spaces of the brain and spinal cord (Banks, Kastin, & 
Broadwell, 1995). IL6 helps to induce coagulation (Laine et al., 2014; Singh, Vennila, Snijesh, 
George, & Sunny, 2015), and enhances the expression of tissue factor which activates the 
coagulation cascade (Poralla, Hertfelder, et al., 2012; Poralla, Traut, et al., 2012). Additionally, 
IL6 activation decreases Vitamin K dependent coagulation factors and subsequent IVH 
development (Poralla, Hertfelder, et al., 2012). Furthermore, IL6 serves a neuroprotective role in 
hypoxic-ischemic injury, with adult brain injury patients experiencing improved long term 
outcomes after administration of exogenous IL6 (Winter, Pringle, Clough, & Church, 2004). 
Neurodevelopmental complications among infants who experience IVH are lessened if they 
receive breast milk (Gibertoni et al., 2015). When adequate amounts of IL6 are present in breast 
milk, infants may receive exogenous coagulative protection against IVH, and neuroprotection to 
infants who had IVH may last into childhood. IL6 has been observed in high amounts in 
umbilical vein blood among infants who develop IVH (Kassal et al., 2005), though other studies 
have found no such relationship (Bhandari et al., 2011; Sorokin et al., 2014). Conflicting infant 
IL6 levels and how they relate to IVH risk, coupled with our results, indicate that exogenous 
milk IL6 should be examined closely as potentially mediating IVH development.  
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Our sample also included very few NEC cases (n=3, 4.1%). While this study was not 
efficiently powered to detect a significant relationship between SNPs, ILs, and subsequent NEC 
diagnoses, we were able to detect significant relationships between SNPs, ILs, and infant fecal 
calprotectin levels. Calprotectin levels are derived mostly from neutrophils and monocytes 
(Selmi et al., 2015), when white blood cell migration to the intestines activates neutrophils to 
release this protein (Yoon et al., 2014). Fecal calprotectin has been directly associated with 
inflammation severity in the small intestine, including NEC (Aydemir et al., 2012; Dabritz, 
Jenke, Wirth, & Foell, 2012; Josefsson, Bunn, & Domellof, 2007; Yoon et al., 2014). Fecal 
calprotectin is also involved in microbiota establishment in preterm infants, including 
Clostridium sp and Staphylococcus sp (Rouge et al., 2010), establishing its potential influence on 
long-term outcomes.  
Our study observed that maternal IL6 SNPs influence IL6 milk levels, and IL6 milk 
levels are associated with subsequent calprotectin levels. There was a significant positive 
association between IL6 milk levels at weeks one and two and week three infant fecal 
calprotectin levels among African Americans, which suggests that milk IL6 is influencing the 
infant’s intestinal inflammatory hemostasis. The risk of NEC among preterm infants peaks 
between 13 and 21 days (Llanos et al., 2002; Snyder et al., 1997), and our findings suggest that 
this window of risk is reflected in infants’ calprotectin levels. There was also a positive 
association between higher IL6 levels at week three and calprotectin levels at week two, which, 
given its nonsequential relationship, appears to be a coincidental finding. 
In vitro IL6 expression is increased in ileum mucosal tissue within the NEC population 
(Lu et al., 2013), and increased serum IL6 levels reflect the clinical severity of NEC (Goepfert et 
al., 2004; Morecroft, Spitz, Hamilton, & Holmes, 1994). Likewise, and as confirmed with the 
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trajectory analysis, lower IL6 milk levels is associated with lower calprotectin levels. This is 
consistent with the pro-inflammatory role of IL6 in the gut, as illustrated by Hegazy (2010), who 
ameliorated colitis in vitro by downregulating IL6 (Hegazy & El-Bedewy, 2010). The 
proinflammatory properties of IL6 include a role in neutrophil transition to monocyte infiltration 
during inflammation, suggesting a magnified effect when IL6 levels are introduced at higher 
rates, like via breast milk. Higher IL6 levels may predispose the infant to a hyperinflammatory 
intestinal environment, thereby increasing calprotectin. Cury (2013) reports that increased levels 
of inflammatory mediators, including IL6, result in a loss of bowel homeostasis, which may lead 
to disease development (Cury et al., 2013). 
The trajectory of IL4 change over time was significantly associated with blood 
transfusions, as indicated by our finding that infants who received milk from IL4 group 2 were 
4.162 times more likely to receive a blood transfusion when compared with infants who received 
milk from group 3. While all groups are linear in shape, group three is much higher, suggesting 
that those infants receive much more IL4 via the breast milk. IL4 has a suppressive role on 
erythropoiesis (Sawada, Sato, & Koike, 1995; Thawani, Tam, & Stevenson, 2009). This is not 
consistent with our findings, which suggest that infants who receive less IL4 via breast milk are 
more likely to require a blood transfusion. It is possible that exogenous IL4 signals the infant to 
make less IL4, thereby balancing IL4 levels and subsequent erythopoietic activity; however, IL4 
group 1 was not associated with blood transfusions and this group had lower milk IL4 than group 
2. There may be a threshold for endogenous IL4 production that group 2 reaches, but to our 
knowledge this has never been studied in the preterm population. This finding should be 
interpreted cautiously, since the overall impact of trajectory grouping on transfusions is not 
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significant, and it is only when comparing groups two and three that we uncover a potential 
relationship.  
The relationship between maternal IL SNPs and subsequent neonatal outcomes suggests 
that milk composition may mediate the relationship between breast milk and neonatal outcomes. 
The three ILs examined in this study have numerous downstream immunological roles, many of 
which have been implicated in neonatal outcomes. For example, IL4 promotes Th2 cellular 
response and T-helper transcription factors are positively correlated with calprotectin levels 
(Garcia-Rodriguez et al., 2012). Likewise, IL6 plays a major role in transitioning neutrophils to 
monocytes during infiltration after injury, and monocyte levels, similar to calprotectin levels, are 
positively associated with NEC (Christensen, Jensen, Maheshwari, & Henry, 2010; Maheshwari 
et al., 2014). IL10 inhibits TNFα, which is involved in systemic inflammation, and this protein is 
positively correlated with fecal calprotectin in infants (Kapel et al., 2005). It is likely that our 
small sample size prevented us from identifying more shared significant relationships between 
maternal SNPs, milk IL levels, and subsequent infant outcomes; however, we believe the results 
from this exploratory aim can be used to design future studies that examine appropriate pathways 
of bioactive milk components and their influence on outcomes.  
While there was only one time period (week three) in which maternal SNP (rs1800896) 
impacted IL10 milk levels, the impact of prepregnancy BMI on milk IL10 levels remained 
consistent over time, though this was observed only among African Americans. There are 
racial/ethnic differences with respect to BMI, and visceral adipose fat is lower in African 
American women when compared with both Hispanic and White women (Carroll, Franks, Smith, 
& Phelps, 2009). Despite lower visceral adipose fat, African American women have higher IL6 
serum concentrations when compared with white women (Carroll et al., 2009). Abdominal 
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obesity is associated with low-grade inflammation and this increases plasma IL6 (Yudkin, 
Stehouwer, Emeis, & Coppack, 1999). Maternal adiposity was positively correlated to cord 
blood IL6 levels (Catalano et al., 2009), but a negative correlation was found in a sample of 
Mexican mothers (Vega-Sanchez et al., 2010), suggesting a race-specific influence of BMI on IL 
production. In all of the models for which BMI was significantly associated with milk IL levels, 
it was an inverse association, suggesting that higher BMIs result in lower IL6 milk concentration 
in African Americans. 
The impact of maternal BMI on interleukin levels among African American mothers 
suggests that, in addition to maternal SNPs, environmental factors impact milk composition. 
Other immunofactors present in milk are greatly influenced by maternal weight, including lower 
levels of TGF-β2 and sCD14 levels in the breast milk of overweight mothers when compared 
with normal weight mothers (Collado et al., 2012). Other lifestyle factors, including exercise (M. 
W. Groer & Shelton, 2009) and smoking (Szlagatys-Sidorkiewicz, Wos, et al., 2013), influence 
the immunolgoical profile of breast milk. It is estimated that between 50-75% of IL10 variability 
can be exlained by polymorphisms (Riiskjaer et al., 2011). The remaining contributors that 
influence IL10 production are unknown, though several studies suggest an epigenetic influence 
(Saraiva & O'Garra, 2010). Epigenetic influences on IL levels may explain why we did not 
uncover more SNP/IL relationships. For example, women who received probiotics/dietary 
counselling have higher IL10 levels in their breast milk compared with women who did not 
receive this intervention (Hoppu, Isolauri, Laakso, Matomaki, & Laitinen, 2012). Elevated IL10 
is also present in breast milk expressed by mothers with allergies (Prokesova et al., 2006), 
though it is unclear if that represents an endogenous or exogenous exposure. These findings 
implore an epigenetic approach to understand the molecular mechanism for breast milk variation.  
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3.7 LIMITATIONS AND CONSIDERATIONS TO CONCLUSIONS 
There were several limitations to this study, including a small sample size. Due to differences in 
allele frequencies across races, we further decreased our power by doing subgroup analyses of 
Caucasians, Hispanics, and African Americans. Our p-value cutoff was more liberal (p≤0.10) 
because of the exploratory nature of the study and the small sample size. This is especially 
relevant to the trajectory analysis, which ideally includes 100 subjects (Nagin, 2005). We did 
obtain good group membership percentages, and far surpassed the minimum of 10% for each 
trajectory group; however, we did not see any relationship between SNP and trajectory group 
and this may be due to inadequate power. Specifically, our analysis that examined IVH as an 
infant outcome was only significant in the African American population, which included only 
two infants in the minor allele absence group. The trend toward significance in the Caucasian 
population suggests a true relationship, especially since there are more infants who belonged to 
both minor allele absence groups. Additionally, our calprotectin analysis should be interpreted 
cautiously, since calprotectin levels follow their own trajectory patterns with a decrease during 
the first week and a subsequent steady increase into the eighth week of life (Josefsson et al., 
2007). This is relevant since we examined cross-sectional calprotectin levels and not patterns 
over time. 
 Much of this study is based on self-reported variables, including ethnicity and pre-
pregnancy BMI. These self-reported variables are less than ideal, since study participants tend to 
under-report weight (Connor Gorber, Tremblay, Moher, & Gorber, 2007). Additionally, self-
reported ethnicity does not adequately capture inherent biological differences, and ancestral 
markers are a more reliable way of obtaining biologically relevant information that accounts for 
admixture (Yaeger et al., 2008). The Hispanic subgroup included both “white Hispanic” and 
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“black Hispanic”, and it could be argued that they should have been assigned Hispanics to either 
the Caucasian or African American groups. Hispanics were examined separately because some 
of the SNPs in this study have markedly different minor allele frequencies among Hispanics 
when compared with Caucasians and/or African Americans. Additionally, HapMap reports a 
separate Hispanic minor allele frequency, further supporting our decision to do a separate 
Hispanic-specific analysis. However, given the small sample size, it may have been 
advantageous to have categorized Hispanics into the Caucasian or African American subgroups. 
HWE was violated for three SNPs (rs2070874, rs2243250, rs1800796), though we only report 
significant findings for one of these (rs1800796). We were able to eliminate genotyping error; 
therefore, we believe HWE violation was due to a biased sample of women who delivered 
preterm infants which enriched for the alleles under investigation. The SNPs included in this 
study have been implicated in a variety of obstetrical complications, including SGA (rs2070874 
and rs2243250) (Engel et al., 2005), spontaneous preterm birth (rs1800795) (Wu et al., 2013), 
and pregnancy loss (rs1800871, rs1800872) (Cochery-Nouvellon et al., 2009).  
 Infants in this study also received donor breast milk, and this milk was not included in the 
analysis of this study. According to Molinari, infants who receive donor milk are exposed to 
variable amounts of protein and bioactive components (Molinari, Casadio, Hartmann, Arthur, & 
Hartmann, 2013). While we acknowledge that this could certainly contaminate our IL/outcomes 
analysis, it is important to note that the Holder pasteurization method which donor milk is 
subjected to eliminates many interleukins, including IL6 and IL10 (Ewaschuk et al., 2011; 
Reeves, Johnson, Vasquez, Maheshwari, & Blanco, 2013; Untalan, Keeney, Palkowetz, Rivera, 
& Goldman, 2009). Ewaschuk  found that Holder pasteurization did not significantly alter IL4 
milk concentration (Ewaschuk et al., 2011) which means that infants in our study who received 
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donor breast milk likely received IL4 from both their MOM and donor breast milk. This may 
explain our findings that infants from the MOM middle-linear IL4 trajectory group were more 
likely to receive blood transfusions than infants who received milk from the high-linear IL4 
trajectory group. It is possible that the infants in Group 2 received more donor breast milk, and 
therefore extra IL4 than present in MOM, suppressing erythopoesis; however, we did not control 
for donor milk administration. It is not possible to measure the bioavailable IL exposure of even 
the infants who received exclusive MOM because it is unclear to what extent IL4, IL6, and IL10 
are bioavailable once they reach the stomach. Calhoun (1999) has demonstrated a sequestration 
that may protect cytokines until they reach the intestine to be absorbed, but this is an area that 
has not been adequately studied (Calhoun, Lunoe, Du, Staba, & Christensen, 1999).  
 Although infants in this study received one maternal allele from all the examined SNPs, 
we do not know which allele they received, and since we do not have infant genotypes or serum 
IL6 levels, we cannot examine the relationship between infant genotype and subsequent IVH; 
however, Baier reports no association between IL6 SNPs and IVH in a race-specific subgroup 
analysis (Baier, 2006). This finding further highlights the potential relevance of breast milk as it 
relates to the predisposition to or protection from IVH. 
3.8 IMPLICATIONS FOR NURSING PRACTICE 
Breast milk is currently treated as unchanging between women in most NICUs, despite a 
growing body of evidence that suggests great variability between women that may impact infant 
outcomes. Protein biomarkers have clinical relevance, including milk lactose and glucose as a 
marker of mastitis (Fetherston, Wells, & Hartmann, 2006), and metabolites to identify diabetic 
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mothers (Arthur, Kent, & Hartmann, 1994). Our study shows that maternal SNPs also contribute 
to the immunological profile of breast milk, specifically ILs, which also impact neonatal 
outcomes. This has relevance to donor breast milk administration practices. Donor breast milk is 
becoming the norm in most NICUs, where the best clinical practice is to provide human milk 
when MOM is unavailable. Most donor breast milk is expressed by women who have delivered 
healthy term infants (Dempsey & Miletin, 2010), so the immunological properties delivered to 
preterm infants via donor breast milk may be suboptimal. Future donor milk administration 
practices may include screening the DNA in breast milk for clinically relevant SNPs that are 
specific to the infants’ needs. 
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APPENDIX A 
DATA-BASED MANUSCRIPT: TABLES AND FIGURES 
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Table 5: Maternal Demographics (n=64) 
 
 
 
 
 
 
 
 
Age 28.27 ( ± 6.79) 
 
Total pregnancies 3.09 ( ± 2.36) 
 
Prepregnancy Body Mass Index (BMI) 27.83 ( ± 7.25) 
 
Ethnicity  
     Caucasian 21 (33.33%) 
 
     African American 25 (39.68%) 
 
     Hispanic 13 (20.63%) 
 
     Asian 2 (3.17%) 
 
     Other 1 (1.59%) 
 
Education  
     Grammar/elementary school 4 (6.25%) 
 
     Middle School 6 (9.38%) 
 
     High School 36 (56.25%) 
 
     College graduate 14 (21.88%) 
 
     Post graduate degree 4 (6.25%) 
 
Delivery method  
     Vaginal 15 (23.44%) 
 
     Cesarean Section 49 (76.56%) 
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Table 6: Infant demographics (n=73) 
Gender  
     Male 38 (52.05%) 
     Female 35 (47.95%) 
Gestational Age at Delivery 28.29 ( ± 2.39) 
Birthweight (grams) 1069.61 ( ± 216.82) 
Apgar 1 minute 5.97 ( ± 1.93) 
Apgar 5 minutes 7.44 ( ± 1.53) 
SNAPPE II Score 19.51 ( ± 16.82) 
Time to enteral feeding 12.6 ( ± 5.09) 
Days on oxygen 15.19 ( ± 21.32) 
Length of stay (days) 70.52 ( ± 37.04) 
ROP (yes) 13 (19.12%) 
BPD (yes) 4 (5.56%) 
Sepsis (yes) 10 (14.08%) 
NEC (yes) 3 (4.17%) 
IVH (yes) 9 (12.86%) 
Blood transfusions (yes) 33 (45.21%) 
Feeding Intolerance (yes) 15 (21.13%) 
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Table 7: Genotype frequency and Hardy-Weinburg Equilibrgium, total population (n=64) 
MAF=Minor Allele Frequency, HWE=Hardy-Weinburg Equilibrium χ2 goodness-of-fit test 
SNP Frequency (%) Study MAF HWE 
rs2070874  T=0.148 p=0.001* 
     Genotype CC 45 (70.31%)   
     Genotype TT 8 (12.5%)   
     Genotype CT 11 (17.19%)   
rs2243250  n/a p=0.00001* 
     Genotype CC 28 (43.75%)   
     Genotype TT 20 (31.25%)   
     Genotype CT 16 (25%)   
rs1800795   C=0.195 p=0.3011 
     Genotype CC 5 (7.81%)   
     Genotype GG 39 (60.94%)   
     Genotype CG 20 (31.25%)   
rs1800796  C=0.109 p=0.0423* 
     Genotype CC 3 (4.69%)   
     Genotype GG 50 (78.13%)   
     Genotype CG 11 (17.19%)   
rs1800871  T=0.227 p=0.252 
     Genotype TT 7 (11.11%)   
     Genotype CC 34 (53.97%)   
     Genotype CT 22 (34.92%)   
rs1800872  A=0.242 p=0.1232 
     Genotype CC 32 (50.79%)   
     Genotype AA 9 (14.29%)   
     Genotype AC 22 (34.92%)   
rs1800896  G=0.313 p=0.7227 
     Genotype GG 11 (17.46%)   
     Genotype AA 23 (36.51%)   
     Genotype AG 29 (46.03%)   
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Table 8: Univariate analysis of maternal SNP and milk interleukin concentrations 
Rs2070874 
Total Population  
CC (n=43) TT (n=7) CT (n=11) p 
     lnIL4 week 1 1.033 (±2.005)  0.047 (±1.543)  1.126 (±2.499) 0.7186 
     lnIL4 week 2 0.679 (±1.777) 0.971 (±0.782) 1.246 (±2.46) 0.659 
     lnIL4 week 3 1.042 (±1.798) 0.307 (±1.386) 1.019 (±2.237) 0.6214 
     lnIL4 first three weeks 1.091 (±1.768)  0.524 (±1.152) 1.157 (±2.36) 0.7297 
     
Caucasian CC (n=19) TT (n=1) CT (n=1) p 
     lnIL4 week 1 1.387 (±1.892) n/a 4.675 (n/a) 0.113* 
     lnIL4 week 2 1.616 (±1.637) 2.228 (n/a) 4.261 (n/a) 0.3075 
     lnIL4 week 3 1.766 (±1.542) 0.476 (n/a) 3.559 (n/a) 0.3806 
     lnIL4 first three weeks 1.701 (±1.447) 1.695 (n/a) 4.263 (n/a) 0.2512 
     
African American CC (n=16) TT (n=3) CT (n=4) P 
     lnIL4 week 1 0.882 (±2.05) 0.326 (±2.073) 0.253 (±2.413) 0.861 
     lnIL4 week 2 0.387 (±1.706) 1.063 (±0.830) 0.115 (±1.946) 0.8159 
     lnIL4 week 3 0.899 (±1.751) 0.614 (±2.122) -0.004 (±1.649) 0.674 
     lnIL4 first three weeks 0.819 (±1.785) 0.389 (±1.769) 0.098 (±1.879) 0.674 
     
Hispanic CC (n=7) TT (n=3) CT (n=3) P 
    lnIl4 week 1 0.3199  (±2.425) -0.511 (n/a) 1.455 (±2.989) 0.7676 
    lnIL4 week 2 -0.946 (0.437) 0.49 (0.195) 1.486 (3.014) 0.1032* 
    lnIL4 week 3 -1.139  (0) -0.056 (0.955) 1.353 (3.031) 0.1135* 
    lnIL4 first three weeks -0.131 (2.054) 0.267 (0.196) 1.435 (3.009) 0.5706 
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MAP=Minor Allele Presence 
 
 
 
 
 
Rs2070874 MAP 
Total Population  
No (n=43) Yes (n=18) p  
     lnIL4 week 1 1.033 (±2.005)  0.856 (±2.283)  0.801  
     lnIL4 week 2 0.679 (±1.778) 1.149 (±1.998) 0.385  
     lnIL4 week 3 1.042 (±1.798) 0.742 (±1.936) 0.5697  
     lnIL4 first three weeks 1.091 (±1.768) 0.91 (±1.962) 0.7253  
     
Caucasian No (n=19) Yes (n=2) p  
     lnIL4 week 1 1.387 (±1.892) 4.675 (n/a) 0.1125*  
     lnIL4 week 2 1.616 (±1.637) 3.244  (n/a) 0.198*  
     lnIL4 week 3 1.766 (±1.542) 2.018 (n/a) 0.8339  
     lnIL4 first three weeks 1.701 (±1.447) 2.979  (n/a) 0.2563  
     
African American No (n=16) Yes (n=7) p  
     lnIL4 week 1 0.882 (±2.05) 0.283 (±1.997) 0.579  
     lnIL4 week 2 0.388 (±1.706) 0.431 (±1.682) 0.9581  
     lnIL4 week 3 0.899 (±1.751) 0.261 (±1.723) 0.4386  
     lnIL4 first three weeks 0.819 (±1.785) 0.223 (±1.683) 0.4622  
     
Hispanic No (n=7) Yes (n=6) p  
    lnIL4 week 1 0.319 (±2.425) 0.963 (±2.631) 0.7144  
    lnIL4 week 2 -0.946  (±0.473) 0.988  (±1.986) 0.0427*  
    lnIL4 week 3 -1.139 (n/a) 0.648  (±2.153) 0.0694*  
    lnIL4 first three weeks -0.131  (±2.053) 0.851  (±2.011) 0.4039  
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rs2243250 
Total Population 
CC (n=27) TT (n=19) CT (n=15) p 
     lnIL4 week 1 0.865 (±1.884) 1.307 (±2.379) 0.866 (±2.157) 0.8115 
     lnIL4 week 2 0.75 (±1.723) 0.865 (±1.892) 0.887 (± 2.098) 0.9697 
     lnIL4 week 3 1.044 (±1.723) 0.827 (±1.967) 0.946 (±1.947) 0.9308 
     lnIL4 first three weeks 1.054 (±1.719) 1.118 (±1.879) 0.908 (±2.004) 0.9454 
     
Caucasian CC (n=16) TT (n=2) CT (n=3) p 
     lnIL4 week 1 1.24 (±1.887) n/a 3.167 (± 2.046) 0.1336* 
     lnIL4 week 2 1.596 (±1.665) 1.299 (±1.313) 3.006 (±1.803) 0.3951 
     lnIL4 week 3 1.886 (±1.429) 0.127 (±0.495) 2.427 (±2.187) 0.2459 
     lnIL4 first three weeks 1.729 (±1.399) 0.906 (±1.115) 2.932 (±1.981) 0.2994 
     
African American CC (n=5) TT (n=13) CT (n=5) p 
     lnIL4 week 1 -0.043 (± 1.084) 1.219 (±2.239) 0.188 (±2.299) 0.4688 
     lnIL4 week 2 0.04 (±1.105) 0.702 (±1.877) -0.056 (±1.614) 0.6441 
     lnIL4 week 3 0.613 (±1.222) 0.95 (±1.941) -0.096 (±1.474) 0.5917 
     lnIL4 first three weeks 0.115 (±1.173) 1.172 (±1.883) -0.228 (±1.548) 0.2409 
     
Hispanic CC (n=6) TT (n=3) CT (n=4) p 
    lnIL4 week 1 0.685 (2.637) 4.724 n/a -0.503(0.905) 0.1372* 
    lnIL4 week 2 -0.908 (0.518) 1.896 (2.502) -0.225 (1.061) 0.0570 
    lnIL4 week 3 -1.139 (n/a) 1.417  (±3.005) -0.375  (±0.885) 0.1189* 
    lnIL4 first three weeks 0.037 (2.196) 1.778 (2.575) -0.341 (0.943) 0.3779 
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rs1800795 
Total Population  
CC (n=5) GG (n=36) CG (n=20) p 
     lnIL6 week 1 2.07 (±0.911) 2.81 (±1.26) 2.492 (±1.498) 0.5529 
     lnIL6 week 2 1.617 (±1.991) 2.169 (±1.019) 1.912 (±1.378) 0.5927 
     lnIL6 week 3 1.735 (±1.301) 1.547 (±1.291) 1.709 (±1.293) 0.8917 
     lnIL6 first three weeks 2.117 (±1.021) 2.351 (±1.097) 2.166 (±1.343) 0.8149 
     
Caucasian CC (n=5) GG (n=6) CG (n=10) p 
     lnIL6 week 1 2.07 (±0.911) 2.267 (±1.623) 2.973 (±1.498) 0.5545 
     lnIL6 week 2 1.617 (±1.991) 1.918 (±1.072) 2.389 (±1.099) 0.5883 
     lnIL6 week 3 1.735 (±1.301) 0.733 (±0.981) 1.994 (±1.324) 0.163 
     lnIL6 first three weeks 2.117 (±1.021) 1.859 (±1.057) 2.579 (±1.271) 0.4767 
     
African American CC (n=0) GG (n=13) CG (n=6) p 
     lnIL6 week 1 n/a 2.905 (±1.279) 1.705 (±1.653) 0.1002* 
     lnIL6 week 2 n/a 2.388 (±1.083) 1.294 (±1.509) 0.0766* 
     lnIL6 week 3 n/a 1.796 (±1.422) 1.242 (±1.38) 0.4539 
     lnIL6 first three weeks n/a 2.587 (±1.24) 1.481 (±1.498) 0.0891* 
     
Hispanic CC (n=0) GG (n=10) CG (n=3) p 
    lnIL6 week 1 n/a 2.766 (±0.711) 2.12 (±0.369) 0.1915* 
    lnIL6 week 2 n/a 2.002 (±0.943) 1.019 (±0.992) 0.1528* 
    lnIL6 week 3 n/a 1.614 (±1.234) 1.063 (±0.873) 0.4967 
    lnIL6 first three weeks n/a 2.175 (±0.829) 1.617 (±0.455) 0.2969 
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rs1800795 MAP 
Total Population 
No (n=36) Yes (n=25) p  
     lnIL6 week 1 2.819 (±1.26) 2.435 (±1.423) 0.3314  
     lnIL6 week 2 2.169 (±1.019) 1.861 (±1.452) 0.3532  
     lnIL6 week 3 1.547 (±1.291) 1.714 (±1.265) 0.6315  
     lnIL6 first three weeks 2.351 (±1.097) 2.156 (±1.265) 0.5241  
     
Caucasian No (n=6) Yes (n=15) p  
     lnIL6 week 1 2.267 (±1.632) 2.748 (±1.396) 0.5458  
     lnIL6 week 2 1.918 (±1.072) 2.151 (±1.391) 0.7217  
     lnIL6 week 3 0.733 (±0.981) 1.919 (±1.273) 0.0575*  
     lnIL6 first three weeks 1.859 (±1.057) 2.425 (±1.178) 0.3197  
     
African American No (n=13) Yes (n=6) p  
     lnIL6 week 1 2.905 (±1.279) 1.705 (±1.653) 0.1002*  
     lnIL6 week 2 2.387 (±1.083) 1.294 (±1.509) 0.0766*  
     lnIL6 week 3 1.796 (±1.422) 1.242 (±1.38) 0.4539  
     lnIL6 first three weeks 2.587 (±1.24) 1.481 (±1.497) 0.0891*  
     
Hispanic No (n=10) TT (n=3) p  
    lnIL6 week 1 2.766 (±0.711) 2.12 (±0.369) 0.1915*  
    lnIL6 week 2 2.002 (±0.943) 1.019 (±0.992) 0.1528*  
    lnIL6 week 3 1.614 (±1.234) 1.063 (±0.873) 0.4967  
    lnIL6 first three weeks 2.175 (±0.829) 1.617 (±0.455) 0.2969  
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rs1800796     
Total Population  CC (n=3) GG (n=49) CG (n=9) p 
     lnIL6 week 1 3.041 (n/a) 2.584 (±1.395) 2.94 (±1.063) 0.8008 
     lnIL6 week 2 1.819 (±0.299) 2.042 (±1.271) 2.097 (±1.095) 0.9592 
     lnIL6 week 3 2.226 (±0.6989) 1.571 (±1.352) 1.701 (±0.93) 0.7629 
     lnIL6 first three weeks 2.414(±0.58) 2.275 (±1.204) 2.205 (±1.157) 0.9644 
     
Caucasian CC (n=0) GG (n=19) CG (n=2) p 
     lnIL6 week 1 n/a 2.456 (±1.333) 5.006 (n/a) 0.0834* 
     lnIL6 week 2 n/a 2.164 (±1.261) 1.338 (±1.588) 0.4007 
     lnIL6 week 3 n/a 1.633 (±1.309) 0.941 (±1.331) 0.4878 
     lnIL6 first three weeks n/a 2.284 (±1.018) 2.068 (±2.764) 0.8076 
     
African American CC (n=0) GG (n=21) CG (n=2) p 
     lnIL6 week 1 n/a 2.549 (±1.562) 2.335 (±0.291) 0.853 
     lnIL6 week 2 n/a 1.953 (±1.27) 3.239 (±0.942) 0.1839* 
     lnIL6 week 3 n/a 1.629 (±1.433) 1.995 (±1.385) 0.7348 
     lnIL6 first three weeks n/a 2.255 (±1.419) 2.754 (±0.707) 0.6340 
     
Hispanic CC (n=2) GG (n=7) CG (n=4) P 
    lnIL6 week 1 3.041 (n/a) 2.391 (±0.854) 2.655 (±0.398) 0.7045 
    lnIL6 week 2 2.031 (n/a) 1.513 (±1.192) 2.113 (±0.76) 0.6584 
    lnIL6 week 3 1.739 (n/a) 1.189 (±1.371) 1.912 (±0.757) 0.6299 
    lnIL6 first three weeks 2.460 (±0.809) 1.861 (±0.867) 2.159(±0.706) 0.6286 
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rs1800796 MAP 
Total Population  No (n=49) Yes (n=12) p  
     lnIL6 week 1 2.584 (±1.395) 2.954 (±0.971) 0.3249  
     lnIL6 week 2 2.04 (±1.271) 2.047 (±0.99) 0.9907  
     lnIL6 week 3 1.57 (±1.352) 1.796 (±0.886) 0.6013  
     lnIL6 first three weeks 2.275 (±1.204) 2.257 (±1.021) 0.9642  
     
Caucasian No (n=19) Yes (n=2) p  
     lnIL6 week 1 2.456 (±1.333) 5.005 (n/a) 0.0834*  
     lnIL6 week 2 2.164 (±1.261) 1.388 (±1.588) 0.4007  
     lnIL6 week 3 1.633 (±1.309) 0.941 (±1.331) 0.4878  
     lnIL6 first three weeks 2.284 (±1.018) 2.068 (±2.764) 0.8076  
     
African American No (n=21) Yes (n=2) P  
     lnIL6 week 1 2.549 (±1.562) 2.335 (±0.291) 0.8530  
     lnIL6 week 2 1.953 (±1.27) 3.239 (±0.942) 0.1839*  
     lnIL6 week 3 1.629 (±1.433) 1.995 (±1.385) 0.7348  
     lnIL6 first three weeks 2.255 (±1.419) 2.754 (±0.707) 0.6340  
     
Hispanic 
     
No (n=7) Yes (n=6) P  
lnIL6 week 1 2.391 (±0.854) 2.751 (±0.378) 0.4624  
    lnIL6 week 2 1.513 (±1.192) 2.096 (±0.659) 0.3485  
    lnIL6 week 3 1.1896 (±1.371) 1.878 (±0.659) 0.3272  
    lnIL6 first three weeks 1.861 (±0.867) 2.263(±0.675) 0.3776  
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rs1800871     
Total Population TT (n=7) CC (n=31) CT (n=22) p 
     lnIL10 week 1 2.364 (±2.175) 1.41 (±1.875) 1.581 (±1.386) 0.5423 
     lnIL10 week 2 1.026 (±1.578) 1.012 (±1.869) 0.96 (±1.369) 0.9931 
     lnIL10 week 3 0.812 (±1.663) 0.669 (±1.769) 0.464 (±1.484) 0.8652 
     lnIl10 first three weeks 1.614(±1.839) 1.149 (±1.757) 1.113 (±1.352) 0.7639 
     
Caucasian TT (n=1) CC (n=13) CT (n=6) p 
     lnIL10 week 1 2.715 (n/a) 1.659 (±2.115) 1.938 (±2.059) 0.8807 
     lnIL10 week 2 1.785 (n/a) 1.137 (±1.808) 1.389 (±2.032) 0.9250 
     lnIL10 week 3 0.285 (n/a) 0.949 (±1.949) 1.116 (±1.727) 0.9193 
     lnIL10 first three weeks 2.01 (n/a) 1.461 (±1.801) 1.414 (±1.893) 0.9546 
     
African American TT (n=1) CC (n=11) CT (n=11) p 
     lnIL10 week 1 4.474 (n/a) 1.255 (±1.614) 1.635 (±1.058) 0.1128* 
     lnIL10 week 2 3.616 (n/a) 0.876 (±1.518) 0.973 (±1.245) 0.1933* 
     lnIL10 week 3 3.904 (n/a) 0.464 (±1.276) 0.256 (±1.214) 0.0385* 
     lnIL10 first three weeks 4.063 (n/a) 0.942 (±1.396) 1.091 (±1.174) 0.0911* 
     
Hispanic TT (n=4) CC (n=6) CT (n=3) p 
    lnIL10 week1 1.545 (±2.483) 1.088 (±2.481) 0.261 (±0.739) 0.8319 
    lnIL10 week 2 0.06 (±1.039) 0.373 (±2.272) 0.371 (±0.751) 0.9668 
    lnIL10 week 3 -0.036 (±0.956) 0.215 (±2.307) -0.489 (±0.596) 0.8604 
    lnIL10 first three weeks 1.133 (±2.031) 0.451 (±2.171) 0.042 (±0.664) 0.7494 
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rs1800871 MAP     
Total Population No (n=31) Yes (n=29)  p  
     lnIL10 week 1 1.41 (±1.875) 1.759 (±1.574) 0.5003  
     lnIL10 week 2 1.012 (±1.869) 0.975 (±1.387) 0.9348  
     lnIL10 week 3 0.668 (±1.769) 0.541 (±1.499) 0.7711  
     lnIL10 first three weeks 1.149 (±1.757) 1.234 (±1.464) 0.8422  
     
Caucasian No (n=13) Yes (n=7) p  
     lnIL10 week 1 1.659 (±2.115) 2.067 (±1.869) 0.7029  
     lnIL10 week 2 1.137 (±1.808) 1.455 (±1.825) 0.7266  
     lnIL10 week 3 0.949 (±1.949) 0.997 (±1.607) 0.9560  
     lnIL10 first three weeks 1.461 (±1.801) 1.499 (±1.743) 0.9640  
     
African American No (n=11) Yes (n=12) p  
     lnIL10 week 1 1.255 (±1.614) 1.919 (1.342) 0.3140  
     lnIL10 week 2 0.876 (±1.518) 1.214 (1.424) 0.6051  
     lnIL10 week 3 0.588 (±1.593) 0.464 (1.276) 0.8469  
     lnIL10 first three weeks 0.942 (±1.396) 1.339 (1.41) 0.5055  
     
Hispanic No (n=6) Yes (n=7) p  
    lnIL10 week1 1.088 (±2.481) 1.031 (±1.927)    0.970  
    lnIL10 week 2 0.373 (±2.272) 0.216 (±0.829) 0.8770  
    lnIL10 week 3 0.215 (±2.307) -0.263 (±0.754) 0.6405  
    lnIL10 first three weeks 0.451 (±2.171) 0.665 (±1.597) 0.8414  
     
 
 
 
 
 
  rs1800872 genotype and   
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IL10 milk concentration 
rs1800872     
Total Population  CC (n=29) AA (n=9) AC (n=22) p 
     lnIL10 week 1 1.472 (±1.931) 2.041 (±2.309) 1.425 (±1.369) 0.7242 
     lnIL10 week 2 0.879 (±1.883) 1.365 (±1.697) 0.996 (±1.352) 0.7926 
     lnIL10 week 3 0.567 (±1.771) 1.163 (±1.779) 0.517 (±1.443) 0.6554 
     lnIL10 first three weeks 1.075 (±1.789) 1.509 (±1.972) 1.18 (±1.308) 0.7833 
     
Caucasian CC (n=14) AA (n=3) AC (n=4) p 
     lnIL10 week 1 1.739 (±2.07) 1.727 (±2.522) 1.319 (±2.214) 0.9451 
     lnIL10 week 2 0.997 (±1.775) 2.592 (±1.141) 1.458 (±2.169) 0.5036 
     lnIL10 week 3 0.909 (±1.901) 1.775 (±2.106) 0.757 (±1.648) 0.8066 
     lnIL10 first three weeks 1.347 (±1.793) 1.435 (±2.339) 1.295 (±1.906) 0.9952 
     
African American CC (n=8) AA (n=1) AC (n=13) p 
     lnIL10 week 1 1.259 (±1.785) 4.474 (n/a) 1.628 (±1.146) 0.1351* 
     lnIL10 week 2 0.549 (±1.459) 3.616 n/a 1.085 (±1.354) 0.1468* 
     lnIL10 week 3 0.077 (±1.094) 3.904 n/a 0.621 (±1.341) 0.0325* 
     lnIL10 first three weeks 0.752 (±1.402) 4.063 n/a 1.185 (±1.248) 0.0821* 
     
Hispanic CC (n=6) AA (n=4) AC (n=3) P 
    lnIL10 week 1 1.088 (±2.481) 1.545 (±2.483) 0.261 (±0.739)    0.8319 
    lnIL10 week 2 0.373 (±2.272) 0.06 (±1.039) 0.371 (±0.751) 0.9668 
    lnIL10 week 3 0.215 (±2.307) -0.036 (±0.956) -0.489 (±0.596) 0.8604 
    lnIL10 first three weeks 0.451 (±2.171) 1.133 (±2.031) 0.042 (±0.665) 0.7494 
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rs1800872 MAP     
Total Population  No (n=29) Yes (n=31)  p  
     lnIL10 week 1 1.472 (±1.931) 1.598 (±1.656) 0.8137  
     lnIL10 week 2 0.879 (±1.883) 1.092 (±1.424) 0.6399  
     lnIL10 week 3 0.567 (±1.771) 0.684 (±1.528) 0.7923  
     lnIL10 first three weeks 1.075 (±1.786) 1.232 (±1.506) 0.7147  
     
Caucasian No (n=14) Yes (n=7) p  
     lnIL10 week 1 1.793 (±2.07) 1.494 (±2.149) 0.8158  
     lnIL10 week 2 0.997 (±1.775) 1.912 (±1.751) 0.3350  
     lnIL10 week 3 0.909 (±1.901) 1.096 (±1.671) 0.8376  
     lnIL10 first three weeks 1.347 (±1.793) 1.355 (±1.909) 0.9931  
     
African American No (n=8) Yes (n=14) P  
     lnIL10 week 1 1.259 (±1.785) 1.865 (±1.367) 0.4341  
     lnIL10 week 2 0.549 (±1.459) 1.28 (±1.474) 0.3028  
     lnIL10 week 3 0.077 (±1.094) 0.895 (±1.592) 0.2228  
     lnIL10 first three weeks 0.752 (±1.402) 1.391 (±1.391) 0.3212  
     
Hispanic No (n=6) Yes (n=7) P  
    lnIL10 week1 1.088 (±2.481) 1.031 (±1.927) 0.970  
    lnIL10 week 2 0.373 (±2.272) 0.216 (±0.829) 0.8770  
    lnIL10 week 3 0.215 (±2.307) -0.263(±0.754) 0.6405  
    lnIL10 first three weeks 0.451 (±2.171) 0.665 (±1.597) 0.8414  
     
 
 
 
 
 
     
77 
rs1800896 
Total Population  GG (n=10) AA (n=22) AG (n=28) p 
     lnIL10 week 1 1.537 (±2.373) 1.983 (±1.878) 1.136 (±1.291) 0.3420 
     lnIL10 week 2 1.469 (±2.191) 0.981 (±1.658) 0.907 (±1.421) 0.6503 
     lnIL10 week 3 1.161(±2.378) 0.809 (±1.626) 0.327 (±1.271) 0.3363 
     lnIL10 first three weeks 1.563(±2.216) 1.404 (±1.669) 0.889 (±1.292) 0.3933 
     
Caucasian GG (n=5) AA (n=7) AG (n=9) p 
     lnIL10 week 1 1.777 (±2.19) 2.572 (±2.081) 0.759 (±1.816) 0.2925 
     lnIL10 week 2 1.674 (±2.077) 1.925 (±2.005) 0.614  (±1.421) 0.3562 
     lnIL10 week 3 1.804 (±2.354) 1.641 (±1.708) 0.05 (±1.148) 0.1136* 
     lnIL10 first three weeks 1.832 (±2.098) 2.083 (±1.761) 0.511 (±1.423) 0.1737* 
     
African American CC (n=3) TT (n=6) CT (n=14) p 
     lnIL10 week 1 0.922 (±2.618) 2.247 (±1.342) 1.424 (±1.019) 0.4036 
     lnIL10 week 2 0.637 (±2.042) 1.726 (±1.641) 0.89 (±1.271) 0.4948 
     lnIL10 week 3 -0.618 (±0.903) 1.461 (±1.829) 0.435 (±1.179) 0.1204* 
     lnIL10 first three weeks 0.725 (±2.156) 2.004 (±1.448) 0.872 (±1.126) 0.2161 
     
Hispanic CC (n=2) TT (n=8) CT (n=2) P 
    lnIL10 week 1 1.979 (±3.897) 0.959 (±1.943) 0.377 (±0.576)    0.7781 
    lnIL10 week 2 2.208 (±3.776) -0.167 (±0.74) 0.71 (±0.747) 0.1999* 
    lnIL10 week 3 2.221 (±3.645) -0.367 (±0.779) -0.510 (±0.763) 0.1372* 
    lnIL10 first three weeks 2.145 (±3.763) 0.448 (±1.524) 0.312 (±0.688) 0.5104 
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rs1800896 MAP     
Total Population No (n=22) Yes (n=38) p  
     lnIL10 week 1 1.983 (±1.878) 1.257 (±1.654) 0.1752*  
     lnIL10 week 2 0.981 (±1.658) 1.059 (±1.65) 0.8697  
     lnIL10 week 3  0.809 (±1.626) 0.552 (±1.649) 0.5820  
     lnIL10 first three weeks 1.404 (±1.669) 1.067 (±1.582) 0.4389  
     
Caucasian No (n=7) Yes (n=14) p  
     lnIL10 week 1 2.572 (±2.081) 1.129 (±1.918) 0.1704*  
     lnIL10 week 2 1.925 (±2.005) 0.992 (±1.687) 0.3255  
     lnIL10 week 3 1.641 (±1.708) 0.676 (±1.81) 0.2820  
     lnIL10 first three weeks 2.083 (±1.761) 0.983 (±1.741) 0.1899*  
     
African American No (n=6) Yes (n=17) p  
     lnIL10 week 1 2.247 (±1.542) 1.308 (±1.403) 0.2058  
     lnIL10 week 2 1.726 (±1.641) 0.843 (±1.363) 0.2415  
     lnIL10 week 3 1.461 (±1.829) 0.237 (±1.183) 0.0919*  
     lnIL10 first three weeks 2.005 (±1.448) 0.847 (±1.27) 0.0777*  
     
Hispanic No (n=8) Yes (n=4) p  
lnIL10 week 1 0.959 (±1.945) 1.178 (±2.455)    0.8854  
    lnIL10 week 2 -0.166 (±0.740) 1.459 (±2.384) 0.1186*  
    lnIL10 week 3 -0.367 (±0.779) 0.855 (±2.666) 0.2717  
    lnIL10 first three weeks 0.448 (±1.524) 1.228 (±2.449) 0.5069  
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Table 9: Multivariate analysis of maternal SNP and milk interleukin concentrations 
Multivariate regression model for Interleukin 4 concentration with minor allele presence rs2070874 
Subgroup Outcome Predictor Estimate p-value  
Caucasian lnIL4 week 1 Minor allele presence – 
no  
-3.271 0.1417  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  0.0126 0.9675  
  Prepregnancy BMI 0.018 0.8156  
      
Caucasian lnIL4 week 2 Minor allele presence – 
no  
-1.619 0.2640  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  0.072 0.8357  
  Prepregnancy BMI 0.016 0.8049  
      
Hispanic lnIL4 week 2 Minor allele presence – 
no  
-2.059 0.1406  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.064 0.8689  
  Prepregnancy BMI -0.075 0.6565  
      
Hispanic lnIL4 week 3 Minor allele presence – 
no  
-1.988 0.1920  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.234 0.5979  
  Prepregnancy BMI -0.013 0.9463  
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Multivariate regression model for Interleukin 4 concentration with genotype rs2243250 
Subgroup Outcome Predictor Estimate p-value  
Caucasian lnIL4 week 1 Genotype CC  -2.019 0.1492  
  Genotype TT n/a n/a  
  Genotype CT (reference)    
  Gestational Age  -0.066 0.8324  
  Prepregnancy BMI 0.025 0.7531  
      
Hispanic lnIL4 week 1 Genotype CC  -0.13 0.9665  
  Genotype TT 4.309 0.2868  
  Genotype CT (reference)    
  Gestational Age  -1.159 0.4261  
  Prepregnancy BMI -0.078 0.8620  
      
Hispanic lnIL4 week 2 Genotype CC  -0.636 0.7221  
  Genotype TT 1.966 0.2601  
  Genotype CT (reference)    
  Gestational Age  -0.266 0.5566  
  Prepregnancy BMI -0.033 0.8738  
      
Hispanic lnIL4 week 3 Genotype CC  -1.15 0.5565  
  Genotype TT 1.737 0.3425  
  Genotype CT (reference)    
  Gestational Age  -0.455 0.3664  
  Prepregnancy BMI 0.058 0.7947  
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Multivariate regression model for Interleukin 6 concentration with minor allele presence rs1800795 
Subgroup Outcome Predictor Estimate p-value  
Caucasian lnIL6 week 3 Minor allele presence – 
no  
-1.134 0.0966*  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.139 0.5439  
  Prepregnancy BMI -0.013 0.7854  
      
African American lnIL6 week 1 Minor allele presence – 
no  
0.510 0.4503  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.111 0.2429  
  Prepregnancy BMI -0.086 0.0411*  
      
African American lnIL6 week 2 Minor allele presence – 
no  
0.661 0.2753  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.038 0.6580  
  Prepregnancy BMI -0.069 0.0640*  
      
African American lnIL6 average  Minor allele presence – 
no  
0.498 0.4054  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.041 0.6244  
  Prepregnancy BMI -0.096 0.0126*  
      
Hispanic lnIL6 week 1 Minor allele presence – 
no  
0.444 0.5059  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  0.205 0.4975  
  Prepregnancy BMI 0.001 0.9933  
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Hispanic lnIL6 week 2 Minor allele presence – 
no  
0.701 0.4613  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.055 0.8479  
  Prepregnancy BMI 0.018 0.8695  
      
      
 
 
Multivariate regression model for Interleukin 6 concentration with minor allele presence rs1800796 
Subgroup Outcome Predictor Estimate p-value  
Caucasian lnIL6 week 1 Minor allele presence – 
no  
-2.725 0.1173  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.069 0.7501  
  Prepregnancy BMI 0.005 0.9300  
      
African American lnIL6 weeks 2 Minor allele presence – 
no  
-1.571 0.0772*  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.102 0.2425  
  Prepregnancy BMI -0.076 0.0288  
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Multivariate regression model for Interleukin 10 concentration with minor allele presence rs1800871 
Subgroup Outcome Predictor Estimate p-value  
African American lnIL10 week 1 Minor allele presence – 
no  
-0.57 0.3882  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.011 0.9131  
  Prepregnancy BMI -0.082 0.0601*  
      
African American lnIL10 week 2 Minor allele presence – 
no  
-0.221 0.7116  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  0.122 0.2368  
  Prepregnancy BMI -0.091 0.0350*  
      
African American lnIL10 week 3 Minor allele presence – 
no  
-0.374 0.5796  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.139 0.3483  
  Prepregnancy BMI -0.086 0.2012  
      
African American lnIL10 average Minor allele presence – 
no  
-0.231 0.6754  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  0.063 0.5073  
  Prepregnancy BMI -0.09 0.0263*  
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Multivariate regression model for Interleukin 10 concentration with minor allele presence rs1800872 
Subgroup Outcome Predictor Estimate p-value  
African American lnIL10 week 1 Minor allele presence – 
no  
-0.883 0.2415  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  0.006 0.9612  
  Prepregnancy BMI -0.099 0.0260*  
      
African American lnIL10 week 2 Minor allele presence – 
no  
-0.769 0.2468  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  0.116 0.3209  
  Prepregnancy BMI -0.099 0.0254*  
      
African American lnIL10 week 3 Minor allele presence – 
no  
-0.962 0.1662  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.148 0.3909  
  Prepregnancy BMI -0.085 0.1885  
      
African American lnIL10 average Minor allele presence – 
no  
-0.68 0.2594  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  0.069 0.5129  
  Prepregnancy BMI -0.099 0.0150*  
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Multivariate regression model for Interleukin 10 concentration with minor allele presence rs1800896 
Subgroup Outcome Predictor Estimate p-value  
Total Population lnIL10 week 1 Minor allele presence – 
no  
0.598 0.2935  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.024 0.8168  
  Prepregnancy BMI -0.049 0.2163  
      
Total Population lnIL10 week 1 Genotype GG 0.227 0.7595  
  Genotype AA 0.673 0.2829  
  Genotype AG (reference)    
  Gestational Age  -0.023 0.8233  
  Prepregnancy BMI -0.047 0.2494  
      
Caucasian lnIL10 week 1 Minor allele presence – 
no  
1.493 0.1950  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.236 0.4608  
  Prepregnancy BMI -0.025 0.7670  
      
Caucasian lnIL10 week 3 Minor allele presence – 
no  
1.154 0.2303  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  0.065 0.8475  
  Prepregnancy BMI 0.061 0.3967  
      
Caucasian lnIL10 average Minor allele presence – 
no  
1.185 0.1863  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.194 0.4526  
  Prepregnancy BMI -0.015 0.8189  
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African American lnIL10 week 3 Minor allele presence – 
no  
1.325 0.0705*  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.153 0.2522  
  Prepregnancy BMI -0.082 0.1746  
      
African American lnIL10 average Minor allele presence – 
no  
1.185 0.1863  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  -0.194 0.4526  
  Prepregnancy BMI -0.015 0.8189  
      
Hispanic lnIL10 week 2 Minor allele presence – 
no  
-2.093 0.2417  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  0.057 0.9015  
  Prepregnancy BMI 0.048 0.8099  
      
Hispanic lnIL10 week 3 Minor allele presence – 
no  
  -1.888 0.3229  
  Minor allele presence – 
yes (reference) 
   
  Gestational Age  0.012 0.9807  
  Prepregnancy BMI 0.063 0.7747  
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Table 10: Univariate analysis of maternal SNP and milk interleukin trajectory group 
rs2070874 Trajectory Group 1 
(n=22) 
Trajectory Group 2 
(n=27)  
Trajectory Group 3 
(n=12) 
 
     CC 14 (22.95%) 21 (34.43%) 8 (13.11%)  
     TT 3 (4.92%) 4 (6.56%) 0  p = 0.2245 
     CT 5 (8.20%) 2 (3.28%) 4 (6.56%)  
 
rs2070874 MAP Trajectory Group 1  
(n=22) 
Trajectory Group 2  
(n=27)  
Trajectory Group 3 
(n=12) 
 
     No 14 (22.95%) 21 (34.43%) 8 (13.11%) p = 0.5467 
     Yes 8 (13.11%) 6 (9.84%) 4 (6.56%)  
 
rs2243250 Trajectory Group 1  
(n=22) 
Trajectory Group 2 
(n=27)  
Trajectory Group 3 
(n=12) 
 
     CC 9 (14.75%) 14 (22.95%) 4 (6.56%)  
     TT 7 (11.48%) 8 (13.11%)  4 (6.56%) p = 0.7962 
     CT 6 (9.84%) 5 (8.2%) 4 (6.56%)  
 
rs1800795 Trajectory Group 1  Trajectory Group 2   
     CC 3 (4.92%) 2 (3.28%) p = 0.5807 
     GG 14 (22.95%) 22 (36.07%)   
     CG 10 (16.39%) 10 (16.39%)  
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rs1800795 MAP Trajectory Group 1  Trajectory Group 2   
     No 14 (22.95%) 22 (36.07%) p = 0.4323 
     Yes 13 (21.31%) 12 (19.67%)  
 
rs1800796 Trajectory Group 1  Trajectory Group 2   
     CC 0 (0%) 3 (4.92%) p = 0.4539  
     GG 23 (37.7%) 26 (42.62%)   
     CG 4 (6.56%) 5 (8.2%)  
 
rs1800796 MAP Trajectory Group 1  Trajectory Group 2   
     No 23 (37.7%) 26 (42.62%) p = 0.522 
     Yes 4 (6.56%) 8 (13.11%)  
 
rs1800871 Trajectory Group 1  Trajectory Group 2  Trajectory Group 3 
     TT 1 (1.67%) 4 (6.67%) 2 (3.33%) 
     CC 11 (18.33%) 13 (21.67%)  7 (11.67%) 
     CT 6 (10%) 12 (20%) 4 (6.67%) 
 
rs1800871 MAP Trajectory Group 1  Trajectory Group 2  Trajectory Group 3  
     No 11 (18.33%) 13 (21.67%) 7 (11.67%) p = 0.5293 
     Yes 7 (11.67%) 16 (26.67%) 6 (10%)  
 
rs1800872 Trajectory Group 1  Trajectory Group 2  Trajectory Group 3  
     CC 11 (18.33%) 12 (20%) 6 (10%)  
     AA 2 (3.33%) 4 (6.67%)  3 (5%) p = 0.7560 
     AC 6 (10%) 12 (20%) 4 (6.67%)  
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rs1800872 MAP Trajectory Group 1  Trajectory Group 2  Trajectory Group 3  
     No 11 (18.33%) 12 (20%) 6 (10%) p =0.6301 
     Yes 8 (13.33%) 16 (26.67%) 7 (11.67%)  
 
rs1800896 Trajectory Group 1  Trajectory Group 2  Trajectory Group 3  
     TT 4 (6.67%) 2 (3.33%) 4 (6.67%) p = 0.2913 
     TT 6 (10%) 11 (18.33%)  5 (8.33%)  
     GT 8 (13.33%) 16 (26.67%) 4 (6.67%)  
 
rs1800896 MAP Trajectory Group 1  Trajectory Group 2  Trajectory Group 3  
     No 6 (10%) 11 (18.33%) 5 (8.33%) p = 1.0  
     Yes 12 (20%) 18 (30%) 8 (13.33%)  
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Table 11: Univariate Analysis of Interleukin Trajectory Group and Continuous Infant Outcomes 
Interleukin 4     
Total Population Trajectory Group 1  
(n=25) 
Trajectory Group 2  
(n=24) 
Trajectory Group 3  
(n=13) 
p 
     LnSNAPPEII 2.867 (±0.714) 2.903 (±0.589) 2.758 (±0.696) 0.8124 
     LOS  63.8 (±25.762) 74.161 (40.670) 59.455 (±19.386) 0.3343 
     Weight at 6 weeks 7.52 (±0.19) 7.501 (±0.156) 7.532 (±0.217) 0.7376 
     Days on oxygen 12.208 (±25.108) 16.419 (±20.508) 14.636 (±16.244) 0.7765 
     lnCalprotectin Week 1 5.239 (±0.909) 4.836 (±0.856) 5.137 (±0.871) 0.3007 
     Ln Calprotectin Week 2 5.475 (±0.747) 5.133 (±0.609) 5.052 (±0.836) 0.2203 
     Ln Calprotectin Week 3 5.224 (±0.688) 5.196 (±0.621) 5.471 (±0.666) 0.4966 
     
 
Interleukin 6     
Total Population Trajectory Group 1   
(n=33) 
Trajectory Group 2  
(n=34) 
p   
     LnSNAPPEII 2.853 (±0.694) 2.861 (±0.625) 0.9657  
     LOS  63.727 (±31.881) 71.912 (±34.049) 0.3139  
     Weight at 6 weeks 7.521 (±0.164) 7.506 (±0.189) 0.7376  
     Days on oxygen 13.781 (±24.247) 15.353 (±18.853) 0.7690  
     lnCalprotectin Week 1 4.917 (±0.892) 5.114 (±0.873) 0.4120  
     Ln Calprotectin Week 2 5.256 (±0.766) 5.213 (±0.680) 0.8390  
     Ln Calprotectin Week 3 5.111 (±0.682) 5.421 (±0.586) 0.0825*  
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Interleukin 10     
Total Population Trajectory Group 1  
(n=23) 
Trajectory Group 2  
(n=32) 
Trajectory Group 3  
(n=13) 
p 
     LnSNAPPEII 2.911 (±0.594) 2.842 (±0.669) 2.801 (±0.747) 0.8846 
     LOS  69.869 (±34.492) 68.825 (±36.376) 62.083 (±19.538) 0.7956 
     Weight at 6 weeks 7.489 (±0.172) 7.538 (±0.169) 7.494 (±0.211) 0.5915 
     Days on oxygen 15.5 (±20.43) 12.25 (±23.923) 19.167 (±16.634) 0.6246 
     lnCalprotectin Week 1 5.021 (±0.999) 4.989 (±0.847) 5.088 (±0.840) 0.9517 
     Ln Calprotectin Week 2 5.249 (±0.731) 5.267 (±0.646) 5.125 (±0.887) 0.8702 
     Ln Calprotectin Week 3 4.976 (±0.577) 5.375 (±0.644) 5.445 (±0.671) 0.0810* 
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Table 12: Univariate Analysis of Interleukin Trajectory Group and Categorical Infant Outcomes 
 
     
Interleukin 4     
Total Population Trajectory Group 1  
(n=25) 
Trajectory Group 2  
(n=24) 
Trajectory Group 3  
(n=13)  
p 
     Sepsis     
        Yes 1 (1.67%) 6 (10%) 0 (%) 0.0785* 
        No 21 (35%) 21 (35%) 11 (18.33%)  
     ROP     
        Yes 3 (5.26%) 4 (7.02%) 1 (1.75%) 1.00 
        No 18 (31.58%) 22 (38.6%) 9 (15.79%)  
     BPD     
        Yes 1 (1.67%) 0 (%) 1 (1.64%) 0.3066 
        No 21 (35%) 27 (44.26) 11 (18.03%)  
     NEC     
        Yes 0 (0%) 2 (3.28%) 0 (%) 0.6754 
        No 22 (36.07%) 25 (40.98%) 12 (19.67%)  
     IVH     
        Yes 3 (5.08%) 5 (8.47%) 1 (1.69%) 0.8035 
        No 19 (32.3%) 21 (35.59%) 10 (16.95%)  
     Blood transfusion     
        Yes 9 (14.75%) 16 (26.23%) 3 (4.92%) 0.1273* 
        No 13 (21.31%) 11 (18.03%) 9 (14.75%)  
     Feeding intolerance     
        Yes 3 (5%) 7 (11.67%) 1 (1.67%) 0.4985 
        No 19 (31.67%) 20 (33.33%) 10 (16.67%)  
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Interleukin 6     
Total Population Trajectory Group 1  
(n=27) 
Trajectory Group 2  
(n=33) 
p   
     Sepsis     
        Yes 2 (3.33%) 5 (8.33%) 0.4422  
        No 25 (41.67%) 28 (46.67%)   
     ROP     
        Yes 3 (5.26%) 5 (8.77%) 1.00  
        No 22 (38.6%) 27 (47.37%)   
     BPD     
        Yes 1 (1.64%) 1 (1.64%) 1.00  
        No 26 (42.62%) 33 (54.1%)   
     NEC     
        Yes 0 (0%) 2 (3.28%) 0.4984  
        No 29 (44.26%) 32 (52.46%)   
     IVH     
        Yes 7 (11.86%) 2 (3.39%) 0.0351*  
        No 19 (32.2%) 31 (52.54%)   
     Blood transfusion     
        Yes 14 (22.95%) 14 (22.95%) 0.4473  
        No 13 (21.31%) 20 (32.79%)   
     Feeding intolerance     
        Yes 4 (6.67%) 7 (11.67%) 0.7391  
        No 23 (38.22%) 26 (43.44%)   
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Interleukin 10     
Total Population Trajectory Group 1  
(n=19) 
Trajectory Group 2  
(n=29) 
Trajectory Group 3  
(n=12)  
p 
     Sepsis     
        Yes 2 (3.33%) 5 (8.33%) 0 (0%) 0.3830 
        No 17 (28.33%) 24 (40%) 12 (20%)  
     ROP     
        Yes 3 (5.26%) 4 (7.02%) 1 (1.75%) 1.000 
        No 15 (26.32%) 24 (42.11%) 10 (17.54%)  
     BPD     
        Yes 0 (0%) 1 (1.64%) 1 (1.64%) 0.4770 
        No 19 (31.15%) 28 (45.90%) 12 (19.67%)  
     NEC     
        Yes 0 (%) 2 3.28%) 0 (%) 0.6989 
        No 19 (31.15%) 27 (44.26%) 13 (21.31%)  
     IVH     
        Yes 5 (8.47%) 3 (5.08%) 1 (1.69%) 0.3581 
        No 14 (23.73%) 25 (42.37%) 11 (18.64%)  
     Blood transfusion     
        Yes 12 (19.67%) 11 (18.03%) 5 (8.20%) 0.2211 
        No 7 (11.48%) 18 (29.51%) 8 (13.11%)  
     Feeding intolerance     
        Yes 4 (6.67%) 5 (8.33%) 2 (3.33%) 1.000 
        No 15 (25%) 24 (40%) 10 (16.67%)  
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Table 13: Multivariate analysis of interleukin trajectory group and continuous infant outcomes 
Outcome Predictor Estimate p-value 
lnCalprotectin Week 3 Interleukin 6 trajectory group 1 -0.312 0.0822* 
 Interleukin 6 trajectory group 2 
(reference) 
  
 Gestational Age  0.081 0.0521* 
 Ratio of mom’s own milk to all 
milk 
0.333 0.395 
    
lnCalprotectin Week 3 Interleukin 10 trajectory group 
1 
-0.391 0.1161 
 Interleukin 10 trajectory group 
2 
-0.006 0.9778 
 Interleukin 10 trajectory group 
3 (reference) 
  
 Gestational age  0.072 0.0877* 
 Ratio of mom’s own milk to all 
milk 
0.359 0.372 
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Table 14: Multivariate analysis of interleukin trajectory group and categorical infant outcomes 
Outcome Odds Ratio Point estimate, 95% 
Confidence Interval 
p 
Sepsis IL4 Group Membership  0.2731 
      IL4 group 1 versus 3 0.132 (0.004, 4.028) 0.1416 
      IL4 group 2 versus 3 1.050 (0.086, 12.818) 0.2594 
 Gestational Age 0.348 (0.155, 0.781) 0.0105* 
 Ratio of mom’s own milk 
to all milk 
0.075 (0.001, 4.81) 0.2228 
    
Blood transfusion IL4 Group Membership  0.1917 
      IL4 group 1 versus 3 1.712 (0.298, 9.837) 0.7956 
      IL4 group 2 versus 3 4.162 (0.778, 22.277) 0.0712* 
 Gestational Age 0.454 (0.298, 0.693) 0.0002* 
 Ratio of mom’s own milk 
to all milk 
1.838 (0.148, 22.815) 0.6357 
    
Intraventricular Hemorrhage IL6 Group Membership  0.0412* 
      IL6 group 1 versus 2 6.275 (1.076, 36.584) 0.0412* 
 Gestational Age 0.632 (0.381, 1.050) 0.0762 
 Ratio of mom’s own milk 
to all milk 
5.285 (0.077, 364.919) 0.4410 
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Table 15: Multivariate analysis of interleukin concentrations and continuous infant outcomes 
Subgroup Outcome Predictor Estimate p-value 
Caucasian Lncalprotectin week 2 lnIL6 week 3 0.303  0.0290* 
  Gestational Age  -0.009 0.9180 
  Ratio of mom’s own milk 
to all milk 
-0.829 0.1984 
     
African American Lncalprotectin week 3 lnIL6 week 1 0.169 0.0794* 
  Gestational Age  0.056 0.2941 
  Ratio of mom’s own milk 
to all milk 
-0.129 0.7946 
     
African American Lncalprotectin week 3 lnIL6 week 2 0.137 0.0978* 
  Gestational Age  0.031 0.5153 
  Ratio of mom’s own milk 
to all milk 
-0.329 0.4946 
*Note: only significant SNP/IL models were included 
Table 16: Multivariate analysis of interleukin concentrations and continuous infant outcomes 
Subgroup Outcome Variable Odds Ratio 95% Confidence 
Interval 
p 
African 
American 
IVH lnIL6 week 1 0.329 (0.085, 1.266) 0.1059* 
  Gestational Age 0.336 (0.085, 1.330) 0.1202 
  Ratio of mom’s own 
milk to all milk 
0.033 (<0.001, 55.895) 0.3689 
      
African 
American 
IVH lnIL6 week 2 0.278  (0.052, 1.496) 0.1362 
  Gestational Age 0.246  (0.034, 1.754) 0.1616 
  Ratio of mom’s own 
milk to all milk 
0.026  (<0.001, 77.223) 0.3724 
*Note: only significant SNP/IL models were included 
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Table 17: Univariate analysis of maternal SNP and continuous infant outcomes 
20708742070874     
Total Population CC (n=48) TT (n=9) CT (n=14) p 
     LnSNAPPEII 2.958 (±0.734) 2.659 (±0.610) 2.815 (±0.454) 0.4436 
     LOS  71.542 (±38.069) 67.667 (±28.579) 68.857 (±40.405) 0.9442 
     Weight at 6 weeks 7.496 (±0.177) 7.586 (±0.168) 7.515 (±0.192) 0.4002 
     Days on oxygen 15.083 (±21.534) 16.111 (±23.645) 14.923 (±20.601) 0.9903 
     lnCalprotectin Week 1 4.986 (±0.884) 5.081 (±0.599) 4.914 (±0.983) 0.9234 
     Ln Calprotectin Week 2 5.239 (±0.636) 5.467 (±0.877) 4.946 (±0.819) 0.2649 
     Ln Calprotectin Week 3 5.287 (±0.659) 5.168 (±0.308) 5.329 (±0.778) 0.8882 
     
Caucasian CC (n=20) TT (n=1) CT (n=1)  
     LnSNAPPEII 2.833 (±0.762) 3.258 (n/a) 2.197 (n/a) 0.6168 
     LOS 61.15 (±14.865 1.23 (n/a) 4.7 (n/a) 0.0019* 
     Weight at 6 weeks 7.555 (±0.133) 7.269 (n/a) 1.138 (n/a) 0.0631* 
     Days on oxygen 11.555 (±15.856) 6.9 (n/a) 0 (n/a) 0.0065* 
     lnCalprotectin Week 1 5.07 (0.759) 5.09 (n/a) 6.19 (n/a) 0.3805 
     lnCalprotectin Week 2 5.334 (±0.574) 4.656 (n/a) 4.968 (n/a) 0.4627 
     lnCalprotectin Week 3 5.289 (±0.495) 4.905 (n/a) 5.803 (n/a) 0.4517 
     
African American CC (n=20) TT (n=4) CT (n=7)  
     LnSNAPPEII 3.142 (±0.559) 2.61 (±0.826) 2.829 (±0.524) 0.2152 
     LOS 71.5 (±42.745) 60.25 (±24.047) 54.286 (±16.70) 0.5435 
     Weight at 6 weeks 7.372 (±0.158) 7.604 (±0.064) 7.446 (±0.246) 0.0091* 
     Days on oxygen 17.70 (±24.989) 9.5 (±13.82) 14.167 (±21.302) 0.7989 
     lnCalprotectin Week 1 4.776 (±0.925) 5.373 (±0.433) 5.257 (±0.862) 0.4165 
     lnCalprotectin Week 2 5.001 (±0.607) 5.489 (±0.726) 4.293 (±0.598) 0.0243* 
     lnCalprotectin Week 3 4.974 (±0.574) 5.024 (±0.079) 4.848 (±0.624) 0.8955 
     
Hispanic CC (n=7) TT (n=3) CT (n=4) p 
     LnSNAPPEII 2.846 (±1.055) 2.677 (±0.417) 2.867 (±0.245) 0.9450 
     LOS 80.857 (±31.243) 68.0 (±20.075) 114.667 (±70.358) 0.3721 
     Weight at 6 weeks 7.532 (±0.231) 7.616 (±0.205) 7.469 (±0.102) 0.6370 
     Days on oxygen 19.714 (±27.134) 12.667 (±17.786) 32.0 (±25.339) 0.6435 
     lnCalprotectin Week 1 5.493 (±1.298) 4.878 (±1.101) 4.295 (±1.158) 0.6486 
     lnCalprotectin Week 2 5.929 (±0.669) 5.960 (±1.536) 5.429 (±0.446) 0.6486 
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     lnCalprotectin Week 3 5.885 (±0.669) 5.204 (±0.347) 4.986 (±0.704) 0.2196 
     
 
2070874 MAP     
Total Population No (n=48) Yes (n=23) P  
     LnSNAPPEII 2.958 (±0.734) 2.751 (±0.516) 0.2454  
     LOS  71.542 (±38.069) 68.391 (±35.526) 0.740  
     Weight at 6 weeks 7.496 (±0.177) 7.542 (±0.183) 0.3220  
     Days on oxygen 15.083 (±21.534) 15.409 (±21.351) 0.9532  
     lnCalprotectin Week 1 4.986 (±0.884) 4.976 (±0.848) 0.9679  
     Ln Calprotectin Week 2 5.239 (±0.636) 5.128 (±0.855) 0.5870  
     Ln Calprotectin Week 3 5.287 (±0.659) 5.273 (±0.634) 0.9391  
     
Caucasian No (n=20) Yes (n=2) P  
     LnSNAPPEII 2.8333 (±0.762) 2.728 (±0.75) 0.8569  
     LOS 61.15 (±14.865) 85.0 (±53.74) 0.103*  
     Weight at 6 weeks 7.555 (±0.133) 7.504 (±0.332) 0.651  
     Days on oxygen 11.55 (±15.856) 34.5 (±48.79) 0.1175*  
     lnCalprotectin Week 1 5.076 (±0.759) 5.642 (±0.778) 0.3319  
     lnCalprotectin Week 2 5.334 (±0.574) 4.812 (±0.220) 0.2298  
     lnCalprotectin Week 3 5.289 (±0.495) 5.354 (±0.635) 0.8558  
     
African American No (n=20) Yes (n=11) p  
     LnSNAPPEII 3.142 (±0.559) 2.742 (±0.627) 0.0941*  
     LOS 71.5 (±42.745) 56.455 (±18.704) 0.2786  
     Weight at 6 weeks 7.37 (±0.157) 7.509 (±0.204) 0.0902*  
     Days on oxygen 17.7 (±24.989) 12.3 (±17.932) 0.5485  
     lnCalprotectin Week 1 4.776 (±0.925) 5.307 (±0.662) 0.1842*  
     lnCalprotectin Week 2 5.001 (±0.607) 4.691 (±0.844) 0.3079  
     lnCalprotectin Week 3 4.974 (±0.574) 4.898 (±0.518) 0.767  
     
Hispanic No (n=7) Yes (n=7) p  
     LnSNAPPEII 2.846 (±1.055) 2.786 (±0.313) 0.8883  
     LOS 80.857 (±31.243) 91.333 (±52.864) 0.6660  
     Weight at 6 weeks 7.532 (±0.232) 7.532 (±0.159) 0.9979  
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     Days on oxygen 19.714 (±27.134) 22.333 (±22.214) 0.8542  
     lnCalprotectin Week 1 5.493 (±1.298) 4.489 (±1.067) 0.2166  
     lnCalprotectin Week 2 5.929 (±0.638) 5.606 (±0.816) 0.5715  
     lnCalprotectin Week 3 5.885 (±0.669) 5.095 (±0.470) 0.0764*  
     
 
22432502243250     
Total Population CC (n=31) TT (n=21) CT (n=19) p 
     LnSNAPPEII 2.95 (±0.811) 2.848 (±0.546) 2.816 (±0.551) 0.7922 
     LOS  74.581 (±35.029) 60.381 (±25.593) 75.105 (±48.908) 0.3314 
     Weight at 6 weeks 7.495 (±0.196) 7.497 (±0.187) 7.559 (±0.138) 0.4693 
     Days on oxygen 18.258 (±25.048) 14.19 (±19.372) 11.056 (±16.126) 0.5121 
     lnCalprotectin Week 1 5.053 (±0.916) 5.116 (±0.768) 4.765 (±0.880) 0.4379 
     Ln Calprotectin Week 2 5.258 (±0.699) 5.162 (±0.842) 5.136 (±0.619) 0.8620 
     Ln Calprotectin Week 3 5.403 (±0.655) 50.35 (±0.497) 5.347 (±0.743) 0.190* 
     
Caucasian CC (n=17) TT (n=2) CT (n=3) p 
     LnSNAPPEII 2.882 (±0.769) 3.258 (n/a) 2.197 (n/a) 0.4189 
     LOS 61.765 (±15.335) 92.5 (±43.134) 52.667 (±14.364) 0.0597* 
     Weight at 6 weeks 7.56 (±0.142) 7.373 (±0.147) 7.616 (±0.126) 0.171* 
     Days on oxygen 12.645 (±16.985) 39.0 (±42.426) 2.333 (±2.517) 0.1093* 
     lnCalprotectin Week 1 5.107 (±0.818) 4.858 (±0.33) 5.447 (±0.724) 0.6971 
     lnCalprotectin Week 2 5.44 (±0.531) 4.607 (±0.069) 4.797 (±0.242) 0.0573* 
     lnCalprotectin Week 3 5.319 (±0.485) 4.756 (±0.209) 5.558 (±0.461) 0.1974* 
     
African American CC (n=8) TT (n=15) CT (n=8) p 
     LnSNAPPEII 3.186 (±0.633) 2.822 (±0.598) 3.163 (±0.557) 0.3112 
     LOS 96.625 (±53.774) 57.333 (±24.127) 52.25 (±13.562) 0.0163* 
     Weight at 6 weeks 7.274 (±0.151) 7.463 (±0.188) 7.515 (±0.162) 0.078* 
     Days on oxygen 29.125 (±34.428) 14.333 (±16.443) 4.143 (±8.821) 0.0939* 
     lnCalprotectin Week 1 4.55 (±0.823) 5.407 (±0.799) 4.632 (±0.817) 0.0730* 
     lnCalprotectin Week 2 4.738 (±0.652) 5.02 (±0.851) 4.854 (±0.557) 0.7134 
     lnCalprotectin Week 3 5.15 (±0.446) 4.946 (±0.429) 4.727 (±0.455) 0.3976 
     
Hispanic CC (n=6) TT (n=3) CT (n=5) p 
101 
     LnSNAPPEII 2.784 (±1.141) 2.848 (±0.124) 2.836 (±0.425) 0.9915 
     LOS 81.5 (±34.175) 61.0 (±22.627) 100.6 (±53.374) 0.5257 
     Weight at 6 weeks 7.504 (±0.241) 7.561 (±0.192) 7.547 (±0.159) 0.9069 
     Days on oxygen 19.667 (±29.723) 2.5 (±3.536) 29.8 (±18.674) 0.4265 
     lnCalprotectin Week 1 5.961 (±1.102) 4.594 (±0.699) 4.367 (±1.147) 0.1891* 
     lnCalprotectin Week 2 6.059 (±0.843) 5.841 (±1.105) 5.445 (±0.456) 0.6533 
     lnCalprotectin Week 3 5.976 (±0.705) 4.969 (±0.679) 5.292 (±0.289) 0.163* 
     
 
1800795     
Total Population CC (n=5) GG (n=45) CG (n=21) p 
     LnSNAPPEII 3.369 (±0.305) 2.969 (±0.652) 2.649 (±0.679) 0.0944* 
     LOS  67 (±36.083) 70.911 (±39.183) 70.524 (±34.064) 0.9759 
     Weight at 6 weeks 7.438 (±0.135) 7.508 (±0.188) 7.541 (±0.167) 0.5591 
     Days on oxygen 21.4 (±39.905) 11.886 (±17.362) 20.619 (±26.012) 0.2444 
     lnCalprotectin Week 1 5.044 (±0.282) 5.005 (±0.797) 4.922 (±1.091) 0.9381 
     Ln Calprotectin Week 2 5.534 (±0.635) 5.094 (±0.81) 5.337 (±0.476) 0.3424 
     Ln Calprotectin Week 3 5.2631 (±0.349) 5.295 (±0.701) 5.258 (±0.589) 0.9809 
     
Caucasian CC (n=5) GG (n=7) CG (n=10) p 
     LnSNAPPEII 3.369 (±0.305) 2.446 (±0.431) 2.768 (±0.831) 0.3068 
     LOS 67 (±36.083) 63 (±17.776) 61.7 (±10.12) 0.8946 
     Weight at 6 weeks 7.438 (±0.135) 7.57 (±0.103) 7.581 (±0.168) 0.2486 
     Days on oxygen 21.4 (±29.9) 4.429 (±4.276) 16.2 (±19.629) 0.3022 
     lnCalprotectin Week 1 5.044 (±0.282) 5.012 (±0.597) 5.266 (±1.019) 0.7941 
     lnCalprotectin Week 2 5.543 (±0.635) 4.87 (±0.495) 5.452 (±0.467) 0.0901* 
     lnCalprotectin Week 3 5.263 (±0.349) 5.291 (±0.546) 5.313 (±0.540) 0.9896 
     
African American CC (n=0) GG (n=25) CG (n=6) p 
     LnSNAPPEII 0 3.078 (±0.614) 2.637 (±0.449) 0.1437* 
     LOS 0 68.76 (±38.285) 55.333 (±27.457) 0.4269 
     Weight at 6 weeks 0 7.442 (±0.196) 7.383 (±0.164) 0.6238 
     Days on oxygen 0 14.452 (±17.088) 21.333 (±40.038) 0.5218 
     lnCalprotectin Week 1 0 4.948 (±0.818) 4.848 (±1.289) 0.8402 
     lnCalprotectin Week 2 0 4.783 (±0.749) 5.191 (±0.467) 0.2259 
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     lnCalprotectin Week 3 0 4.914 (±0.513) 5.082 (±0.707) 0.5557 
     
Hispanic CC (n=0) GG (n=10) CG (n=4) p 
     LnSNAPPEII 0 2.979 (±0.746) 2.406 (±0.665) 0.2066 
     LOS 0 74.889 (±29.817) 110.0 (±56.739) 0.1627* 
     Weight at 6 weeks 0 7.534 (±0.216) 7.526 (±0.164) 0.9434 
     Days on oxygen 0 15.778 (±24.748) 32.5 (±20.273) 0.2634 
     lnCalprotectin Week 1 0 5.316 (±1.132) 4.254 (±1.162) 0.1884* 
     lnCalprotectin Week 2 0 5.829 (±0.753) 5.311 (±0.732) 0.4175 
     lnCalprotectin Week 3 0 5.708 (±0.719) 5.013 (±0.077) 0.2278 
     
 
1800795 MAP1800795 MAP     
Total Population No (n=45) Yes (n=26) p  
     LnSNAPPEII 2.969 (±0.653) 2.743 (±0.684) 0.2005*  
     LOS  70.911 (±39.183) 69.846 (±33.743) 0.9081  
     Weight at 6 weeks 7.508 (±0.188) 7.523 (±0.164) 0.7541  
     Days on oxygen 11.886 (±17.362) 20.769 (±26.166) 0.0923*  
     lnCalprotectin Week 1 5.005 (±0.797) 4.944 (±0.989) 0.7969  
     Ln Calprotectin Week 2 5.094 (±0.81) 5.376 (±0.499) 0.1657*  
     Ln Calprotectin Week 3 5.295 (±0.701) 5.259 (±0.550) 0.8440  
     
Caucasian No (n=7) Yes (n=15) p  
     LnSNAPPEII 2.446 (±0.431) 2.906 (±0.776) 0.3465  
     LOS 63 (±17.776) 63.467 (±21.084) 0.9601  
     Weight at 6 weeks 7.57 (±0.103) 7.54 (±0.168) 0.6716  
     Days on oxygen 4.429 (±4.276) 17.933 (±22.575) 0.1368*  
     lnCalprotectin Week 1 5.012 (±0.597) 5.198 (±0.851) 0.616  
     lnCalprotectin Week 2 4.87 (±0.495) 5.479 (±0.501) 0.0267*  
     lnCalprotectin Week 3 5.291 (±0.546) 5.299 (±0.478) 0.9732  
     
African American No (n=25) Yes (n=6) p  
     LnSNAPPEII 3.078 (±0.614) 2.637 (±0.449) 0.1437*  
     LOS 68.76 (±38.285) 55.333 (±27.457) 0.4269  
     Weight at 6 weeks 7.442 (±0.196) 7.383 (±0.164) 0.6238  
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     Days on oxygen 14.452 (±17.088) 21.333 (±40.038) 0.5218  
     lnCalprotectin Week 1 4.948 (±0.818) 4.848 (±1.289) 0.8402  
     lnCalprotectin Week 2 4.783 (±0.749) 5.191 (±0.467) 0.2259  
     lnCalprotectin Week 3 4.914 (±0.513) 5.082 (±0.707) 0.5557  
     
Hispanic No (n=10) Yes (n=4) p  
     LnSNAPPEII 2.979 (±0.746) 2.406 (±0.665) 0.2066  
     LOS 74.889 (±29.817) 110.0 (±56.739) 0.1627*  
     Weight at 6 weeks 7.534 (±0.216) 7.526 (±0.164) 0.9434  
     Days on oxygen 15.778 (±24.748) 32.5 (±20.273) 0.2634  
     lnCalprotectin Week 1 5.316 (±1.132) 4.254 (±1.162) 0.1884*  
     lnCalprotectin Week 2 5.829 (±0.753) 5.311 (±0.732) 0.4175  
     lnCalprotectin Week 3 5.708 (±0.719) 5.013 (±0.077) 0.2278  
     
 
1800796      
Total Population GG (n=3) AA (n=58) AG (n=11) p 
     LnSNAPPEII 3.105 (±0.998) 2.845 (±0.659) 3.028 (±0.665) 0.6419 
     LOS  146 (±97.581) 67.569 (±28.194) 72.364 (±54.099) 0.0110* 
     Weight at 6 weeks 7.491 (±0.152) 7.498 (±0.183) 7.615 (±0.128) 0.2260 
     Days on oxygen 3.0  (±2.8285) 16.105 (±22.457) 12.636 (±16.439) 0.6389 
     lnCalprotectin Week 1 5.287 (±1.437) 4.979 (±0.897) 4.907 (±0.545) 0.8046 
     Ln Calprotectin Week 2 4.874 (n/a) 5.158 (±0.684) 5.382 (±0.876) 0.5996 
     Ln Calprotectin Week 3 6.194 (±0.656) 5.211 (±0.615) 5.319 (±0.639) 0.036* 
     
Caucasian GG (n=0) AA (n=20) AG (n=2) p 
     LnSNAPPEII 0 2.802 (±0.758) 3.09 (n/a) 0.7176 
     LOS 0 64.4 (±20.109) 52.5 (±13.435) 0.4279 
     Weight at 6 weeks 0 7.559 (±0.153) 7.469 (±0.01) 0.4273 
     Days on oxygen 0 14.55 (±20.379) 4.5 (±6.364) 0.504 
     lnCalprotectin Week 1 0 5.139 (±0.789) 5.077 (±0.6396) 0.916 
     lnCalprotectin Week 2 0 5.326 (±0.572) 4.875 (±0.449) 0.303 
     lnCalprotectin Week 3 0 5.352 (±0.484) 4.851 (±0.343) 0.1805* 
     
African American GG (n=0) AA (n=27) AG (n=4) p 
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     LnSNAPPEII 0 2.921 (±0.564) 3.649 (±0.645) 0.0467* 
     LOS 0 60.963 (±21.517) 101.25 (±85.885) 0.0367* 
     Weight at 6 weeks 0 7.434 (± 0.189) 0 (n/a) n/a 
     Days on oxygen 0 15.384 (±23.233) 19.25 (±21.654) 0.7574 
     lnCalprotectin Week 1 0 4.969 (±0.926) 4.663 (±0.400) 0.5840 
     lnCalprotectin Week 2 0 4.879 (±0.690) 4.910 (±0.886) 0.9384 
     lnCalprotectin Week 3 0 4.867 (±0.494) 5.511 (±0.650) 0.0547* 
     
Hispanic GG (n=2) AA (n=9) AG (n=4) p 
     LnSNAPPEII 3.559 (±0.869) 2.661 (±0.816) 2.754 (±0.427) 0.3345 
     LOS 77.0 (n/a) 92.556 (±47.355) 68 (±20.075) 0.6910 
     Weight at 6 weeks 7.383 (n/a) 7.485 (±0.200P) 7.675 (±0.097) 0.1893* 
     Days on oxygen 5.0 (n/a) 23.778 (±27.376) 17.667 (±16.623) 0.7659 
     lnCalprotectin Week 1 5.493 (±1.969) 4.618 (±1.315) 4.945 (±0.794) 0.7356 
     lnCalprotectin Week 2 4.874 (n/a) 5.647 (±0.678) 6.105 (±0.816) 0.3848 
     lnCalprotectin Week 3 5.949 (±0.708) 5.783 (±0.675) 4.959 (±0.472) 0.1976* 
     
 
1800796 MAP     
Total Population No (n=58) Yes (n=13) p  
     LnSNAPPEII 2.846 (±1.609) 3.047 (±0.709) 0.3526  
     LOS  67.569 (±28.195) 83.692 (±63.222) 0.1575*  
     Weight at 6 weeks 7.498 (±0.184) 7.59 (±0.131) 0.1370*  
     Days on oxygen 16.105 (±22.457) 11.154 (±15.459) 0.4539  
     lnCalprotectin Week 1 4.979 (±0.898) 4.995 (±0.771) 0.9527  
     Ln Calprotectin Week 2 5.158 (±0.684) 5.339 (±0.848) 0.4457  
     Ln Calprotectin Week 3 5.211 (±0.615) 5.521 (±0.725) 0.1319*  
     
Caucasian No (n=20) Yes (n=2) p  
     LnSNAPPEII 2.802 (±0.758) 3.091 (n/a) 0.7176  
     LOS 64.40 (±20.109) 52.5 (±13.43) 0.4279  
     Weight at 6 weeks 7.559 (±0.153) 7.469 (±0.015) 0.4273  
     Days on oxygen 14.55 (±20.379) 1.5 (±6.364) 0.504  
     lnCalprotectin Week 1 5.139 (±0.789) 5.077 (±0.639) 0.916  
     lnCalprotectin Week 2 5.326 (±0.572) 4.875 (±0.449) 0.303  
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     lnCalprotectin Week 3 5.352 (±0.484) 4.851 (±0.343) 0.1805*  
     
African American No (n=27) Yes (n=4) p  
     LnSNAPPEII 2.921 (±0.564) 3.649 (±0.645) 0.0467*  
     LOS 60.963 (±21.517) 101.25 (±85.885) 0.0367*  
     Weight at 6 weeks 7.434  (± 0.189) 0 (n/a) n/a  
     Days on oxygen 15.384 (±23.233) 19.25 (±21.654) 0.7574  
     lnCalprotectin Week 1 4.969 (±0.926) 4.663 (±0.400) 0.5840  
     lnCalprotectin Week 2 4.879 (±0.690) 4.910 (±0.886) 0.9384  
     lnCalprotectin Week 3 4.867 (±0.494) 5.511 (±0.650) 0.0547*  
     
Hispanic No (n=9) Yes (n=6) p  
     LnSNAPPEII 2.661 (±0.816) 3.022 (±0.659) 0.3925  
     LOS 92.556 (±47.355) 70.25 (±16.998) 0.3886  
     Weight at 6 weeks 7.485 (±0.200) 7.616 (±0.155) 0.231  
     Days on oxygen 23.778 (±27.376) 14.5 (±14.9778) 0.5434  
     lnCalprotectin Week 1 4.618 (±1.315) 5.164 (±1.173) 0.5079  
     lnCalprotectin Week 2 5.647 (±0.678) 5.797 (±0.906) 0.7827  
     lnCalprotectin Week 3 5.783 (±0.675) 5.356 (±0.729) 0.3645  
     
 
1800871     
Total Population TT (n=7) CC (n=40) CT (n=24) p 
     LnSNAPPEII 3.062 (±0.643) 2.894 (±0.691) 2.804 (±0.672) 0.7082 
     LOS  58.667 (±17.489) 75.075 (±38.711) 67.792 (±37.383) 0.5189 
     Weight at 6 weeks 7.534 (±0.178) 7.501 (±0.181) 7.528 (±0.182) 0.8358 
     Days on oxygen 8.333 (±7.005) 18.0 (±24.515) 12.917 (±17.90) 0.4668 
     lnCalprotectin Week 1 5.199 (±0.969) 4.927 (±0.783) 5.204 (±4.046) 0.7453 
     Ln Calprotectin Week 2 5.507 (±0.560) 5.228 (±0.665) 4.976 (±0.892) 0.3050 
     Ln Calprotectin Week 3 5.849 (±0.539) 5.274 (±0.631) 5.149 (±0.654) 0.0980* 
     
Caucasian TT (n=1) CC (n=14) CT (n=6) p 
     LnSNAPPEII 2.89 (n/a) 2.824 (±0.729) 2.714 (±1.033) 0.9676 
     LOS 57 (n/a) 64.74 (±20.447) 67.5 (±14.46) 0.8686 
     Weight at 6 weeks 7.719 (n/a) 7.533 (±0.146) 7.563 (±0.158) 0.4838 
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     Days on oxygen 10 (n/a) 12.429 (±19.782) 5.625 (±1.004) 0.7863 
     lnCalprotectin Week 1 5.473 (n/a) 4.948 (±0.647) 5.625 (±1.004) 0.2411 
     lnCalprotectin Week 2 5.881 (n/a) 5.363 (±0.538) 4.671 (±0.259) 0.079* 
     lnCalprotectin Week 3 n/a 5.333 (±0.466) 5.198 (±0.594) 0.6133 
     
African American TT (n=1) CC (n=17) CT (n=13) p 
     LnSNAPPEII n/a 3.094 (±0.603) 2.934 (±0.60) 0.3324 
     LOS 36.0 (n/a) 77.118 (±44.084) 54.154 (±18.032) 0.1640* 
     Weight at 6 weeks n/a 7.435 (±0.20) 7.433 (±0.186) 0.9743 
     Days on oxygen 4.0 (n/a) 19.562 (±27.043) 12.307 (±16.977) 0.6178 
     lnCalprotectin Week 1 4.874 (n/a) 5.068 (±0.769) 4.681 (±1.111) 0.6211 
     lnCalprotectin Week 2 4.857 (n/a) 4.956 (±0.712) 4.754 (±0.764) 0.8206 
     lnCalprotectin Week 3 n/a 4.972 (±0.596) 4.982 (±0.514) 0.8493 
     
Hispanic TT (n=4) CC (n=8) CT (n=3) p 
     LnSNAPPEII 3.321 (±0.643) 2.894 (±0.691) 2.804 (±0.672) 0.7082 
     LOS 58.667 (±17.489) 75.075 (±38.711) 670792 (±37.383) 0.5189 
     Weight at 6 weeks 7.534 (±0.178) 7.501 (±0.181) 7.528 (±0.182) 0.8358 
     Days on oxygen 8.333 (±7.005) 18.0 (±24.515) 12.917 (±17.9) 0.4668 
     lnCalprotectin Week 1 5.199 (±0.969) 4.927 (±0.783) 5.024 (±1.046) 0.7453 
     lnCalprotectin Week 2 5.507 (±0.560) 5.228 (±0.665) 4.976 (±0.892) 0.3050 
     lnCalprotectin Week 3 5.849 (±0.539) 5.274 (±0.631) 5.149 (±0.654) 0.0980* 
     
 
1800871 MAP     
Total Population No (n=40) Yes (n=31) p  
     LnSNAPPEII 2.894 (±0.691) 2.863 (±0.662) 0.8621  
     LOS  75.075 (±38.71) 65.967 (±34.276) 0.3102  
     Weight at 6 weeks 7.501 (±0.181) 7.529 (±0.178) 0.5497  
     Days on oxygen 18 (±24.515) 12 (±16.312) 0.2514  
     lnCalprotectin Week 1 4.927 (±0.783) 5.077 (±1.004) 0.5263  
     Ln Calprotectin Week 2 5.228 (±0.665) 5.143 (±0.826) 0.6830  
     Ln Calprotectin Week 3 5.274 (±0.631) 5.295 (±0.686) 0.9065  
     
Caucasian No (n=14) Yes (n=7) p  
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     LnSNAPPEII 2.824 (±0.729) 2.749 (±0.897) 0.8637  
     LOS 64.714 (±20.447) 66 (±13.784) 0.8829  
     Weight at 6 weeks 7.533 (±0.146) 7.585 (±0.156) 0.4536  
     Days on oxygen 12.429 (±19.782) 17.857 (±21.302) 0.5698  
     lnCalprotectin Week 1 4.948 (±0.647) 5.599 (±0.90) 0.0885*  
     lnCalprotectin Week 2 5.363 (±0.538) 4.973 (±0.641) 0.2368  
     lnCalprotectin Week 3 5.334 (±0.466) 5.198 (±0.594)0. 0.6133  
     
African American No (n=17) Yes (n=14) p  
     LnSNAPPEII 3.094 (±0.603) 2.872 (±0.61) 0.3469  
     LOS 77.118 (±44.084) 52.857 (±17.991) 0.0639  
     Weight at 6 weeks 7.435 (±0.20) 7.433 (±0.186) 0.9743  
     Days on oxygen 19.562 (±27.043) 11.714 (±16.462) 0.3539  
     lnCalprotectin Week 1 5.068 (±0.769) 4.703 (±1.042) 0.339  
     lnCalprotectin Week 2 4.956 (±0.712) 4.766 (±0.716) 0.5338  
     lnCalprotectin Week 3 4.972 (±0.597) 4.928 (±0.514) 0.8493  
     
Hispanic No (n=8) Yes (n=7) p  
     LnSNAPPEII 2.693 (±0.852) 2.938 (±0.612) 0.5618  
     LOS 93.286 (±52.554) 76.833 (±23.404) 0.495  
     Weight at 6 weeks 7.492 (±0.198) 7.584 (±0.183) 0.3939  
     Days on oxygen 28.857 (±29.249) 11.667 (±12.801) 0.211  
     lnCalprotectin Week 1 4.541 (±1.263) 5.241 (±1.179) 0.3919  
     lnCalprotectin Week 2 5.668 (±0.673) 5.769 (±0.916) 0.853  
     lnCalprotectin Week 3 5.584 (±0.896) 5.555 (±0.545) 0.9530  
     
 
1800872     
Total Population CC (n=39) AA (n=9) AC (n=24) p 
     LnSNAPPEII 2.883 (±0.713) 2.963 (±0.626) 2.878 (±0.653) 0.9505 
     LOS  77.684 (±37.757) 55.75 (±19.64) 66.042 (±38.589) 0.2201 
     Weight at 6 weeks 7.507 (±0.172) 7.562 (±0.160) 7.521 (±0.202) 0.9474 
     Days on oxygen 16.703 (±20.513) 7 (±6.503) 16.208 (±25.578) 0.5023 
     lnCalprotectin Week 1 4.903 (±0.787) 5.169 (±0.858) 5.091 (±1.071) 0.6389 
     Ln Calprotectin Week 2 5.173 (±0.689) 5.507 (±0.560) 5.131 (±0.844) 0.5367 
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     Ln Calprotectin Week 3 5.272 (±0.652) 5.848 (±0.482) 5.117 (±0.634) 0.0552* 
     
Caucasian CC (n=15) AA (n=3) AC (n=4) p 
     LnSNAPPEII 2.824 (±0.789) 2.741 (±0.487) 2.886 (±1.192) 0.9748 
     LOS 67.73 (±19.692) 50.333 (±22.745) 56.5 (±14.978) 0.2931 
     Weight at 6 weeks 7.523 (±0.139) 7.602 (±0.164) 7.627 (±0.18) 0.4163 
     Days on oxygen 12.8 (±18.88) 5.333 (±4.509) 23 (±28.959) 0.5019 
     lnCalprotectin Week 1 4.933 (±0.626) 5.2 (±0.412) 5.99 (±1.169) 0.0798* 
     lnCalprotectin Week 2 5.299 (±0.572) 5.881 (n/a) 4.797 (±0.242) 0.2891 
     lnCalprotectin Week 3 5.258 (±0.509) 5.845 (n/a) 5.289 (±0.445) 0.5415 
     
African American CC (n=14) AA (n=1) AC (n=5) p 
     LnSNAPPEII 3.113 (±0.646) 2.197 (n/a) 2.968 (±0.563) 0.3512 
     LOS 82.143 (±44.487) 36.0 (n/a) 56.067 (±21.215) 0.1001* 
     Weight at 6 weeks 7.458 (±0.193) (n/a) 7.411 (±0.191) 0.5767 
     Days on oxygen 16.231 (±16.996) 4.0 (n/a) 17.467 (±28.099) 0.8587 
     lnCalprotectin Week 1 5.042 (±0.813) 4.874 (n/a) 4.839 (±1.075) 0.8767 
     lnCalprotectin Week 2 4.804 (±0.718) 4.857 (n/a) 4.976 (±0.746) 0.8534 
     lnCalprotectin Week 3 4.978 (±0.661) (n/a) 4.901 (±0.49) 0.7586 
     
Hispanic CC (n=8) AA (n=4) AC (n=3) p 
     LnSNAPPEII 2.693 (±0.852) 3.321 (±0.584) 2.428 (±0.400) 0.2614 
     LOS 93.286 (±52.54) 72.667 (±7.505) 81.0 (±35.511) 0.780 
     Weight at 6 weeks 7.492 (±0.198) 7.468 (±0.199) 7.7 (±0.065) 0.2350 
     Days on oxygen 28.857 (±29.249) 12.0 (±7.549) 11.333 (±18.771) 0.4750 
     lnCalprotectin Week 1 4.541 (±1.263) 5.137 (±1.335) 5.656 n/a 0.667 
     lnCalprotectin Week 2 5.668 (±0.673) 5.345 (±0.417) 7.046 n/a 0.1220* 
     lnCalprotectin Week 3 5.584 (±0.896) 5.704 (±0.498) 4.956 n/a 0.6875 
     
 
1800872 MAP     
Total Population No (n=39) Yes (n=33) p  
     LnSNAPPEII 2.883 (±0.713) 2.901 (±0.636) 0.9157  
     LOS  77.684 (±37.757) 63.469 (±34.82) 0.1087*  
     Weight at 6 weeks 7.507 (±0.172) 7.522 (±0.19) 0.7454  
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     Days on oxygen 16.703 (±20.513) 13.906 (±22.614) 0.5920  
     lnCalprotectin Week 1 4.903 (±0.787) 5.119 (±0.977) 0.3540  
     Ln Calprotectin Week 2 5.173 (±0.689) 5.238 (±0.779) 0.7484  
     Ln Calprotectin Week 3 5.272 (±0.652) 5.293 (±0.672) 0.9105  
     
Caucasian No (n=15) Yes (n=7) p  
     LnSNAPPEII 2.824 (±0.0729) 2.813 (±0.818) 0.9785  
     LOS 67.733 (±19.692) 53.857 (±17.189) 0.1258*  
     Weight at 6 weeks 7.523 (±0.138) 7.619 (±0.158) 0.1841*  
     Days on oxygen 12.8 (±18.88) 15.429 (±22.699) 0.7781  
     lnCalprotectin Week 1 4.933 (±0.625) 5.599 (±0.897) 0.0707  
     lnCalprotectin Week 2 5.299 (±0.572) 5.158 (±0.649) 0.7051  
     lnCalprotectin Week 3 5.258 (±0.509) 5.428 (±0.457) 0.5583  
     
African American No (n=14) Yes (n=16) p  
     LnSNAPPEII 3.113 (±0.646) 2.93 (±0.58) 0.4464  
     LOS 82.143 (±44.487) 54.813 (±21.1) 0.0366*  
     Weight at 6 weeks 7.458 (±0.194) 7.41 (±0.191) 0.5767  
     Days on oxygen 16.231 (±16.996) 16.625 (±27.354) 0.9642  
     lnCalprotectin Week 1 5.042 (±0.813) 4.842 (±1.014) 0.6043  
     lnCalprotectin Week 2 4.804 (±0.718) 4.965 (±0.712) 0.5839  
     lnCalprotectin Week 3 4.978 (±0.661) 4.901 (±0.49) 0.7586  
     
Hispanic No (n=8) Yes (n=7) p  
     LnSNAPPEII 2.693 (±0.852) 2.938 (±0.672) 0.5618  
     LOS 93.286 (±52.554) 76.833 (±23.404) 0.4950  
     Weight at 6 weeks 7.492 (±0.198) 7.584 (±0.183) 0.3939  
     Days on oxygen 28.857 (±29.249) 11.667 (±12.801) 0.2110  
     lnCalprotectin Week 1 4.541 (±1.263) 5.241 (±1.179) 0.3919  
     lnCalprotectin Week 2 5.668 (±0.673) 5.769 (±0.916) 0.8530  
     lnCalprotectin Week 3 5.584 (±0.896) 5.555 (±0.545) 0.9530  
     
18008960896     
Total Population GG (n=13) AA (n=32) AG (n=34) p 
     LnSNAPPEII 2.803 (±0.472) 2.868 (±0.766) 2.914 (±0.678) 0.9004 
     LOS  76.75 (±38.581) 59.125 (±23.184) 75.735 (±43.461) 0.1987* 
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     Weight at 6 weeks 7.529 (±0.163) 7.542 (±0.179) 7.496 (±0.181) 0.6594 
     Days on oxygen 15.333 (±18.593) 17.833 (±27.142) 13.0 (±17.897) 0.7084 
     lnCalprotectin Week 1 4.741 (±1.031) 5.115 (±0.766) 4.992 (±0.867) 0.5031 
     Ln Calprotectin Week 2 5.106 (±0.689) 5.631 (±0.709) 4.981 (±0.661) 0.0164* 
     Ln Calprotectin Week 3 5.227 (±0.584) 5.499 (±0.669) 5.145 (±0.648) 0.1896* 
     
Caucasian GG (n=5) AA (n=8) AG (n=9) p 
     LnSNAPPEII 2.563 (±0.634) 2.769 (±0.864) 3.008 (±0.694) 0.7036 
     LOS 62.2 (±10.257) 56.75 (±16.59) 69.77 (±25.114) 0.4103 
     Weight at 6 weeks 7.62 (±0.103) 7.554 (±0.119) 7.508 (±0.183) 0.4152 
     Days on oxygen 12 (±15.443) 13.75 (±21.393) 14.444 (±22.187) 0.9776 
     lnCalprotectin Week 1 5.034 (±1.014) 4.896 (±0.557) 5.361 (±0.802) 0.484 
     lnCalprotectin Week 2 5.415 (±0.369) 5.667 (±0.54) 4.946 (±0.537) 0.0573* 
     lnCalprotectin Week 3 5.632 (±0.451) 5.479 (±0.379) 4.99 (±0.441) 0.0436* 
     
African American GG (n=5) AA (n=6) AG (n=20)  p 
     LnSNAPPEII 2.953 (±0.505) 2.947 (±0.649) 3.022 (±0.641) 0.9598 
     LOS 66.0 (±8.155) 55.83 (±28.673) 69.3 (±42.678) 0.7427 
     Weight at 6 weeks 7.447 (±0.222) 7.329 (±0.142) 7.452 (±0.191) 0.6048 
     Days on oxygen 7.8 (±10.257) 27.667 (±38.79) 14.316 (±17.954) 0.3212 
     lnCalprotectin Week 1 5.009 (±0.951) 5.093 (±0.631) 4.845 (±0.971) 0.8539 
     lnCalprotectin Week 2 4.493 (±0.782) 4.969 (±0.406) 4.962 (±0.729) 0.4962 
     lnCalprotectin Week 3 5.006 (±0.491) 4.697 (±0.462) 5.004 (±0.591) 0.6142 
     
Hispanic GG (n=3) AA (n=9) AG (n=2) p 
     LnSNAPPEII 2.842 (±0.293) 2.989 (±0.836) 1.903(±0.416) 0.2131 
     LOS 140.0 (±77.782) 68.5 (±26.333) 97.0 (±26.87) 0.0843* 
     Weight at 6 weeks 7.516 (±0.045) 7.586 (±0.204) 7.512 (±0.174) 0.7861 
     Days on oxygen 42.5 (±24.749) 19.0 (±26.338) 6.5 (±0.7.778) 0.3677 
     lnCalprotectin Week 1 3.903 (±1.043) 5.409 (±1.133) 4.742 n/a 0.2250 
     lnCalprotectin Week 2 5.408 (±0.544) 5.947 (±0.886) n/a 0.3855 
     lnCalprotectin Week 3 4.488 n/a 5.823 (±0.644) 5.067 n/a 0.1869* 
     
1800896 MAP     
Total Population No (n=25) Yes (n=47) p  
     LnSNAPPEII 2.868 (±0.766) 2.886 (±0.629) 0.920  
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     LOS  59.125 (±23.84) 76.0 (±41.823) 0.0715*  
     Weight at 6 weeks 7.542 (±0.179) 7.507 (±0.174) 0.4676  
     Days on oxygen 17.833 (±27.142) 13.622 (±17.902) 0.4417  
     lnCalprotectin Week 1 5.115 (±0.766) 4.915 (±0.914) 0.4051  
     Ln Calprotectin Week 2 5.631 (±0.709) 5.021 (±0.663) 0.0046*  
     Ln Calprotectin Week 3 5.49 (±0.668) 5.166 (±0.626) 0.0715*  
     
Caucasian No (n=8) Yes (n=14) p  
     LnSNAPPEII 2.769 (±0.864) 2.859 (±0.672) 0.8162  
     LOS 56.75 (±16.593) 67.071 (±20.849) 0.2455  
     Weight at 6 weeks 7.554 (±0.119) 7.548 (±0.163) 0.9376  
     Days on oxygen 13.75 (±21.393) 13.571 (±19.437) 0.9842  
     lnCalprotectin Week 1 4.896 (±0.557) 5.26 (±0.843) 0.3203  
     lnCalprotectin Week 2 5.667 (±0.54) 5.126 (±0.519) 0.0681*  
     lnCalprotectin Week 3 5.479 (±0.379) 5.205 (±0.528) 0.2766  
     
African American No (n=6) Yes (n=25)  p  
     LnSNAPPEII 2.947 (±0.649) 3.01 (±0.61) 0.8367  
     LOS 55.833 (±28.673) 68.64 (±38.142) 0.4487  
     Weight at 6 weeks 7.329 (±0.142) 7.451 (±0.194) 0.3103  
     Days on oxygen 27.667 (±38.79) 0.12.958 (±16.669) 0.1594*  
     lnCalprotectin Week 1 5.093 (±0.631) 4.889 (±0.942) 0.6533  
     lnCalprotectin Week 2 4.969 (±0.406) 4.873 (±0.743) 0.8309  
     lnCalprotectin Week 3 4.697 (±0.462) 5.004 (±0.559) 0.3174  
     
Hispanic No (n=9) Yes (n=6) p  
     LnSNAPPEII 2.989 (±0.836) 2.466 (±0.592) 0.2510  
     LOS 68.5 (±26.333) 118.5 (±53.607) 0.0503*  
     Weight at 6 weeks 7.586 (±0.204) 7.515 (±0.093) 0.4771  
     Days on oxygen 19.0 (±26.338) 24.5 (±25.619) 0.7381  
     lnCalprotectin Week 1 5.049 (±1.133) 4.113 (±0.949) 0.0966*  
     lnCalprotectin Week 2 5.947 (±0.887) 5.408 (±0.543) 0.3855  
     lnCalprotectin Week 3 5.822 (±0.644) 4.778 (±0.409) 0.0723*  
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Table 18: Univariate analysis of maternal SNP and categorical infant outcomes 
  Categorical Infant 
Outcomes - rs2070874 
  
2070874     
Total Population CC (n=49) TT (n=9) CT (n=15) p 
     Sepsis     
        Yes 5 (10.2%) 3 (33.3%) 2 (13.3%) 0.218 
        No 42 (85.7%) 6 (66.7%) 13 (86.7%)  
     ROP     
        Yes 7 (14.3%) 4 (44.4%) 2 (13.3%) 0.132* 
        No 37 (75.6%) 5 (55.6%) 13 (86.7%)  
     BPD     
        Yes 4 (8.26%) 0 (0%) 0 (0%) 0.748 
        No 44 (89.8%) 9 (100%) 15 (100%)  
     NEC     
        Yes 1 (2%) 1 (11.1%) 1 (6.7%) 0.256 
        No 47 (95.9%) 8 (88.9%) 14 (93.3%)  
     IVH     
        Yes 9 (18.4%) 0 (0%) 0 (0%) 0.082* 
        No 37 (75.5%) 9 (100%) 15 (100%)  
     Blood transfusion     
        Yes 24 (48.9%) 4 (44.4%) 5 (33.3%) 0.593 
        No 25 (51%) 5 (55.6%) 10 (66.7%)  
     Feeding intolerance     
        Yes 10 (10.4%) 1 (11.1%) 4 (26.7%) 0.606 
        No 39 (49.6%) 8 (88.9%) 9 (60%)  
     
Caucasian CC (n=20) TT (n=1) CT (n=1)  
     Sepsis     
         Yes 2 (10%) 1 (100%) 0 (0%) 0.260 
         No 18 (90%) 0 (0%) 1 (100%)  
     ROP     
         Yes 2 (10%) 1 (100%) 0 (0%) 0.260 
         No 18 (90%) 0 (0%) 1 (100%)  
     BPD     
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         Yes 1 (5%) 0 (0%) 0 (0%) 1.0 
         No 19 (95%) 1 (100%) 1 (100%)  
     NEC     
         Yes 0 (0%) 0 (0%) 0 (0%) n/a 
         No 20 (100%) 1 (100%) 1 (100%)  
     IVH     
         Yes 4 (20%) 0 (0%) 0 (0%) 1.0 
         No 16 (80%) 1 (100%) 1 (100%)  
     Blood transfusion     
         Yes 8 (40%) 1 (100%) 0 (0%) 0.662 
         No 12 (60%) 0 (0%) 1 (100%)  
     Feeding intolerance     
         Yes 4 (20%) 0 (0%) 0 (0%) 1.0 
         No 16 (80%) 1 (100%) 1 (100%)  
African American CC (n=20)  TT (n=4) CT (n=7) P 
     Sepsis     
         Yes 3 (15%) 1 (25%) 1 (14.3%) 0.80 
         No 17 (85%) 3 (75%) 6 (85.7%)  
     ROP     
         Yes 3 (21.4%) 0 (0%) 0 (0%) 0.709 
         No 14 (70%) 4 (100%) 7 (100%)  
     BPD     
         Yes 3 (15%) 0 (0%) 0 (0%) 0.704 
         No 17 (85%) 4 (100%) 7 (100%)  
     NEC     
         Yes 0 (0%) 0 (0%) 1 (14.3%) 0.355 
         No 20 (100%) 4 (100%) 6 (85.7%)  
     IVH     
         Yes 3 (15%) 0 (0%) 0 (0%) 0.707 
         No 15 (75%) 4 (100%) 7 (100%)  
     Blood transfusion     
         Yes 11 (55%) 1 (25%) 3 (42.9%) 0.667 
         No 9 (45%) 3 (75%) 4 (57.1%)  
     Feeding intolerance     
         Yes 2 (10%) 0 (0%) 1 (14.3%) 1.0 
         No 18 (90%) 4 (100%) 5 (71.4%)  
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Hispanic CC (n=8)  TT (n=3) CT (n=4) P 
     Sepsis     
         Yes 0 (0%) 1 (33.3%) 1 (25%) 0.269 
         No 6 (75%) 2 (66.7%) 3 (75%)  
     ROP     
         Yes 2 (25%) 2 (66.7%) 2 (50%) 0.790 
         No 4 (50%) 1 (33.3%) 2 (50%)  
     BPD     
         Yes 0 (0%) 0 (0%) 0 (0%) n/a 
         No 7 (87.5%) 3 (100%) 4 (100%)  
     NEC     
         Yes 0 (0%) 1 (33.3%) 0 (0%) 0.214 
         No 7 (87.5%) 2 (66.7%) 4 (100%)  
     IVH     
         Yes 2 (25%) 0 (0%) 0 (0%) 0.692 
         No 5 (62.5%) 3 (100%) 4 (100%)  
     Blood transfusion     
         Yes 4 (50%) 2 (66.7%) 2 (50%) 1.0 
         No 4 (50%) 1 (33.3%) 2 (50%)  
     Feeding intolerance     
         Yes 3 (37.5%) 1 (33.3%) 3 (75%) 0.339 
         No 5 (62.5%) 2 (66.7%) 0 (0%)  
 
 
 
 
  Minor Allele Presence 
rs2070874 
  
2070874 MAP     
Total Population No (n=49) Yes (n=24) p  
     Sepsis     
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        Yes 5 (10.2%) 5 (20.8%) 0.289  
        No 42 (85.7%) 19 (79.2%)   
     ROP     
        Yes 7 (14.3%) 6 (25%) 0.520  
        No 37 (75.5%) 18 (75%)   
     BPD     
        Yes 4 (8.2%) 0 (0%) 0.294  
        No 44 (89.8%) 24 (100%)   
     NEC     
        Yes 1 (2%) 2 (8.3%) 0.256  
        No 47 (95.9%) 22 (91.7%)   
     IVH     
        Yes 9 (18.4%) 0 (0%) 0.023*  
        No 37 (75.5%) 24 (100%)   
     Blood transfusion     
        Yes 24 (48.9%) 9 (37.5%) 0.455  
        No 25 (51%) 15 (62.5%)   
     Feeding intolerance     
        Yes 10 (20.4%) 5 (20.8%) 1.0  
        No 39 (79.6%) 17 (70.8%)   
     
Caucasian No (n=20) Yes (n=2) P  
     Sepsis     
        Yes 2 (10%) 1 (50%) 0.260  
        No 18 (90%) 1 (50%)   
     ROP     
        Yes 2 (10%) 1 (50%) 0.260  
        No 18 (90%) 1 (50%)   
     BPD     
        Yes 2 (10%) 0 (0%) 1.0  
        No 19 (90%) 1 (50%)   
NEC     
        Yes 0 (0%) 0 (0%) n/a  
        No 20 (100%) 2 (100%)   
IVH     
        Yes 2 (10%) 0 (0%) 1.0  
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        No 16 (80%) 2 (100%)   
Blood transfusion     
        Yes 1 (5%) 1 (50%) 1.0  
        No 12 (60%) 1 (50%)   
Feeding intolerance     
        Yes 2 (10%) 0 (0%) 1.0  
        No 16 (80%) 2 (100%)   
     
African American No (n=20) Yes (n=11) p  
     Sepsis     
         Yes 3 (15%) 2 (18.2%) 1.0  
         No 17 (85%) 9 (81.8%)   
     ROP     
         Yes 3 (21.4%) 0 (0%) 0.258  
         No 14 (70%) 11 (100%)   
     BPD     
         Yes 3 (21.4%) 0 (0%) 0.535  
         No 17 (85%) 11 (100%)   
     NEC     
         Yes 0 (0%) 1 (9.1%) 0.355  
         No 20 (100%) 10 (90.9%)   
     IVH     
         Yes 3 (15%) 0 (0%) 0.268  
         No 15 (75%) 11 (100%)   
     Blood transfusion     
         Yes 11 (55%) 4 (36.3%) 0.458  
         No 9 (45%) 7 (63.4%)   
     Feeding intolerance     
         Yes 2 (10%) 1 (9.1%) 1.0  
         No 18 (90%) 9 (81.8%)   
     
Hispanic No (n=8) Yes (n=7) P  
     Sepsis     
         Yes 0 (0%) 2 (28.6%) 0.462  
         No 6 (75%) 5 (71.3%)   
     ROP     
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         Yes 2 (25%) 4 (57.1%) 0.592  
         No 4 (50%) 3 (48.9%)   
     BPD     
         Yes 0 (0%) 0 (0%) n/a  
         No 7 (87.5%) 7 (100%)   
     NEC     
         Yes 0 (0%) 1 (14.3%) 1.0  
         No 7 (87.5%) 6 (85.7%)   
     IVH     
         Yes 2 (25%) 0 (0%) 0.462  
         No 5 (62.5%) 7 (100%)   
     Blood transfusion     
         Yes 4 (50%) 4 (57.1%) 1.0  
         No 4 (50%) 3 (42.8%)   
     Feeding intolerance     
         Yes 3 (37.5%) 4 (57.1%) 0.592  
         No 5 (62.5%) 2 (28.6%)   
 
 
 
 
 
 
  Categorical Infant 
Outcomes - rs2243250 
  
2243250     
Total Population CC (n=32) TT (n=22) CT (n=19) P 
     Sepsis     
        Yes 5 (15.6 4 (18.2%) 1 (5.6%) 0.468 
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        No 25 (78.1 18 (81.8%) 18 (94.7%)  
     ROP     
        Yes 6 (18.8 4 (18.2%) 3 (15.8%) 1.0 
        No 23 (71.9 16 (72.7%) 16 (84.2%)  
     BPD     
        Yes 4 (12.5 0 (0%) 0 (0%) 0.120* 
        No 27 (84.4 22 (100%) 19 (100%)  
     NEC     
        Yes 0 (0 2 (9.1%) 1 (5.3%) 0.179 
        No 31 (96.9 20 (90.9%) 18 (94.7%)  
     IVH     
        Yes 6 (18.8 3 (13.6%) 0 (0%) 0.127* 
        No 25 (78.1 17 (77.3%) 19 (100%)  
     Blood transfusion     
        Yes 18 (56.3 10 (45.5%) 5 (26.3%) 0.128* 
        No 14 (43.8 12 (54.5%) 14 (76.7%)  
     Feeding intolerance     
        Yes 8 (25 3 (13.6%) 4 (21.1%) 0.703 
        No 24 (75 18 (18.8%) 14 (73.7%)  
     
Caucasian CC (n=17) TT (n=2) CT (n=3)  
     Sepsis     
          Yes 2 (13.3%) 1 (50%) 0 (0%) 0.294 
          No 15 (88.2%) 1 (50%) 3 (100%)  
     ROP     
          Yes 1 (5.9%) 1 (50%) 1 (33.3%) 0.117* 
          No 16 (94.1%) 1 (50%) 2 (66.7%)  
     BPD     
          Yes 1 (5.9%) 0 (0%) 0 (0%) 1.0 
          No 16 (94.1%) 2 (100%) 3 (100%)  
     NEC     
          Yes 0 (0%) 0 (0%) 0 (0%) n/a 
          No 17 (100%) 2 (100%) 3 (100%)  
     IVH     
          Yes 3 (76.7%) 1 (50%) 0 (0%) 0.396 
          No 14 (82.3%) 1 (50%) 3 (100%)  
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     Blood transfusion     
          Yes 7 (41.2%) 2 (100%) 0 (0%) 0.131* 
          No 10 (58.8%) 0 (0%) 3 (100%)  
     Feeding intolerance     
          Yes 3 (17.7%) 1 (50%) 0 (0%) 0.396 
          No 14 (82.3%) 1 (50%) 3 (100%)  
     
African American CC (n=8) TT (n=15) CT (n=8) P 
     Sepsis     
          Yes 3 (37.5%) 2 (13.3%) 0 (0%) 0.125* 
          No 5 (62.5%) 13 (86.7%) 8 (100%)  
     ROP     
          Yes 3 (37.5%) 0 (0%) 0 (0%) 0.011* 
          No 4 (50%) 13 (86.7%) 8 (100%)  
     BPD     
          Yes 3 (37.5%) 0 (0%) 0 (0%) 0.025* 
          No 5 (62.5%) 15 (100%) 8 (100%)  
     NEC     
          Yes 0 (0%) 1 (6.7%) 0 (0%) 1.0 
          No 8 (100%) 14 (93.3%) 8 (100%)  
     IVH     
          Yes 1 (12.5%) 2 (13.3%) 0 (0%) 0.772 
          No 7 (87.5%) 11 (73.3%) 8 (100%)  
     Blood transfusion     
          Yes 7 (12.5%) 7 (46.7%) 1 (12.5%) 0.011* 
          No 1 (87.5%) 8 (53.3%) 7 (87.5%)  
     Feeding intolerance     
          Yes 2 (25%) 1 (6.7%) 0 (0%) 0.0293* 
          No 6 (75%) 14 (93.3%) 7 (87.5%)  
     
Hispanic CC (n=7) TT (n=3) CT (n=5) p 
     Sepsis     
          Yes 0 (0%) 1 (33.3%) 1 (20%) 0.679 
          No 5 (71.4%) 2 (66.7%) 4 (80%)  
     ROP     
          Yes 2 (28.6%) 2 (66.7%) 2 (40%) 1.0 
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          No 3 (42.9%) 1 (33.3%) 3 (60%)  
     BPD     
          Yes 0 (0%) 0 (0%) 0 (0%) n/a 
          No 6 (85.7%) 3 (100%) 5 (100%)  
     NEC     
          Yes 0 (0%) 1 (33.3%) 0 (0%) 0.214 
          No 6 (85.7%) 2 (66.7%) 5 (100%)  
     IVH     
          Yes 2 (28.6%) 0 (0%) 0 (0%) 0.473 
          No 4 (57.1%) 3 (100%) 5 (100%)  
     Blood transfusion     
          Yes 4 (57.1%) 1 (33.3%) 3 (60%) 1.0 
          No 3 (42.9%) 2 (66.7%) 2 (40%)  
     Feeding intolerance     
          Yes 3 (42.9%) 1 (33.3%) 3 (60%) 1.0 
          No 4 (57.1%) 1 (33.3%) 2 (40%)  
 
 
  Categorical Infant 
Outcomes – rs1800795 
  
1800795     
Total Population CC (n=5) GG (n=47) CG (n=21) P 
     Sepsis     
        Yes 1 (20%) 6 (12.8%) 3 (14.3%) 0.869 
        No 4 (80%) 39 (82.9%) 18 (85.7%)  
     ROP     
        Yes 1 (20%) 10 (21.3%) 2 (9.5%) 0.546 
        No 4 (80%) 34 (72.3%) 17 (80.1%)  
     BPD     
        Yes 0 (0%) 2 (4.3%) 2 (9.5%) 0.690 
        No 5 (100%) 44 (93.6%) 19 (90.5%)  
     NEC     
        Yes 0 (0%) 3 (6.4%) 0 (0%) 0.636 
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        No 5 (100%) 43 (91.5%) 21 (100%)  
     IVH     
        Yes 1 (20%) 5 (10.6%) 3 (14.3%) 0.606 
        No 4 (80%) 40 (85.1%) 17 (80.1%)  
     Blood transfusion     
        Yes 4 (80%) 19 (41.3%) 10 (47.6%) 0.235 
        No 1 (20%) 28 (60.9%) 11 (52.4%)  
     Feeding intolerance     
        Yes 1 (20%) 10 (21.3%) 4 (19.1%) 1.0 
        No 4 (80%) 35 (74.5%) 17 (80.9%)  
     
Caucasian CC (n=5) GG (n=7) CG (n=10)  
     Sepsis     
          Yes 1 (20%) 0 (0%) 2 (20%) 0.568 
          No 4 (80%) 7 (100%) 8 (80%)  
     ROP     
          Yes 1 (20%) 2 (28.6%) 0 (0%) 0.208* 
          No 4 (80%) 5 (71.4%) 10 (100%)  
     BPD     
          Yes 0 (0%) 0 (0%) 1 (10%) 1.0 
          No 5 (100%) 7 (100%) 9 (90%)  
     NEC     
          Yes 0 (0%) 0 (0%) 0 (0%) n/a 
          No 5 (100%) 7 (100%) 10 (100%)  
     IVH     
          Yes 1 (20%) 2 (28.6%) 1 (10%) 0.785 
          No 4 (80%) 5 (71.4%) 9 (90%)  
     Blood transfusion     
          Yes 4 (80%) 1 (14.3%) 4 (40%) 0.082* 
          No 1 (20%) 6 (85.7%) 6 (60%)  
     Feeding intolerance     
          Yes 1 (20%) 2 (28.6%) 1 (10%) 0.785 
          No 4 (80%) 5 (71.4%) 9 (90%)  
     
African American CC (n=0) GG (n=25) CG (n=6) P 
     Sepsis     
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          Yes 0 (0%) 5 (20%) 0 (0%) 0.553 
          No 0 (0%) 20 (80%) 6 (100%)  
     ROP     
          Yes 0 (0%) 3 (12%) 0 (0%) 1.0 
          No 0 (0%) 21 (84%) 4 (66.7%)  
     BPD     
          Yes 0 (0%) 2 (8%) 1 (16.7%) 0.488 
          No 0 (0%) 23 (92%) 5 (83.3%)  
     NEC     
          Yes 0 (0%) 1 (4%) 0 (0%) 1.0 
          No 0 (0%) 24 (96%) 6 (100%)  
     IVH     
          Yes 0 (0%) 1 (4%) 2 (33.3%) 0.068* 
          No 0 (0%) 23 (92%) 3 (50%)  
     Blood transfusion     
          Yes 0 (0%) 12 (48%) 3 (50%) 1.0 
          No 0 (0%) 13 (52%) 3 (50%)  
     Feeding intolerance     
          Yes 0 (0%) 2 (8%) 1 (16.7%) 0.501 
          No 0 (0%) 22 (88%) 5 (83.3%)  
     
Hispanic CC (n=0) GG (n=11) CG (n=4) P 
     Sepsis     
          Yes 0 (0%) 1 (9.1%) 1 (25%) 1.0 
          No 0 (0%) 8 (72.7%) 3 (75%)  
     ROP     
          Yes 0 (0%) 4 (36.4%) 2 (50%) 1.0 
          No 0 (0%) 5 (45.5%) 2 (50%)  
     BPD     
          Yes 0 (0%) 0 (0%) 0 (0%) n/a 
          No 0 (0%) 10 (90.9%) 4 (100%)  
     NEC     
          Yes 0 (0%) 1 (9.1%) 0 (0%) 1.0 
          No 0 (0%) 9 (81.8%) 4 (100%)  
     IVH     
          Yes 0 (0%) 2 (18.2%) 0 (0%) 1.0 
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          No 0 (0%) 8 (72.7%) 4 (100%)  
     Blood transfusion     
          Yes 0 (0%) 5 (45.5%) 3 (75%) 0.569 
          No 0 (0%) 6 (54.5%) 1 (25%)  
     Feeding intolerance     
          Yes 0 (0%) 5 (45.5%) 2 (50%) 1.0 
          No 0 (0%) 5 (45.5%) 2 (50%)  
 
 
 
 
  Minor Allele Presence 
rs1800795 
  
1800795 MAP     
Total Population No (n=47) Yes (n=26) p  
     Sepsis     
        Yes 6 (12.8%) 4 (15.4%) 1.0  
        No 39 (82.9%) 22 (84.6%)   
     ROP     
        Yes 10 (21.3%) 3 (11.5%) 0.355  
        No 34 (72.3%) 21 (80.8%)   
     BPD     
        Yes 2 (4.3%) 2 (7.7%) 0.616  
        No 44 (93.6%) 24 (92.3%)   
     NEC     
        Yes 3 (6.4%) 0 (0%) 0.549  
        No 43 (91.5%) 26 (100%)   
     IVH     
        Yes 5 (10.6%) 4 (15.3%) 0.712  
        No 40 (86.1%) 21 (80.7%)   
     Blood transfusion     
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        Yes 19 (41.3%) 14 (53.9%) 0.330  
        No 28 (60.9%) 12 (46.2%)   
     Feeding intolerance     
        Yes 10 (21.3%) 5 (19.2%) 1.0  
        No 35 (74.5%) 21 (80.8%)   
     
Caucasian No (n=7) Yes (n=15)  P  
     Sepsis     
        Yes 0 (0%) 3 (20%) 0.523  
        No 7 (100%) 12 (80%)   
     ROP     
        Yes 2 (28.6%) 1 (6.7%) 0.227  
        No 5 (71.4%) 14 (93.3%)   
     BPD     
        Yes 0 (0%) 1 (6.7%) 1.0  
        No 7 (100%) 14 (93.3%)   
NEC     
        Yes 0 (0%) 0 (0%) n/a  
        No 7 (100%) 15 (100%)   
IVH     
        Yes 2 (28.6%) 2 (20%) 0.565  
        No 5 (71.4%) 13 (80%)   
Blood transfusion     
        Yes 1 (14.3%) 8 (53.3%) 0.165*  
        No 6 (85.7%) 7 (46.7%)   
Feeding intolerance     
        Yes 2 (28.6%) 2 (20%) 0.565  
        No 5 (71.4%) 13 (80%)   
     
African American No (n=25) Yes (n=6)  p  
     Sepsis     
         Yes 5 (20%) 0 (0%) 0.553  
         No 20 (80%) 6 (100%)   
     ROP     
         Yes 3 (12%) 0 (0%) 1.0  
         No 21 (84%) 4 (66.7%)   
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     BPD     
         Yes 2 (8%) 1 (16.7%) 0.488  
         No 23 (92%) 5 (83.3%)   
     NEC     
         Yes 1 (4%) 0 (0%) 1.0  
         No 24 (96%) 6 (100%)   
     IVH     
         Yes 1 (4%) 2 (33.3%) 0.068*  
         No 23 (92%) 3 (50%)   
     Blood transfusion     
         Yes 12 (48%) 3 (50%) 1.0  
         No 13 (52%) 3 (50%)   
     Feeding intolerance     
         Yes 2 (8%) 1 (16.7%) 0.501  
         No 22 (88%) 5 (83.3%)   
     
Hispanic No (n=12) Yes (n=4) P  
     Sepsis     
         Yes 1 (8.3%) 1 (25%) 1.0  
         No 8 (66.7%) 3 (75%)   
     ROP     
         Yes 4 (33.3%) 2 (50%) 1.0  
         No 5 (41.7%) 2 (50%)   
     BPD     
         Yes 0 (0%) 0 (0%) n/a  
         No 10 (83.3%) 4 (100%)   
     NEC     
         Yes 1 (8.3%) 0 (0%) 1.0  
         No 9 (75%) 4 (100%)   
     IVH     
         Yes 4 (33.3%) 0 (0%) 1.0  
         No 8 (66.7%) 2 (50%)   
     Blood transfusion     
         Yes 5 (41.7%) 3 (75%) 0.569  
         No 6 (50%) 1 (25%)   
     Feeding intolerance     
126 
         Yes 5 (41.7%) 2 (50%) n/a  
         No 5 (41.7%) 2 (50%)   
 
 
 
 
  Categorical Infant 
Outcomes rs1800796 
  
1800796     
Total Population GG (n=3) AA (n=58) AG (n=12) p 
     Sepsis     
        Yes 1 (33.3 7 (12.1%) 2 (16.7%) 0.225 
        No 1 (33.3 50 (86.2%) 10 (83.3%)  
     ROP     
        Yes 1 (33.3 8 (13.8%) 4 (33.3%) 0.132* 
        No 1 (33.3 46 (79.3%) 8 (66.7%)  
     BPD     
        Yes 0 (0 2 (3.5%) 2 (16.7%) 0.275 
        No 3 (100 55 (94.8%) 10 (83.3%)  
     NEC     
        Yes 2 (66.7 1 (1.7%) 0 (0%) 0.003* 
        No 1 (33.3 56 (96.6%) 12 (100%)  
     IVH     
        Yes 1 (33.3 7 (12.1%) 1 (8.3%) 0.569 
        No 2 (66.7 48 (82.8%) 11 (91.7%)  
     Blood transfusion     
        Yes 3 (100 26 (44.8%) 4 (33.3%) 0.120* 
        No 0 (0 32 (55.2%) 8 (66.7%)  
     Feeding intolerance     
        Yes 3 (100 10 (17.2%) 2 (16.7%) 0.014* 
        No 0 (0 47 (81%) 9 (75%)  
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Caucasian GG (n=0) AA (n=20) AG (n=2) p 
     Sepsis     
          Yes 0 (0 3 (15%) 0 (0%) 1.0 
          No 0 (0 17 (85%) 2 (100%)  
     ROP     
          Yes 0 (0 3 (15%) 0 (0%) 1.0 
          No 0 (0 17 (85%) 2 (100%)  
     BPD     
          Yes 0 (0 1 (5%) 0 (0%) 1.0 
          No 0 (0 19 (95%) 2 (100%)  
     NEC     
          Yes 0 (0 0 (0%) 0 (0%) n/a 
          No 0 (0 20 (100%) 2 (100%)  
     IVH     
          Yes 0 (0 3 (15%) 1 (50%) 0.338 
          No 0 (0 17 (85%) 1 (50%)  
     Blood transfusion     
          Yes 0 (0 8 (40%) 1 (50%) 1.0 
          No 0 (0 12 (60%) 1 (50%)  
     Feeding intolerance     
          Yes 0 (0 3 (15%) 1 (50%) 0.338 
          No 0 (0 17 (85%) 1 (50%)  
     
African American GG (n=0) AA (n=27) AG (n=4) p 
     Sepsis     
          Yes 0 (0%) 3 (11.1%) 2 (50%) 0.112* 
          No 0 (0%) 24 (88.9%) 2 (50%)  
     ROP     
          Yes 0 (0%) 1 (3.7%) 2 (50%) 0.045* 
          No 0 (0%) 23 (85.2%) 2 (50%)  
     BPD     
          Yes 0 (0%) 1 (3.7%) 2 (50%) 0.037* 
          No 0 (0%) 26 (96.3%) 2 (50%)  
     NEC     
          Yes 0 (0%) 1 (3.7%) 0 (0%) 1.0 
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          No 0 (0%) 26 (96.3%) 4 (100%)  
     IVH     
          Yes 0 (0%) 3 (11.1%) 0 (0%) 1.0 
          No 0 (0%) 22 (81.5%) 4 (100%)  
     Blood transfusion     
          Yes 0 (0%) 13 (48.2%) 2 (50%) 1.0 
          No 0 (0%) 14 (51.9%) 2 (50%)  
     Feeding intolerance     
          Yes 0 (0%) 2 (7.4%) 1 (25%) 0.360 
          No 0 (0%) 24 (88.9%) 3 (75%)  
     
Hispanic GG (n=2) AA (n=9) AG (n=4) p 
     Sepsis     
          Yes 1 (50%) 1 (11.1%) 0 (0%) 0.231 
          No 0 (0%) 7 (77.8%) 4 (100%)  
     ROP     
          Yes 1 (50%) 4 (44.4%) 1 (25%) 0.559 
          No 0 (0%) 4 (44.4%) 3 (75%)  
     BPD     
          Yes 0 (50%) 0 (0%) 0 (0%) n/a 
          No 2 (100%) 8 (88.9%) 4 (100%)  
     NEC     
          Yes 1 (50%) 0 (0%) 0 (0%) 0.143* 
          No 1 (50%) 8 (88.9%) 4 (100%)  
     IVH     
          Yes 1 (50%) 1 (11.1%) 0 (0%) 0.341 
          No 1 (50%) 7 (77.8%) 4 (100%)  
     Blood transfusion     
          Yes 2 (100%) 5 (55.6%) 1 (25%) 0.386 
          No 0 (0%) 4 (44.4%) 3 (75%)  
     Feeding intolerance     
          Yes 2 (100%) 5 (55.6%) 0 (0%) 0.094* 
          No 0 (0%) 4 (44.4%) 3 (75%)  
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  Minor Allele Presence 
rs1800796 
  
1800796 MAP     
Total Population No (n=57) Yes (n=15) P  
     Sepsis     
        Yes 7 (12.3%) 3 (20%) 0.402  
        No 50 (87.7%) 11 (73.3%)   
     ROP     
        Yes 8 (14%) 5 (33.3%) 0.122*  
        No 46 (80.7%) 9 (60%)   
     BPD     
        Yes 2 (3.5%) 2 (13.3%) 0.189*  
        No 55 (96.5%) 13 (86.7%)   
     NEC     
        Yes 1 (1.8%) 2 (13.3%) 0.108*  
        No 56 (98.2%) 13 (86.7%)   
     IVH     
        Yes 7 (12.3%) 2 (13.3%) 1.0  
        No 48 (84.2%) 13 (86.7%)   
     Blood transfusion     
        Yes 26 (45.6%) 7 (46.7%) 1.0  
        No 32 (56.1%) 8 (53.3%)   
     Feeding intolerance     
        Yes 10 (17.5%) 5 (33.3%) 0.155*  
        No 47 (82.5%) 9 (60%)   
     
Caucasian No (n=20)  Yes (n=2) p  
     Sepsis     
        Yes 3 (15%) 0 (0%) 1.0  
        No 17 (85%) 2 (100%)   
     ROP     
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        Yes 3 (15%) 0 (0%) 1.0  
        No 17 (85%) 2 (100%)   
     BPD     
        Yes 1 (5%) 0 (0%) 1.0  
        No 19 (95%) 2 (100%)   
NEC     
        Yes 0 (0%) 0 (0%) n/a  
        No 20 (100%) 2 (100%)   
IVH     
        Yes 3 (15%) 1 (50%) 0.338  
        No 17 (85%) 1 (50%)   
Blood transfusion     
        Yes 8 (40%) 1 (50%) 1.0  
        No 12 (60%) 1 (50%)   
Feeding intolerance     
        Yes 3 (15%) 1 (50%) 0.338  
        No 17 (85%) 1 (50%)   
     
African American No (n=27) Yes (n=4) p  
     Sepsis     
         Yes 3 (11.1%) 2 (50%) 0.112*  
         No 24 (88.9%) 2 (50%)   
     ROP     
         Yes 1 (3.7%) 2 (50%) 0.045*  
         No 23 (85.2%) 2 (50%)   
     BPD     
         Yes 1 (3.7%) 2 (50%) 0.037*  
         No 26 (96.3%) 2 (50%)   
     NEC     
         Yes 1 (3.7%) 0 (0%) 1.0  
         No 26 (96.3%) 4 (100%)   
     IVH     
         Yes 3 (11.1%) 0 (0%) 1.0  
         No 22 (81.5%) 4 (100%)   
     Blood transfusion     
         Yes 12 (44.4%) 2 (50%) 1.0  
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         No 14 (51.9%) 2 (50%)   
     Feeding intolerance     
         Yes 2 (7.4%) 1 (25%) 0.360  
         No 24 (88.9%) 3 (75%)   
     
Hispanic No (n=9) Yes (n=6) p  
     Sepsis     
         Yes 1 (11.1%) 1 (16.7%) 1.0  
         No 7 (77.8%) 4 (66.7%)   
     ROP     
         Yes 4 (44.4%) 2 (33.3%) 1.0  
         No 4 (44.4%) 3 (50%)   
     BPD     
         Yes 0 (0%) 0 (0%) n/a  
         No 8 (88.9%) 6 (100%)   
     NEC     
         Yes 0 (0%) 1 (16.7%) 0.429  
         No 8 (88.9%) 5 (83.3%)   
     IVH     
         Yes 1 (11.1%) 1 (16.7%) 1.0  
         No 7 (77.8%) 5 (83.3%)   
     Blood transfusion     
         Yes 5 (55.6%) 3 (50%) 1.0  
         No 4 (44.4%) 3 (50%)   
     Feeding intolerance     
         Yes 5 (55.6%) 2 (33.3%) 1.0  
         No 4 (44.4%) 3 (50%)   
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  Categorical Infant 
Outcomes rs1800871 
  
1800871     
Total Population TT  (n=7) CC (n=40) CT (n=24) p 
     Sepsis     
        Yes 1 (14.3 8 (20%) 1 (4.4%) 0.160* 
        No 5 (71.4 32 (80%) 23 (95.7%)  
     ROP     
        Yes 1 (14.3 9 (22.5%) 3 (12.5%) 0.709 
        No 4 (57.1 30 (75%) 20 (83.3%)  
     BPD     
        Yes 0 (0 4 (10%) 0 (0%) 0.40 
        No 7 (100 36 (90%) 24 (100%)  
     NEC     
        Yes 1 (14.3 0 (0%) 2 (8.3%) 0.058* 
        No 6 (85.7 40 (100%) 22 (91.7%)  
     IVH     
        Yes 1 (14.3 4 (10%) 4 (16.7%) 0.551 
        No 5 (71.4 36 (90%) 19 (79.2%)  
     Blood transfusion     
        Yes 2 (28.6 18 (45%) 12 (50%) 0.646 
        No 5 (74.4 23 (57.5%) 12 (50%)  
     Feeding intolerance     
        Yes 3 (42.9 7 (17.5%) 5 (20.8%) 0.333 
        No 4 (57.1 32 (80%) 19 (79.2%)  
     
     
Caucasian TT  (n=1) CC (n=14) CT (n=6) p 
     Sepsis     
          Yes 0 (0%) 3 (21.4%) 0 (0%) 0.589 
          No 1 (100%) 11 (78.6%) 6 (100%)  
     ROP     
          Yes 0 (0%) 2 (14.3%) 1 (16.7%) 1.0 
          No 1 (100%) 12 (85.7%) 5 (83.3%)  
     BPD     
          Yes 0 (0%) 1 (7.1%) 0 (0%) 1.0 
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          No 1 (100%) 13 (92.9%) 6 (100%)  
     NEC     
          Yes 0 (0%) 0 (0%) 0 (0%) n/a 
          No 1 (100%) 14 (100%) 6 (100%)  
     IVH     
          Yes 0 (0%) 1 (7.1%) 3 (50%) 0.088* 
          No 1 (100%) 13 (92.9%) 3 (50%)  
     Blood transfusion     
          Yes 0 (0%) 5 (35.7%) 3 (50%) 0.779 
          No 1 (100%) 9 (64.3%) 3 (50%)  
     Feeding intolerance     
          Yes 0 (0%) 2 (14.3%) 2 (33.3%) 0.635 
          No 1 (100%) 12 (85.7%) 4 (66.7%)  
     
African American TT  (n=1) CC (n=17) CT (n=13) p 
     Sepsis     
          Yes 0 (0%) 4 (23.5%) 1 (7.7%) 0.459 
          No 1 (100%) 13 (76.5%) 12 (97.3%)  
     ROP     
          Yes 0 (0%) 3 (17.7%) 0 (0%) 0.238 
          No 0 (0%) 13 (76.5%) 12 (92.3%)  
     BPD     
          Yes 0 (0%) 3 (17.7%) 0 (0%) 0.312 
          No 1 (100%) 14 (82.3%) 13 (100%)  
     NEC     
          Yes 0 (0%) 0 (0%) 1 (7.7%) 0.452 
          No 1 (100%) 17 (100%) 12 (92.3%)  
     IVH     
          Yes 0 (0%) 2 (11.8%) 1 (7.7%) 1.0 
          No 0 (0%) 15 (88.2%) 11 (84.6%)  
     Blood transfusion     
          Yes 0 (0%) 9 (52.9%) 6 (46.2%) 1.0 
          No 1 (100%) 8 (47.1%) 7 (53.8%)  
     Feeding intolerance     
          Yes 0 (0%) 1 (5.9%) 2 (15.4%) 0.616 
          No  1 (100%) 15 (88.2%) 11 (84.6%)  
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Hispanic TT  (n=4) CC (n=8) CT (n=3) p 
     Sepsis     
          Yes 1 (25%) 1 (12.5%) 0 (0%) 1.0 
          No 2 (50%) 6 (75%) 3 (100%)  
     ROP     
          Yes 1 (25%) 3 (37.5%) 2 (66.6%) 1.0 
          No 2 (50%) 4 (50%) 1 (33.3%)  
     BPD     
          Yes 0 (0%) 0 (0%) 0 (0%) n/a 
          No 4 (100%) 7 (87.5%) 3 (100%)  
     NEC     
          Yes 1 (25%) 0 (0%) 0 (0%) 0.500 
          No 3 (75%) 7 (87.5%) 3 (100%)  
     IVH     
          Yes 1 (25%) 1 (12.5%) 0 (0%) 1.0 
          No 3 (75%) 6 (75%) 3 (100%)  
     Blood transfusion     
          Yes 2 (50%) 4 (50%) 2 (66.7%) 1.0 
          No 2 (50%) 4 (50%) 1 (33.3%)  
     Feeding intolerance     
          Yes 3 (75%) 4 (50%) 0 (0%) 0.241 
          No 1 (25%) 3 (37.5%) 3 (100%)  
 
 
 
 
  Minor Allele Presence 
rs1800871 
  
1800871 MAP     
Total Population No (n=40) Yes (n=31) P  
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     Sepsis     
        Yes 8 (20%) 2 (6.5%) 0.171*  
        No 32 (80%) 28 (90.3%)   
     ROP     
        Yes 9 (22.5%) 4 (12.9%) 0.533  
        No 30 (75%) 24 (77.4%)   
     BPD     
        Yes 4 (10%) 0 (0%) 0.126*  
        No 36 (90%) 31 (100%)   
     NEC     
        Yes 0 (0%) 3 (9.7%) 0.079*  
        No 40 (100%) 28 (90.3%)   
     IVH     
        Yes 4 (10%) 5 (16.1%) 0.477  
        No 36 (90%) 24 (77.4%)   
     Blood transfusion     
        Yes 18 (45%) 14 (45.2%) 1.0  
        No 23 (57.5%) 17 (54.8%)   
     Feeding intolerance     
        Yes 7 (17.5%) 8 (25.8%) 0.560  
        No 32 (80%) 23 (74.2%)   
     
Caucasian No (n=14) Yes (n=7) P  
     Sepsis     
        Yes 3 (21.4%) 0 (0%) 0.521  
        No 11 (78.6%) 7 (100%)   
     ROP     
        Yes 2 (14.3%) 1 (14.3%) 1.0  
        No 12 (85.7%) 6 (85.7%)   
     BPD     
        Yes 1 (7.1%) 0 (0%) 1.0  
        No 13 (92.9%) 7 (100%)   
NEC     
        Yes 0 (0%) 0 (0%) n/a  
        No 14 (100%) 7 (100%)   
IVH     
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        Yes 1 (7.1%) 3 (42.9%) 0.088*  
        No 13 (92.9%) 4 (57.1%)   
Blood transfusion     
        Yes 5 (35.7%) 3 (42.9%) 1.0  
        No 9 (64.3%) 4 (57.1%)   
Feeding intolerance     
        Yes 2 (14.3%) 2 (28.6%) 0.574  
        No 12 (85.7%) 5 (71.4%)   
     
African American No (n=17) Yes (n=14) P  
     Sepsis     
         Yes 4 (2.4%) 1 (7.1%) 0.344  
         No 13 (76.5%) 13 (92.9%)   
     ROP     
         Yes 3 (17.6%) 0 (0%) 0.238  
         No 13 (76.5%) 12 (85.7%)   
     BPD     
         Yes 3 (17.6%) 0 (0%) 0.232  
         No 14 (82.4%) 14 (100%)   
     NEC     
         Yes 0 (0%) 1 (7.1%) 0.452  
         No 17 (100%) 13 (92.9%)   
     IVH     
         Yes 2 (11.8%) 1 (7.1%) 1.0  
         No 15 (88.2%) 11 (78.6%)   
     Blood transfusion     
         Yes 9 (52.9%) 6 (42.9%) 0.722  
         No 8 (47.1%) 8 (57.1%)   
     Feeding intolerance     
         Yes 1 (5.9%) 2 (14.3%) 0.586  
         No 15 (88.2%) 12 (85.7%)   
     
Hispanic No (n=8) Yes (n=7) P  
     Sepsis     
         Yes 1 (12.5%) 1 (14.3%) 1.0  
         No 6 (75%) 5 (71.4%)   
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     ROP     
         Yes 3 (37.5%) 3 (42.8%) 1.0  
         No 4 (50%) 3 (42.8%)   
     BPD     
         Yes 0 (0%) 0 (0%) n/a  
         No 7 (87.5%) 7 (100%)   
     NEC     
         Yes 0 (0%) 1 (14.3%) 1.0  
         No 7 (87.5%) 6 (85.7%)   
     IVH     
         Yes 1 (12.5%) 1 (14.3%) 1.0  
         No 6 (75%) 6 (85.7%)   
     Blood transfusion     
         Yes 4 (50%) 4 (57.1%) 1.0  
         No 4 (50%) 3 (42.9%)   
     Feeding intolerance     
         Yes 4 (50%) 3 (42.9%) 1.0  
         No 3 (37.5%) 4 (57.1%)   
 
 
 
 
  Categorical Infant 
Outcomes – rs1800872 
  
1800872     
Total Population CC (n=39) AA (n=9) AC (n=24) p 
     Sepsis     
        Yes 8 (20.5%) 1 (11.1 1 (4.2%) 0.189* 
        No 30 (76.9%) 7 (77.8 23 (95.8%)  
     ROP     
        Yes 9 (23.1%) 2 (22.2 2 (8.3%) 0.314 
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        No 29 (74.4%) 5 (55.6 21 (87.5%)  
     BPD     
        Yes 3 (7.7%) 0 (0 1 (4.2%) 1.0 
        No 35 (89.7%) 9 (100 23 (95.8%)  
     NEC     
        Yes 0 (0%) 1 (11.1 2 (8.3%) 0.119* 
        No 38 (97.4%) 8 (88.9 22 (92.7%)  
     IVH     
        Yes 5 (12.8%) 1 (11.1 3 (12.5%) 1.0 
        No 33 (84.6%) 7 (77.8 21 (87.5%)  
     Blood transfusion     
        Yes 18 (46.2%) 3 (33.3 12 (50%) 0.711 
        No 21 (53.9%) 6 (66.7 12 (50%)  
     Feeding intolerance     
        Yes 8 (20.5%) 3 (33.3 4 (16.7%) 0.601 
        No 29 (74.4%) 6 (66.7 20 (83.3%)  
     
Caucasian CC (n=15) AA (n=3) AC (n=4) p 
     Sepsis     
          Yes 3 (20%) 0 (0%) 0 (0%) 1.0 
          No 12 (80%) 3 (100%) 4 (100%)  
     ROP     
          Yes 2 (13.3%) 1 (33.3%) 0 (0%) 0.432 
          No 13 (86.7%) 2 (66.7%) 4 (100%)  
     BPD     
          Yes 1 (6.7%) 0 (0%) 0 (0%) 1.0 
          No 14 (93.3%) 3 (100%) 4 (100%)  
     NEC     
          Yes 0 (0%) 0 (0%) 0 (0%) n/a 
          No 15 (100%) 3 (100%) 4 (100%)  
     IVH     
          Yes 3 (20%) 0 (0%) 1 (25%) 1.0 
          No 12 (80%) 3 (100%) 3 (75%)  
     Blood transfusion     
          Yes 6 (40%) 1 (33.3%) 2 (50%) 1.0 
          No 9 (60%) 2 (66.7%) 2 (50%)  
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     Feeding intolerance     
          Yes 3 (20%) 0 (0%) 1 (25%) 1.0 
          No 12 (80%) 3 (100%) 3 (75%)  
     
African American CC (n=14) AA (n=1) AC (n=15) p 
     Sepsis     
          Yes 4 (28.6%) 0 (0%) 1 (6.7%) 0.307 
          No 10 (71.4%) 1 (100%) 14 (93.3%)  
     ROP     
          Yes 4 (28.6%) 0 (0%) 0 (0%) 0.222 
          No 11 (78.6%) 0 (0%) 14 (93.3%)  
     BPD     
          Yes 2 (14.3%) 0 (0%) 1 (6.7%) 0.638 
          No 12 (85.7%) 1 (100%) 14 (93.3%)  
     NEC     
          Yes 0 (0%) 0 (0%) 1 (6.7%) 1.0 
          No 14 (100%) 1 (100%) 14 (93.3%)  
     IVH     
          Yes 1 (7.4%) 0 (0%) 2 (13.3%) 1.0 
          No 13 (92.9%) 0 (0%) 13 (86.7%)  
     Blood transfusion     
          Yes 8 (57.1%) 0 (0%) 7 (46.7%) 0.715 
          No 6 (42.9%) 1 (100%) 8 (53.3%)  
     Feeding intolerance     
          Yes 1 (7.4%) 0 (0%) 2 (2%) 1.0 
          No 12 (85.7%) 1 (100%) 13 (86.7%)  
     
Hispanic CC (n=8) AA (n=4) AC (n=3) p 
     Sepsis     
          Yes 1 (12.5%) 1 (25%) 0 (0%) 1.0 
          No 6 (75%) 2 (50%) 3 (100%)  
     ROP     
          Yes 3 (37.5%) 1 (25%) 2 (66.7%) 1.0 
          No 4 (50%) 2 (50%) 1 (33.3%)  
     BPD     
          Yes 0 (0%) 0 (0%) 0 (0%) n/a 
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          No 7 (87.5%) 4 (100%) 3 (100%)  
     NEC     
          Yes 0 (0%) 1 (25%) 0 (0%) 0.500 
          No 7 (87.5%) 3 (75%) 3 (100%)  
     IVH     
          Yes 1 (12.5%) 1 (25%) 0 (0%) 1.0 
          No 6 (75%) 3 (75%) 3 (100%)  
     Blood transfusion     
          Yes 4 (50%) 2 (50%) 2 (66.7%) 1.0 
          No 4 (50%) 2 (50%) 1 (33.3%)  
     Feeding intolerance     
          Yes 4 (50%) 3 (75%) 0 (0%) 0.241 
          No 3 (37.5%) 1 (25%) 3 (100%)  
 
 
 
 
  Minor Allele Presence 
rs1800872 
  
1800872     
Total Population No (n=39) Yes (n=33) P  
     Sepsis     
        Yes 8 (20.5%) 2 (6.1%) 0.097*  
        No 30 (76.9%) 30 (90.9%)   
     ROP     
        Yes 9 (23.1%) 4 (12.1%) 0.360  
        No 29 (74.4%) 26 (78.8%)   
     BPD     
        Yes 3 (7.7%) 1 (3%) 0.618  
        No 35 (89.7%) 32 (97%)   
     NEC     
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        Yes 0 (0%) 3 (9.1%) 0.095*  
        No 38 (97.4%) 30 (90.9%)   
     IVH     
        Yes 5 (12.8%) 4 (12.1%) 1.0  
        No 33 (84.6%) 28 (84.9%)   
     Blood transfusion     
        Yes 18 (46.1%) 15 (45.5%) 1.0  
        No 21 (53.9%) 18 (54.5%)   
     Feeding intolerance     
        Yes 8 (20.5%) 7 (21.2%) 1.0  
        No 29 (74.4%) 26 (78.8%)   
     
Caucasian No (n=15) Yes (n=7) P  
     Sepsis     
        Yes 3 (20%) 0 (0%) 0.523  
        No 12 (80%) 7 (100%)   
     ROP     
        Yes 2 (13.3%) 1 (14.3%) 1.0  
        No 13 (86.7%) 6 (85.7%)   
     BPD     
        Yes 1 (6.7%) 0 (0%) 1.0  
        No 14 (93.3%) 7 (100%)   
     NEC     
        Yes 0 (0%) 0 (0%) n/a  
        No 15 (100%) 7 (100%)   
     IVH     
        Yes 3 (20%) 1 (14.3%) 1.0  
        No 12 (80%) 6 (85.7%)   
     Blood transfusion     
        Yes 6 (40%) 3 (42.9%) 1.0  
        No 9 (60%) 4 (57.1%)   
     Feeding intolerance     
        Yes 3 (20%) 1 (14.3%) 1.0  
        No 12 (80%) 6 (85.7%)   
     
African American No (n=14) Yes (n=16) P  
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     Sepsis     
        Yes 4 (28.6%) 1 (6.3%) 0.157*  
        No 10 (71.4%) 15 (93.8%)   
     ROP     
        Yes 3 (21.4%) 0 (0%) 0.222  
        No 11 (78.6%) 14 (87.5%)   
     BPD     
        Yes 2 (14.3%) 1 (6.3%) 0.586  
        No 12 (85.7%) 15 (93.7%)   
     NEC     
        Yes 0 (0%) 1 (6.3%) 1.0  
        No 14 (100%) 15 (93.7%)   
     IVH     
        Yes 1 (7.1%) 2 (12.5%) 1.0  
        No 13 (92.9%) 13 (81.3%)   
     Blood transfusion     
        Yes 8 (57.1%) 7 (43.8%) 0.715  
        No 6 (42.9%) 9 (56.2%)   
     Feeding intolerance     
        Yes 1 (7.1%) 2 (12.5%) 1.0  
        No 12 (85.7%) 14 (87.5%)   
     
Hispanic No (n=8) Yes (n=7) P  
     Sepsis     
         Yes 1 (12.5%) 1 (20%) 1.0  
         No 6 (75%) 5 (71.3%)   
     ROP     
         Yes 3 (37.5%) 3 (42.9%) 1.0  
         No 4 (50%) 3 (42.9%)   
     BPD     
         Yes 0 (0%) 0 (0%) n/a  
         No 7 (87.5%) 7 (100%)   
     NEC     
         Yes 0 (0%) 1 (20%) 1.0  
         No 7 (87.5%) 6 (85.7%)   
     IVH     
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         Yes 1 (12.5%) 1 (20%) 1.0  
         No 6 (75%) 6 (85.7%)   
     Blood transfusion     
         Yes 4 (50%) 4 (57.1%) 1.0  
         No 4 (50%) 3 (42.9%)   
     Feeding intolerance     
         Yes 4 (50%) 3 (42.9%) 1.0  
         No 3 (37.5%) 4 (57.1%)   
 
 
 
 
  Categorical Infant 
Outcomes – rs1800896 
  
1800896     
Total Population GG (n=13) AA (n=32) AG (n=34) p 
     Sepsis     
        Yes 2 (15.4%) 1 (3.1%) 7 (20.6%) 0.283 
        No 11 (84.6%) 22 (68.8%) 27 (79.4%)  
     ROP     
        Yes 3 (23.1%) 5 (15.6%) 5 (14.7%) 0.657 
        No 10 (76.9%) 16 (50%) 28 (82.4%)  
     BPD     
        Yes 1 (7.7%) 1 (3.1%) 2 (5.9%) 1.0 
        No 12 (92.3%) 23 (71.9%) 32 (94.1%)  
     NEC     
        Yes 0 (0%) 1 (12.5%) 2 (5.9%) 1.0 
        No 13 (100%) 23 (87.5%) 32 (94.1%)  
     IVH     
        Yes 1 (7.7%) 4 (12.5%) 4 (11.8%) 0.715 
        No 12 (92.3%) 28 (87.5%) 30 (88.2%)  
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     Blood transfusion     
        Yes 7 (53.9%) 9 (28.1%) 16 (47.1%) 0.519 
        No 6 (46.1%) 16 (50%) 18 (52.9%)  
     Feeding intolerance     
        Yes 3 (23.1%) 6 (18.8%) 5 (14.7%) 0.667 
        No 9 (69.2%) 19 (50%) 28 (82.4%)  
     
Caucasian GG (n=5) AA (n=8) AG (n=9) p 
     Sepsis     
          Yes 1 (20%) 0 (0%) 2 (22.2%) 0.416 
          No 4 (80%) 8 (100%) 7 (77.8%)  
     ROP     
          Yes 0 (0%) 1 (12.5%) 2 (22.2%) 0.766 
          No 5 (100%) 7 (87.5%) 7 (77.8%)  
     BPD     
          Yes 1 (20%) 0 (0%) 0 (0%) 0.227 
          No 4 (80%) 8 (100%) 9 (100%)  
     NEC     
          Yes 0 (0%) 0 (0%) 0 (0%) n/a 
          No 5 (100%) 8 (100%) 9 (100%)  
     IVH     
          Yes 1 (20%) 0 (0%) 3 (33.3%) 0.234 
          No 4 (80%) 8 (100%) 6 (66.7%)  
     Blood transfusion     
          Yes 2 (40%) 2 (25%) 5 (55.6%) 0.557 
          No 3 (60%) 6 (75%) 4 (44.4%)  
     Feeding intolerance     
          Yes 1 (20%) 2 (25%) 1 (11.1%) 0.803 
          No 4 (80%) 6 (75%) 8 (88.9%)  
     
African American GG (n=5) AA (n=6) AG (n=20) p 
     Sepsis     
          Yes 0 (0%) 0 (0%) 5 (25%) 0.384 
          No 5 (100%) 6 (100%) 15 (75%)  
     ROP     
          Yes 1 (20%) 0 (0%) 2 (10%) 0.704 
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          No 4 (80%) 4 (66.7%) 17 (85%)  
     BPD     
          Yes 0 (0%) 1 (2.8%) 2 (10%) 1.0 
          No 5 (100%) 5 (83.3%) 18 (90%)  
     NEC     
          Yes 0 (0%) 0 (0%) 1 (5%) 1.0 
          No 5 (100%) 6 (100%) 19 (95%)  
     IVH     
          Yes 0 (0%) 2 (33.3%) 1 (5%) 0.056* 
          No 5 (100%) 2 (33.3%) 19 (95%)  
     Blood transfusion     
          Yes 3 (60%) 3 (50%) 9 (45%) 0.877 
          No 2 (40%) 3 (50%) 11 (55%)  
     Feeding intolerance     
          Yes 0 (0%) 0 (0%) 3 (15%) 0.747 
          No 5 (100%) 6 (100%) 16 (80%)  
     
Hispanic GG (n=3) AA (n=9) AG (n=2) p 
     Sepsis     
          Yes 1 (33.3%) 1 (11.1%) 0 (0%) 1.0 
          No 2 (66.7%) 6 (66.7%) 2 (100%)  
     ROP     
          Yes 2 (66.7%) 3 (33.3%) 1 (50%) 1.0 
          No 1 (33.3%) 4 (44.4%) 1 (50%)  
     BPD     
          Yes 0 (0%) 0 (0%) 0 (0%) n/a 
          No 3 (100%) 8 (88.9%) 2 (100%)  
     NEC     
          Yes 0 (0%) 1 (11.1%) 0 (0%) 1.0 
          No 3 (100%) 7 (77.8%) 2 (100%)  
     IVH     
          Yes 0 (0%) 2 (22.2%) 0 (0%) 1.0 
          No 3 (100%) 6 (66.7%) 2 (100%)  
     Blood transfusion     
          Yes 2 (66.7%) 4 (44.4%) 1 (50%) 1.0 
          No 1 (33.3%) 5 (55.6%) 1 (50%)  
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     Feeding intolerance     
          Yes 2 (66.7%) 4 (44.4%) 0 (0%) 0.217 
          No 0 (0%) 5 (55.6%) 2 (100%)  
     
 
 
 
 
 
  Minor Allele Presence 
rs1800896 
  
1800896 MAP     
Total Population No (n=25) Yes (n=47) p  
     Sepsis     
        Yes 1 (4%) 9 (19.1%) 0.149*  
        No 22 (88%) 38 (80.9%)   
     ROP     
        Yes 5 (20%) 8 (17%) 0.526  
        No 16 (64%) 38 (81%)   
     BPD     
        Yes 1 (4%) 3 (6.4%) 1.0  
        No 23 (92%) 44 (93.6%)   
     NEC     
        Yes 1 (4%) 2 (4.3%) 1.0  
        No 23 (92%) 45 (95.7%)   
     IVH     
        Yes 4 (16%) 5 (10.6%) 0.452  
        No 18 (72%) 42 (89.4%)   
     Blood transfusion     
        Yes 9 (36%) 23 (48.9%) 0.329  
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        No 16 (64%) 24 (51.1%)   
     Feeding intolerance     
        Yes 6 (24%) 8 (17%) 0.548  
        No 19 (76%) 37 (78.7%)   
     
Caucasian No (n=8) Yes (n=14) p  
     Sepsis     
        Yes 0 (0%) 3 (21.4%) 0.273  
        No 8 (100%) 11 (78.6%)   
     ROP     
        Yes 1 (12.5%) 2 (14.3%) 1.0  
        No 7 (87.5%) 12 (85.7%)   
     BPD     
        Yes 0 (0%) 1 (7.1%) 1.0  
        No 8 (100%) 13 (92.9%)   
NEC     
        Yes 0 (0%) 0 (0%) n/a  
        No 8 (100%) 14 (100%)   
IVH     
        Yes 0 (0%) 4 (28.6%) 0.254  
        No 8 (100%) 10 (71.4%)   
Blood transfusion     
        Yes 2 (25%) 7 (50%) 0.380  
        No 6 (75%) 7 (50%)   
Feeding intolerance     
        Yes 2 (25%) 2 (14.3%) 0.602  
        No 6 (75%) 12 (85.7%)   
     
African American No (n=6) Yes (n=25) p  
     Sepsis     
        Yes 0 (0%) 5 (20%) 0.553  
        No 6 (100%) 20 (80%)   
     ROP     
        Yes 0 (0%) 3 (12%) 1.0  
        No 4 (66.7%) 21 (84%)   
     BPD     
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        Yes 1 (16.7%) 2 (8%) 0.488  
        No 5 (83.3%) 23 (92%)   
     NEC     
        Yes 0 (0%) 1 (4%) 1.0  
        No 6 (100%) 24 (96%)   
     IVH     
        Yes 2 (33.3%) 1 (4%) 0.042*  
        No 2 (33.3%) 24 (96%)   
     Blood transfusion     
        Yes 3 (50%) 12 (48%) 1.0  
        No 3 (50%) 13 (52%)   
     Feeding intolerance     
        Yes 0 (0%) 3 (12%) 1.0  
        No 6 (100%) 21 (84%)   
     
Hispanic No (n=9) Yes (n=6) p  
     Sepsis     
         Yes 1 (11.1%) 1 (16.7%) 1.0  
         No 6 (66.7%) 4 (66.7%)   
     ROP     
         Yes 3 (33.3%) 3 (50%) 1.0  
         No 4 (44.4%) 2 (33.3%)   
     BPD     
         Yes 0 (0%) 0 (0%) n/a  
         No 8 (88.9%) 5 (83.3%)   
     NEC     
         Yes 1 (11.1%) 0 (0%) 1.0  
         No 7 (77.8%) 5 (83.3%)   
     IVH     
         Yes 2 (22.2%) 0 (0%) 0.487  
         No 6 (66.7%) 5 (83.3%)   
     Blood transfusion     
         Yes 3 (33.3%) 4 (66.7%) 1.0  
         No 5 (55.6%) 2 (33.3%)   
     Feeding intolerance     
         Yes 4 (44.4%) 2 (33.3%) 1.0  
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         No 5 (55.6%) 2 (33.3%)   
ROP=retinopathy of prematurity; BPD=bronchopulmonary dysplasia; NEC=necrotizing enterocolitis; IVH=intraventricular hemorrhage 
 
Table 19: Multivariate analysis of maternal IL SNP and continuous infant outcomes 
African Americans: multivariate model for continuous infant outcomes with minor allele presence rs2070874 
Outcome Predictor Estimate p-value  
lnWeight at 6 weeks Minor allele presence – no  0.105 0.2627  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.621 0.0107  
 Ratio of mom’s own milk to all milk -0.344 0.026*  
     
lnCalprotectin Week 1 Minor allele presence – no  -0.242 0.5666  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -0.021 0.7258  
 Ratio of mom’s own milk to all milk -1.197 0.1025  
     
lnCalprotectin Week 2 Minor allele presence – no  0.5807 0.0589*  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.030 0.5764  
 Ratio of mom’s own milk to all milk -1.111 0.0730*  
     
lnSNAPPEII Minor allele presence – no  0.284 0.2424  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -0.085 0.0426*  
 Ratio of mom’s own milk to all milk 0.207 0.6327  
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Caucasians: multivariate model for continuous infant outcomes with minor allele presence rs2070874 
Outcome Predictor Estimate p-value  
Length of Stay Minor allele presence – no  -10.701 0.3684  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -6.836 0.0025*  
 Ratio of mom’s own milk to all milk 11.978 0.3908  
     
Days on oxygen Minor allele presence – no  -10.364 0.3968  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -6.761 0.0034*  
 Ratio of mom’s own milk to all milk 9.584 0.5031  
     
Weight at 6 weeks Minor allele presence – no  -0.0169 0.8754  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.055 0.0190*  
 Ratio of mom’s own milk to all milk 0.042 0.7419  
     
 
 
Hispanics: multivariate model for continuous infant outcomes with minor allele presence rs2070874 
Outcome Predictor Estimate p-value  
lnCalprotectin Week 3 Minor allele presence – no  0.548 0.238  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.113 0.447  
 Ratio of mom’s own milk to all milk -8.510 0.1836  
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Caucasians: multivariate model for continuous infant outcomes with genotype rs2243250 
Outcome Predictor Estimate p-value  
Length of stay Genotype CC  2.978 0.7390  
 Genotype TT 25.261 0.0720*  
 Genotype CT (reference)    
 Gestational Age  -6.403 0.0027*  
 Ratio of mom’s own milk to all milk 11.728 0.3629  
     
lnWeight at 6 weeks Genotype CC  -0.005 0.9550  
 Genotype TT -0.0157 0.2326  
 Genotype CT (reference)    
 Gestational Age  0.047 0.0372*  
 Ratio of mom’s own milk to all milk 0.063 0.6038  
     
Days on oxygen Genotype CC  4.283 0.6555  
 Genotype TT 22.394 0.1312  
 Genotype CT (reference)    
 Gestational Age  -6.402 0.0046*  
 Ratio of mom’s own milk to all milk 9.629 0.4839  
     
lnCalprotectin Week 2 Genotype CC  0.611 0.1651  
 Genotype TT -0.266 0.6481  
 Genotype CT (reference)    
 Gestational Age  -0.042 0.6741  
 Ratio of mom’s own milk to all milk 0.002 0.9966  
     
lnCalprotectin Week 3 Genotype CC  -0.155 0.6540  
 Genotype TT -0.694 0.1744  
 Genotype CT (reference)    
 Gestational Age  0.063 0.4862  
 Ratio of mom’s own milk to all milk 0.136 0.7811  
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African Americans: multivariate model for continuous infant outcomes with genotype rs2243250 
Outcome Predictor Estimate p-value  
Length of stay Genotype CC  24.923 0.0518*  
 Genotype TT -2.289 0.8295  
 Genotype CT (reference)    
 Gestational Age  -8.657 <0.001*  
 Ratio of mom’s own milk to all milk -17.174 0.3158  
     
lnWeight at 6 weeks Genotype CC  -0.114 0.2894  
 Genotype TT -0.059 0.5111  
 Genotype CT (reference)    
 Gestational Age  0.0369 0.1258  
 Ratio of mom’s own milk to all milk -0.262 0.0851*  
     
Days on oxygen Genotype CC  19.173 0.0809*  
 Genotype TT 10.610 0.2608  
 Genotype CT (reference)    
 Gestational Age  -2.952 0.0424*  
 Ratio of mom’s own milk to all milk 12.779 0.3733  
     
lnCalprotectin Week 1 Genotype CC  -47.301 0.6484  
 Genotype TT 138.096 0.1520  
 Genotype CT (reference)    
 Gestational Age  -12.937 0.3433  
 Ratio of mom’s own milk to all milk -197.385 0.1856  
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Hispanics: multivariate model for continuous infant outcomes with genotype rs2243250 
Outcome Predictor Estimate p-value  
lnCalprotectin week 1 Genotype CC  360.22 0.1605  
 Genotype TT -100.711 0.7002  
 Genotype CT (reference)    
 Gestational Age  -48.106 0.4751  
 Ratio of mom’s own milk to all milk 495.52 0.4717  
     
lnCalprotectin Week 3 Genotype CC  0.468 0.3610  
 Genotype TT -0.339 0.5638  
 Genotype CT (reference)    
 Gestational Age  0.142 0.3377  
 Ratio of mom’s own milk to all milk -8.309 0.2048  
     
 
Total population: multivariate model for continuous infant outcomes with genotype rs2243250 
Outcome Predictor Estimate p-value  
lnCalprotectin week 3 Genotype CC  29.27 0.6261  
 Genotype TT -89.557 0.1615  
 Genotype CT (reference)    
 Gestational Age  16.294 0.1533  
 Ratio of mom’s own milk to all milk 111.78 0.2880  
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Caucasians: multivariate model for continuous infant outcomes with minor allele presence rs1800795 
Outcome Predictor Estimate p-value  
Days on oxygen Minor allele presence – no  -8.332 0.2698  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -6.95 0.0021*  
 Ratio of mom’s own milk to all milk 6.801 0.6396  
     
lnCalprotectin Week 2 Minor allele presence – no  -0.743 0.0222*  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.011 0.9038  
 Ratio of mom’s own milk to all milk -0.535 0.3383  
    
 
 
 
 
African Americans: multivariate model for continuous infant outcomes with minor allele presence rs1800795 
Outcome Predictor Estimate p-value  
lnSNAPPEII Minor allele presence – no  0.344 0.2235  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -0.066 0.1187  
 Ratio of mom’s own milk to all milk 0.513 0.1984  
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Hispanics: multivariate model for continuous infant outcomes with minor allele presence rs1800795 
Outcome Predictor Estimate p-value  
Length of stay Minor allele presence – no  9.701 0.6945  
 Minor allele presence – yes (reference)    
 Gestational Age  -7.122 0.2932  
 Ratio of mom’s own milk to all milk -184.046 0.0350*  
     
lnCalprotectin Week 1 Minor allele presence – no  0.241 0.7971  
 Minor allele presence – yes (reference)    
 Gestational Age  -0.063 0.8116  
 Ratio of mom’s own milk to all milk 4.662 0.1360  
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Total Population: multivariate model for continuous infant outcomes with minor allele presence rs1800795 
Outcome Predictor Estimate p-value  
lnSNAPPEII Minor allele presence – no  0.179 0.2790  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -0.11 0.0023*  
 Ratio of mom’s own milk to all milk -0.187 0.5745  
     
lnSNAPPEII Genotype CC  0.721 0.0652*  
 Genotype GG 0.276 0.1075*  
 Genotype CG (reference)    
 Gestational Age  -0.108 0.0023*  
 Ratio of mom’s own milk to all milk -0.079 0.8117  
     
Days on oxygen Minor allele presence – no  -9.588 0.0316*  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -5.048 <0.001*  
 Ratio of mom’s own milk to all milk 1.02 0.9076  
     
Days on oxygen Genotype CC  1.529 0.8622  
 Genotype GG -9.29 0.0533*  
 Genotype CG (reference)    
 Gestational Age  -5.048 <0.001*  
 Ratio of mom’s own milk to all milk 1.107 0.9008  
     
lnCalprotectin week 2 Minor allele presence – no  -0.253 0.2117  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.079 0.0940*  
 Ratio of mom’s own milk to all milk 0.209 0.6038  
     
lnCalprotectin week 2 Genotype CC  0.279 0.4870  
 Genotype GG -0.163 0.3716  
 Genotype CG (reference)    
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 Gestational Age  0.083 0.0833*  
 Ratio of mom’s own milk to all milk 0.217 0.5932  
 
Caucasians: multivariate model for continuous infant outcomes with minor allele presence rs1800796 
Outcome Predictor Estimate p-value  
lnCalprotectin week 3 Minor allele presence – no  0.815 0.0429*  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.167 0.0530*  
 Ratio of mom’s own milk to all milk 0.252 0.5708  
     
 
African Americans: multivariate model for continuous infant outcomes with minor allele presence rs1800796 
Outcome Predictor Estimate p-value  
Length of stay Minor allele presence – no  -32.318 0.0158*  
 Minor allele presence – yes (reference)    
 Gestational Age  -9.142 <0.001  
 Ratio of mom’s own milk to all milk -10.227 0.5371  
     
lnSNAPPEII Minor allele presence – no  -0.668 0.0497*  
 Minor allele presence – yes (reference)    
 Gestational Age  -0.059 0.1350  
 Ratio of mom’s own milk to all milk 0.579 0.1310  
     
lnCalprotectin Week 3 Minor allele presence – no  -0.602 0.0868*  
 Minor allele presence – yes (reference)    
 Gestational Age  0.016 0.7278  
 Ratio of mom’s own milk to all milk -0.214 0.6610  
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Hispanics: multivariate model for continuous infant outcomes with minor allele presence rs1800796 
Outcome Predictor Estimate p-value  
lnWeight at 6 weeks Minor allele presence – no  -0.195 0.0272*  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.089 0.0027*  
 Ratio of mom’s own milk to all milk -0.519 0.0822*  
     
lnCalprotectin Week 3 Minor allele presence – no  0.125 0.7941  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.159 0.3460  
 Ratio of mom’s own milk to all milk -10.593 0.1481  
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Total population: multivariate model for continuous infant outcomes with minor allele presence rs1800796 
Outcome Predictor Estimate p-value  
Length of stay Minor allele presence – no  -17.986 0.0688*  
 Minor allele presence – yes (reference)    
 Gestational Age  -8.573 <0.0001  
 Ratio of mom’s own milk to all milk -12.514 0.4299  
     
Length of stay Genotype GG 69.376 0.0034*  
 Genotype AA -7.257 0.4626  
 Genotype AG (reference)    
 Gestational Age  -8.411 <0.0001  
 Ratio of mom’s own milk to all milk -12.07 0.4194  
     
lnWeight at 6 weeks Minor allele presence – no  -0.066 0.2108  
 Minor allele presence – yes (reference)    
 Gestational Age  0.055 <0.0001  
 Ratio of mom’s own milk to all milk -0.091 0.2689  
     
lnWeight at 6 weeks Genotype GG -0.100 0.3925  
 Genotype AA -0.088 0.1368  
 Genotype AG (reference)    
 Gestational Age  0.055 <0.001  
 Ratio of mom’s own milk to all milk -0.097 0.2414  
     
lnCalprotectin week 3 Minor allele presence – no  -0.291 0.1607  
 Minor allele presence – yes (reference)    
 Gestational Age  0.052 0.1958  
 Ratio of mom’s own milk to all milk 0.229 0.5473  
     
lnCalprotectin Week 3 Genotype GG 0.974 0.0213*  
 Genotype AA -0.063 0.7730  
 Genotype AG (reference)    
 Gestational Age  0.065 0.0968*  
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 Ratio of mom’s own milk to all milk 0.257 0.4826  
     
 
Caucasians: multivariate model for continuous infant outcomes with minor allele presence rs1800871 
Outcome Predictor Estimate p-value  
Length of stay Minor allele presence – no  15.709 0.0989*  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -9.041 <0.0001*  
 Ratio of mom’s own milk to all milk -9.104 0.6104  
     
lnCalprotectin week 1 Minor allele presence – no  -0.763 0.0890*  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -0.103 0.4835  
 Ratio of mom’s own milk to all milk -0.357 0.6594  
     
lnCalprotectin Week 2 Minor allele presence – no  0.428 0.2402  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -0.013 0.8998  
 Ratio of mom’s own milk to all milk 0.231 0.6998  
 
 
African Americans: multivariate model for continuous infant outcomes with minor allele presence rs1800871 
Outcome Predictor Estimate p-value  
Length of stay Minor allele presence – no  15.709 0.0989*  
 Minor allele presence – yes (reference)    
 Gestational Age  -9.041 <0.0001*  
 Ratio of mom’s own milk to all milk -9.104 0.6104  
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Hispanics: multivariate model for continuous infant outcomes with minor allele presence rs1800871 
Outcome Predictor Estimate p-value  
lnCalprotectin week 2 Minor allele presence – no  0.048 0.9084  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.402 0.0282*  
 Ratio of mom’s own milk to all milk -0.302 0.8316  
     
 
Total Population: multivariate model for continuous infant outcomes with minor allele presence rs1800871 
Outcome Predictor Estimate p-value  
lnCalprotectin Week 3 Minor allele presence - no -0.001 0.9949  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.055 0.1737  
 Ratio of mom’s own milk to all milk 0.286 0.4647  
     
lnCalprotectin Week 3 Genotype TT 0.732 0.0270*  
 Genotype CC 0.143 0.4381  
 Genotype CT (reference)    
 Gestational Age  0.059 0.1299  
 Ratio of mom’s own milk to all milk 0.174 0.6452  
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Caucasians: multivariate model for continuous infant outcomes with minor allele presence rs1800872 
Outcome Predictor Estimate p-value  
Length of stay Minor allele presence – no  7.761 0.2763  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -6.747 0.0026*  
 Ratio of mom’s own milk to all milk 14.478 0.2895  
     
lnWeight at 6 weeks Minor allele presence – no  -0.082 0.2041  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.052 0.0168*  
 Ratio of mom’s own milk to all milk 0.039 0.7411  
     
lnCalprotectin week 1 Minor allele presence – no  -0.997 0.0196*  
 Minor allele presence – yes 
(reference) 
-0.202 0.0987*  
 Gestational Age  -0.044 0.9474  
 Ratio of mom’s own milk to all milk    
     
     
 
 
African Americans: multivariate model for continuous infant outcomes with minor allele presence rs1800872 
Outcome Predictor Estimate p-value  
Length of stay Minor allele presence – no  10.012 0.3255  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -9.762 <0.0001  
 Ratio of mom’s own milk to all milk -18.816 0.3375  
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Hispanics: multivariate model for continuous infant outcomes with minor allele presence rs1800872 
Outcome Predictor Estimate p-value  
lnCalprotectin week 2 Minor allele presence – no  0.408 0.9084  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.402 0.0282*  
 Ratio of mom’s own milk to all milk -0.302 0.8316  
     
Total Population: multivariate model for continuous infant outcomes with minor allele presence rs1800872 
Outcome Predictor Estimate p-value  
Length of Stay Minor allele presence – no  6.078 0.4546  
 Minor allele presence – yes (reference)    
 Gestational Age  -8.157 <0.001*  
 Ratio of mom’s own milk to all milk -8.832 0.5927  
     
Length of Stay Genotype CC 4.422 0.6140  
 Genotype AA -7.109 0.6036  
 Genotype AC (reference)    
 Gestational Age  -8.057 <0.001*  
 Ratio of mom’s own milk to all milk -6.864 0.6868  
     
lnCalprotectin Week 3 Minor allele presence – no  0.006 0.9710  
 Minor allele presence – yes (reference)    
 Gestational Age  0.065 0.1499  
 Ratio of mom’s own milk to all milk 0.341 0.3990  
     
lnCalprotectin Week 3 Genotype CC 0.203 0.2892  
 Genotype AA 0.768 0.0158*  
 Genotype AC (reference)    
 Gestational Age  0.063 0.1466  
 Ratio of mom’s own milk to all milk 0.074 0.8523  
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Caucasians: multivariate model for continuous infant outcomes with minor allele presence rs1800896 
Outcome Predictor Estimate p-value  
lnCalprotectin Week 2 Minor allele presence – no  0.582 0.0737*  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -0.058 0.5695  
 Ratio of mom’s own milk to all milk -0.136 0.8034  
     
lnCalprotectin Week 3 Minor allele presence – no  0.244 0.3576  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.083 0.3316  
 Ratio of mom’s own milk to all milk -0.026 0.9582  
  
 
  
 
 
 
African Americans: multivariate model for continuous infant outcomes with minor allele presence rs1800896 
Outcome Predictor Estimate p-value  
Days on oxygen Minor allele presence – no  21.589 0.0320*  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -4.699 0.0016*  
 Ratio of mom’s own milk to all milk -5.597 0.7021  
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Hispanics: multivariate model for continuous infant outcomes with minor allele presence rs1800896 
Outcome Predictor Estimate p-value  
Length of stay Minor allele presence – no  2.249 0.8656  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -9.808 <0.0001  
 Ratio of mom’s own milk to all milk -17.667 0.3866  
     
lnCalprotectin Week 1 Minor allele presence – no  0.614 0.5005  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -0.084 0.7390  
 Ratio of mom’s own milk to all milk 4.011 0.1763  
     
lnCalprotectin Week 3 Minor allele presence – no  0.771 0.2073  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.119 0.4411  
 Ratio of mom’s own milk to all milk -8.200 0.2258  
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Total Population: multivariate model for continuous infant outcomes with minor allele presence rs1800896 
Outcome Predictor Estimate p-value  
Length of stay Minor allele presence – no  -12.461 0.1594  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  -7.938 <0.0001  
 Ratio of mom’s own milk to all 
milk 
-1.298 0.9396  
     
Length of stay Genotype GG -1.128 0.9199  
 Genotype AA -12.832 0.1841  
 Genotype AG (reference)    
 Gestational Age  -7.932 <0.0001  
 Ratio of mom’s own milk to all 
milk 
-0.854 0.9618  
     
lnCalprotectin Week 2 Minor allele presence – no  0.644 0.0057*  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.058 0.2023  
 Ratio of mom’s own milk to all 
milk 
-0.251 0.5478  
     
lnCalprotectin week 2 Genotype GG 0.220 0.3795  
 Genotype AA 0.741 0.0045*  
 Genotype AG (reference)    
 Gestational Age  0.055 0.2297  
 Ratio of mom’s own milk to all 
milk 
-0.379 0.3928  
     
lnCalprotectin Week 3 Minor allele presence – no  0.342 0.0825*  
 Minor allele presence – yes 
(reference) 
   
 Gestational Age  0.050 0.2098  
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 Ratio of mom’s own milk to all 
milk 
0.050 0.9006  
     
lnCalprotectin week 3 Genotype GG 0.139 0.5982  
 Genotype AA 0.387 0.0744*  
 Genotype AG (reference)    
 Gestational Age  0.051 0.2076  
 Ratio of mom’s own milk to all 
milk 
-0.013 0.9760  
 
Table 20: Multivariate analysis of maternal SNP and categorical infant outcomes 
Total Population: multivariate model for categorical infant outcomes with rs2070874 
Outcome Predictor OR, 95% CI p 
ROP MAP – no  0.2250 
      MAP – no versus yes 0.437 (0.115, 0.1665) 0.2250 
 Gestational Age 0.633 (0.433, 0.927) 0.0188* 
 Ratio of mom’s own milk to all milk 0.877 (0.0.54, 14.340) 0.9268 
ROP Genotype   
      Genotype CC versus CT 0.885 (0.149, 5.240) 0.1636 
      Genotype TT versus CT 4.558 (0.552, 37.640) 0.2171 
 Gestational Age 0.642 (0.433, 0.952) 0.0706* 
 Ratio of mom’s own milk to all milk 1.290 (0.079, 21.171) 0.0277* 
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Total Population: multivariate model for categorical infant outcomes with rs2243250 
Outcome Predictor OR, 95% CI p 
Transfusion Genotype   
      Genotype CC versus CT 2.752 (0.618, 12.261) 0.404 
      Genotype TT versus CT 2.224 (0.462, 10.719) 0.3098 
 Gestational Age 0.464 (0.311, 0.693) 0.6472 
 Ratio of mom’s own milk to all milk 1.048 (0.090, 12.181) 0.0002* 
 
Caucasians: multivariate model for categorical infant outcomes with minor allele presence rs1800795 
Outcome Predictor OR, 95% CI p 
ROP MAP – no  0.1560 
      MAP – no versus yes 10.605 (0.406, 276.879) 0.1560 
 Gestational Age 0.580 (0.190, 1.774) 0.3399 
 Ratio of mom’s own milk to all milk 0.910 (0.004, 197.685) 0.9727 
Transfusion MAP – no  0.1145 
      MAP – no versus yes 0.102 (0.006, 1.738) 0.1145 
 Gestational Age 0.675 (0.374, 1.220) 0.1933 
 Ratio of mom’s own milk to all milk 0.089 (<0.001, 13.987) 0.3479 
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African Americans: multivariate model for categorical infant outcomes minor allele presence rs1800795 
Outcome Predictor OR, 95% CI p 
IVH MAP - no  0.1116 
      MAP – no versus yes <0.001 (<0.0001, 6.715) 0.1116 
 Gestational Age 0.219 (0.029, 1.649) 0.1403 
 Ratio of mom’s own milk to all milk <0.001 (<0.001, 510.404) 0.2910 
 
 
African Americans: multivariate model for categorical infant outcomes minor allele presence rs1800796 
Outcome Predictor OR, 95% CI p 
Sepsis MAP - no  0.5109 
      MAP – no versus yes 0.076 (<0.001, 165.882) 0.5109 
 Gestational Age 0.334 (0.119, 0.938) 0.0375* 
 Ratio of mom’s own milk to all milk 0.149 (0.001, 20.377) 0.4485 
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Hispanics: multivariate model for categorical infant outcomes minor allele presence rs1800796 
Outcome Predictor OR, 95% CI p 
Feeding Intolerance MAP - no  0.5982 
      MAP – no versus yes 2.626 (0.072, 95.151) 0.5982 
 Gestational Age 0.187 (0.018, 1.947) 0.1609 
 Ratio of mom’s own milk to all milk <0.001 (<0.001, >999.999) 0.6131 
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Total Population: multivariate model for categorical infant outcomes with rs1800796 
Outcome Predictor OR, 95% CI p 
ROP MAP – no  0.0573* 
      MAP – no versus yes 0.223 (0.048, 1.048) 0.0573* 
 Gestational Age 0.630 (0.429, 0.925) 0.0185* 
 Ratio of mom’s own milk to all milk 0.440 (0.023, 8.441) 0.5859 
ROP Genotype  0.1492 
      Genotype GG versus AG 1.955 (0.078, 49.084) 0.3782 
      Genotype AA versus AG 0.253 (0.048, 1.325) 0.0687* 
 Gestational Age 0.630 (0.429, 0.925) 0.0185* 
 Ratio of mom’s own milk to all milk 0.447 (0.023, 8.597) 0.5938 
BPD MAP – no  0.3860 
      MAP – no versus yes 0.337 (0.029, 3.941) 0.3860 
 Gestational Age 0.438 (0.199, 0.963) 0.0400* 
 Ratio of mom’s own milk to all milk 0.320 (0.001, 78.279) 0.6845 
NEC MAP – no  0.0883* 
      MAP – no versus yes 0.106 (0.008, 1.401) 0.0883* 
 Gestational Age 0.910 (0.557, 1.488) 0.7075 
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 Ratio of mom’s own milk to all milk 0.326 (0.001, 93.334) 0.6975 
Transfusion MAP – no  0.7995 
      MAP – no versus yes 0.817 (0.172, 3.875) 0.7995 
 Gestational Age 0.454 (0.306, 0.675) <0.001* 
 Ratio of mom’s own milk to all milk 0.941 (0.080, 11.132) 0.9617 
Feeding intolerance MAP – no  0.1282 
      MAP – no versus yes 0.313 (0.070, 1.398) 0.1282 
 Gestational Age 0.632 (0.444, 0.899) 0.0108* 
 Ratio of mom’s own milk to all milk 0.353 (0.024, 5.232) 0.4491 
 
 
Caucasians: multivariate model for categorical infant outcomes minor allele presence rs1800871 
Outcome Predictor OR, 95% CI p 
IVH MAP - no  0.1189 
      MAP – no versus yes 0.116 (0.008, 1.737) 0.1189 
 Gestational Age 0.481 (0.559, 3.923) 0.4299 
 Ratio of mom’s own milk to all milk 151.263 (<0.001, >999.999) 0.4524 
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Total Population: multivariate model for categorical infant outcomes with rs1800871 
Outcome Predictor OR, 95% CI p 
Sepsis MAP – no  0.6683 
      MAP – no versus yes 1.52 (0.224, 10.318) 0.6683 
 Gestational Age 0.363 (0.186, 0.712) 0.0032* 
 Ratio of mom’s own milk to all milk 0.199 (0.006, 60587) 0.3662 
Sepsis Genotype   
      Genotype TT versus CT 7.386 (0.283, 193.11) 0.4778 
      Genotype CC versus CT 2.693 (0.249, 29.173) 0.2914 
 Gestational Age 0.352 (0.176, 0.703) 0.9930 
 Ratio of mom’s own milk to all milk 0.152 (0.004, 5.585) 0.0031* 
 
African Americans: multivariate model for categorical infant outcomes minor allele presence rs1800872 
Outcome Predictor OR, 95% CI p 
Sepsis MAP - no  0.8579 
      MAP – no versus yes 0.722 (0.021, 25.407) 0.8579 
 Gestational Age 0.269 (0.075, 0.964) 0.0438* 
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 Ratio of mom’s own milk to all milk 0.090 (<0.001, 24.030) 0.3977 
 
Total Population: multivariate model for categorical infant outcomes with rs1800872 
Outcome Predictor OR, 95% CI p 
Sepsis MAP – no  0.6620 
      MAP – no versus yes 1.531 (0.227, 10.322) 0.6620 
 Gestational Age 0.364 (0.186, 0.714) 0.0033* 
 Ratio of mom’s own milk to all milk 0.197 (0.006, 6.412) 0.3607 
Sepsis Genotype   
      Genotype CC versus AC 2.696 (0.250, 29.095) 0.4861 
      Genotype AA versus AC 7.162 (0.276, 186.138) 0.9943 
 Gestational Age 0.350 (0.175, 0.700) 0.3004 
 Ratio of mom’s own milk to all milk 0.147 (0.004, 5.392) 0.0030* 
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Total Population: multivariate model for categorical infant outcomes with rs1800896 
Outcome Predictor OR, 95% CI p 
Sepsis MAP – no  0.1819 
      MAP – no versus yes 0.194 (0.017, 2.155) 0.1819 
 Gestational Age 0.337 (0.165, 0.687) 0.0028* 
 Ratio of mom’s own milk to all milk 0.315 (0.010, 10.394) 0.5170 
Sepsis Genotype  0.3975 
      Genotype GG versus AG 0.780 (0.107, 5.677) 0.5548 
      Genotype AA versus AG 0.178 (0.015, 2.171) 0.1963 
 Gestational Age 0.339 (0.166, 0.692) 0.0030* 
 Ratio of mom’s own milk to all milk 0.341 (0.010, 11.721) 0.5507 
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Figure 2: Interleukin 4 Trajectory Groups 
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Figure 3: Interleukin 6 Trajectory Groups 
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Figure 4: Interleukin 10 Trajectory Groups 
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